Gene	Gene synonym	Ensembl	Gene description	Chromosome	Position	Protein class	Evidence	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Prognostic p-value	RNA cancer category	RNA tissue category	RNA TS	RNA TS TPM	TPM max in non-specific	RNA cell line category	RNA CS	RNA CS TPM
AAAS		ENSG00000094914	Aladin WD repeat nucleoporin	12	53307456-53324864	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA040086	Approved		Approved	Nuclear membrane<br>Centrosome<br>Cytosol	Renal cancer:2.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 46.2	Expressed in all		
AARS	AlaRS, CMT2N	ENSG00000090861	Alanyl-tRNA synthetase	16	70252295-70289543	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB034261, HPA040870, HPA044223	Supported		Enhanced	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 178.0	Expressed in all		
AARS2	AARSL, bA444E17.1, KIAA1270	ENSG00000124608	Alanyl-tRNA synthetase 2, mitochondrial	6	44299654-44313326	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035636, HPA061396	Approved		Enhanced	Mitochondria		Expressed in all	Mixed			parathyroid gland: 11.4	Expressed in all		
AASS	LKRSDH, LORSDH	ENSG00000008311	Aminoadipate-semialdehyde synthase	7	122075647-122144280	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020637, HPA020728, HPA020734	Enhanced		Enhanced	Vesicles<br>Mitochondria	Liver cancer:9.81e-4 (favourable)	Expressed in all	Mixed			ovary: 30.7	Cell line enhanced		AN3-CA: 49.4;NTERA-2: 51.8
ABCA12	DKFZP434G232, ICR2B, LI2	ENSG00000144452	ATP binding cassette subfamily A member 12	2	214931542-215138428	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA078239			Approved	Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Group enriched	6	breast: 7.7;skin: 25.2	tonsil: 2.5	Group enriched	6	hTCEpi: 28.4;SK-BR-3: 13.8;T-47d: 9.1
ABCA3	ABC-C, ABC3, EST111653, LBM180	ENSG00000167972	ATP binding cassette subfamily A member 3	16	2275881-2340746	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007884	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		lung: 135.5	cerebral cortex: 51.5	Cell line enhanced		SCLC-21H: 53.9;T-47d: 71.7
ABCA4	ABCR, ARMD2, CORD3, FFM, RP19, STGD, STGD1	ENSG00000198691	ATP binding cassette subfamily A member 4	1	93992835-94121132	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Lung cancer:2.45e-4 (favourable), Urothelial cancer:2.72e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		epididymis: 9.9	kidney: 4.2	Cell line enhanced		BEWO: 2.8;EFO-21: 6.2;SK-BR-3: 1.9
ABCA7	ABCX	ENSG00000064687	ATP binding cassette subfamily A member 7	19	1040101-1065572	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041564	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:1.12e-4 (favourable), Colorectal cancer:7.26e-4 (unfavourable)	Expressed in all	Mixed			spleen: 25.3	Cell line enhanced		HMC-1: 52.2
ABCB1	ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1	ENSG00000085563	ATP binding cassette subfamily B member 1	7	87503633-87713323	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001716, HPA002199	Enhanced		Approved	Nucleoplasm<br>Focal adhesion sites<br>Cytosol	Renal cancer:2.95e-4 (favourable), Pancreatic cancer:3.33e-4 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 137.8;small intestine: 82.4	kidney: 37.3	Cell line enhanced		CACO-2: 56.6;HEL: 34.4;SH-SY5Y: 85.9
ABCB11	ABC16, BSEP, PFIC-2, PFIC2, PGY4, SPGP	ENSG00000073734	ATP binding cassette subfamily B member 11	2	168922938-169031322	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019035	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	13	liver: 19.1	testis: 1.4	Not detected		
ABCB4	GBD1, MDR2, MDR3, PFIC-3, PGY3	ENSG00000005471	ATP binding cassette subfamily B member 4	7	87401697-87480435	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049395, HPA053288	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites		Tissue enriched	Tissue enriched	6	liver: 69.3	adrenal gland: 10.7	Group enriched	6	SH-SY5Y: 14.2;WM-115: 25.6
ABCB6	EST45597, MTABC3, umat	ENSG00000115657	ATP binding cassette subfamily B member 6 (Langereis blood group)	2	219209768-219218990	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046723, HPA058011	Approved		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Mitochondria<br>Cytosol	Renal cancer:1.52e-7 (unfavourable), Liver cancer:9.45e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 32.7	Mixed		
ABCB7	ABC7, ASAT, Atm1p, EST140535	ENSG00000131269	ATP binding cassette subfamily B member 7	X	75053172-75156732	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA034982	Approved		Supported	Mitochondria	Renal cancer:5.31e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.7	Expressed in all		
ABCC6	ARA, EST349056, MLP1, MRP6, PXE, URG7	ENSG00000091262	ATP binding cassette subfamily C member 6	16	16148928-16223522	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038105			Supported	Plasma membrane	Liver cancer:3.82e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 16.9;liver: 23.4	duodenum: 13.0	Cell line enriched	6	Hep G2: 45.5
ABCC9	CMD1O, SUR2	ENSG00000069431	ATP binding cassette subfamily C member 9	12	21797401-21942529	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007279	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.85e-5 (unfavourable)	Mixed	Mixed			smooth muscle: 37.2	Cell line enhanced		ASC diff: 18.7;CACO-2: 21.7;HSkMC: 23.7;U-138 MG: 27.1
ABCD1	adrenoleukodystrophy, ALD, ALDP, AMN	ENSG00000101986	ATP binding cassette subfamily D member 1	X	153724868-153744762	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:5.50e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 19.3	Cell line enhanced		EFO-21: 65.5;PC-3: 46.4
ABCD3	PMP70, PXMP1, ZWS2	ENSG00000117528	ATP binding cassette subfamily D member 3	1	94418455-94518666	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032026, HPA032027, CAB032516, CAB075749	Enhanced		Enhanced	Peroxisomes	Colorectal cancer:1.16e-5 (favourable), Renal cancer:4.84e-5 (favourable)	Expressed in all	Expressed in all			liver: 66.4	Expressed in all		
ABCD4	EST352188, P70R, PMP69, PXMP1L	ENSG00000119688	ATP binding cassette subfamily D member 4	14	74285423-74303056	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003396	Approved					Expressed in all	Expressed in all			fallopian tube: 13.8	Expressed in all		
ABCG5	STSL	ENSG00000138075	ATP binding cassette subfamily G member 5	2	43812472-43838865	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016514			Approved	Nucleus	Liver cancer:2.60e-5 (favourable)	Tissue enriched	Group enriched	32	duodenum: 56.5;liver: 28.4;small intestine: 56.2	gallbladder: 1.4	Cell line enriched	37	Hep G2: 6.3
ABCG8	GBD4	ENSG00000143921	ATP binding cassette subfamily G member 8	2	43838964-43878466	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019556	Uncertain		Approved	Vesicles		Tissue enriched	Group enriched	25	duodenum: 50.0;liver: 34.0;small intestine: 55.5	gallbladder: 1.8	Cell line enriched	44	Hep G2: 6.9
ABHD12	ABHD12A, BEM46L2, C20orf22, dJ965G21.2, DKFZP434P106	ENSG00000100997	Abhydrolase domain containing 12	20	25294743-25390983	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026866	Uncertain				Cervical cancer:1.30e-5 (favourable), Breast cancer:3.81e-5 (unfavourable), Liver cancer:7.18e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 137.3	Expressed in all		
ABHD5	CGI-58, NCIE2	ENSG00000011198	Abhydrolase domain containing 5	3	43690113-43734371	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB020685, HPA035851, HPA035852	Approved		Approved	Vesicles	Renal cancer:9.17e-5 (favourable), Colorectal cancer:8.89e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 50.6	Expressed in all		
ACACA	ACAC, ACC, ACC1	ENSG00000278540	Acetyl-CoA carboxylase alpha	17	37084988-37406818	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB013715, HPA036650, HPA063018	Approved		Supported	Nucleoli fibrillar center<br>Actin filaments<br>Cytosol	Liver cancer:1.24e-5 (unfavourable)	Expressed in all	Mixed			breast: 28.8	Expressed in all		
ACADL	ACAD4, LCAD	ENSG00000115361	Acyl-CoA dehydrogenase, long chain	2	210187939-210225491	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA011990	Enhanced	Supported			Renal cancer:1.58e-11 (favourable)	Group enriched	Tissue enhanced		thyroid gland: 32.0	prostate: 27.0	Cell line enhanced		HAP1: 1.6;HeLa: 2.5;RPTEC TERT1: 2.5;U-2 OS: 1.9
ACADM	ACAD1, MCAD, MCADH	ENSG00000117054	Acyl-CoA dehydrogenase, C-4 to C-12 straight chain	1	75724347-75787575	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006198, HPA026542	Enhanced		Enhanced	Mitochondria	Renal cancer:3.83e-8 (favourable), Colorectal cancer:7.30e-4 (favourable)	Expressed in all	Expressed in all			kidney: 328.0	Expressed in all		
ACADS	ACAD3, SCAD	ENSG00000122971	Acyl-CoA dehydrogenase, C-2 to C-3 short chain	12	120725735-120740008	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004799, CAB019284, HPA022271	Enhanced		Enhanced	Mitochondria	Renal cancer:3.33e-6 (favourable), Urothelial cancer:6.34e-5 (favourable), Liver cancer:2.43e-4 (favourable), Endometrial cancer:5.05e-4 (favourable), Glioma:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 81.2	Cell line enhanced		HMC-1: 30.0
ACADSB	ACAD7, SBCAD	ENSG00000196177	Acyl-CoA dehydrogenase, short/branched chain	10	123008979-123058311	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041458	Enhanced		Supported	Mitochondria	Renal cancer:6.37e-12 (favourable), Pancreatic cancer:3.40e-4 (favourable)	Expressed in all	Expressed in all			liver: 186.7	Expressed in all		
ACADVL	ACAD6, LCACD, VLCAD	ENSG00000072778	Acyl-CoA dehydrogenase, very long chain	17	7217125-7225273	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019006, HPA020595	Enhanced		Supported	Nucleus<br>Nucleoli<br>Mitochondria	Pancreatic cancer:6.87e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 453.7	Expressed in all		
ACAT1	ACAT, THIL	ENSG00000075239	Acetyl-CoA acetyltransferase 1	11	108121516-108147776	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004428, HPA007569	Enhanced		Enhanced	Mitochondria	Renal cancer:0.00e+0 (favourable), Liver cancer:1.43e-5 (favourable)	Expressed in all	Expressed in all			kidney: 534.2	Expressed in all		
ACO2	ACONM	ENSG00000100412	Aconitase 2	22	41469125-41528989	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001097	Enhanced	Supported	Supported	Mitochondria	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			heart muscle: 308.9	Expressed in all		
ACOX1	PALMCOX	ENSG00000161533	Acyl-CoA oxidase 1	17	75941507-75979363	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB021094, HPA021192, HPA021195, HPA028759	Approved		Enhanced	Nucleus<br>Vesicles	Renal cancer:5.25e-7 (favourable)	Expressed in all	Expressed in all			liver: 98.4	Expressed in all		
ACP2	LAP	ENSG00000134575	Acid phosphatase 2, lysosomal	11	47239302-47248906	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 41.2	Expressed in all		
ACP5	HPAP, TRAP	ENSG00000102575	Acid phosphatase 5, tartrate resistant	19	11574660-11579008	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002584, HPA057655, HPA059463	Enhanced		Approved	Cytosol		Expressed in all	Tissue enhanced		lung: 254.0	lymph node: 86.3	Cell line enhanced		BEWO: 36.2;SK-MEL-30: 85.3;U-138 MG: 97.5
ACPT		ENSG00000142513	Acid phosphatase, testicular	19	50790415-50795224	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 1.4;testis: 2.2	parathyroid gland: 0.5	Cell line enhanced		HEK93: 1.3;U-266/84: 1.3
ACSL4	ACS4, FACL4, LACS4, MRX63, MRX68	ENSG00000068366	Acyl-CoA synthetase long-chain family member 4	X	109624244-109733403	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000286, HPA005552	Enhanced		Approved	Golgi apparatus<br>Mitochondria	Urothelial cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 70.7	Cell line enhanced		HMC-1: 324.7
ACSL6	ACS2, FACL6, KIAA0837, LACS2, LACS5	ENSG00000164398	Acyl-CoA synthetase long-chain family member 6	5	131949973-132012243	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040470	Enhanced					Group enriched	Group enriched	6	bone marrow: 18.0;cerebral cortex: 61.9;parathyroid gland: 22.5;seminal vesicle: 29.0;testis: 51.4	adrenal gland: 6.4	Group enriched	6	SCLC-21H: 13.0;U-937: 5.2
ACTN2		ENSG00000077522	Actinin alpha 2	1	236686454-236764631	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA006035, HPA008315	Enhanced					Tissue enhanced	Group enriched	28	heart muscle: 477.5;skeletal muscle: 758.7	esophagus: 22.4	Cell line enhanced		HEK93: 1.8;HSkMC: 5.5;hTEC/SVTERT24-B: 4.9
ACVR1	ACVR1A, ACVRLK2, ALK2, SKR1	ENSG00000115170	Activin A receptor type 1	2	157736444-157875862	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007505, HPA046514	Approved		Approved	Nucleoli<br>Cytosol	Urothelial cancer:5.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.2	Mixed		
ACVR1B	ActRIB, ACVRLK4, ALK4, SKR2	ENSG00000135503	Activin A receptor type 1B	12	51951667-51997078	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026126, HPA063761	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 54.6	Expressed in all		
ACVR2B	ActR-IIB	ENSG00000114739	Activin A receptor type 2B	3	38453851-38493142	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA007398, CAB025115, HPA040384	Approved		Approved	Nucleus<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 6.4	Cell line enhanced		AF22: 20.5;NTERA-2: 25.8
ACVRL1	ACVRLK1, ALK1, HHT, HHT2, ORW2	ENSG00000139567	Activin A receptor like type 1	12	51906908-51923361	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007041	Approved					Expressed in all	Tissue enhanced		placenta: 126.4	lung: 76.4	Cell line enhanced		ASC diff: 42.2;EFO-21: 52.0;HUVEC TERT2: 171.4;TIME: 130.8
ACY1		ENSG00000243989	Aminoacylase 1	3	51983278-51989202	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003695, HPA036174, HPA036175	Enhanced				Renal cancer:2.93e-4 (favourable), Urothelial cancer:6.77e-4 (favourable)	Expressed in all	Group enriched	5	duodenum: 130.8;kidney: 356.0;liver: 114.9;small intestine: 103.3	parathyroid gland: 35.0	Mixed		
ADAM10	CD156c, HsT18717, kuz, MADM	ENSG00000137845	ADAM metallopeptidase domain 10	15	58588807-58749978	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB001709, HPA050670	Approved		Supported	Vesicles<br>Plasma membrane	Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 47.9	Expressed in all		
ADAM17	CD156B, cSVP, TACE	ENSG00000151694	ADAM metallopeptidase domain 17	2	9488486-9555792	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA010738, CAB025906, HPA051575	Approved		Supported	Cytosol	Urothelial cancer:4.23e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 33.8	Expressed in all		
ADAMTS13	C9orf8, DKFZp434C2322, FLJ42993, MGC118899, MGC118900, TTP, vWF-CP, VWFCP	ENSG00000160323	ADAM metallopeptidase with thrombospondin type 1 motif 13	9	133414358-133459402	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042014, HPA042844	Uncertain					Mixed	Mixed			liver: 6.2	Mixed		
ADAMTS2	ADAM-TS2, ADAMTS-3, hPCPNI, NPI, PCINP	ENSG00000087116	ADAM metallopeptidase with thrombospondin type 1 motif 2	5	179110851-179345430	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028444	Uncertain		Approved	Vesicles<br>Plasma membrane	Renal cancer:1.71e-8 (unfavourable)	Expressed in all	Mixed			placenta: 14.7	Cell line enhanced		HHSteC: 100.5;HSkMC: 69.6
ADAR	ADAR1, G1P1, IFI4	ENSG00000160710	Adenosine deaminase, RNA specific	1	154582062-154627999	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003890, HPA051519, CAB056157	Enhanced		Enhanced	Nucleus<br>Nucleoli	Renal cancer:7.30e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 121.4	Expressed in all		
ADCY1	AC1, DFNB44	ENSG00000164742	Adenylate cyclase 1	7	45574140-45723116	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018364, HPA068274	Uncertain		Approved	Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 35.0	cervix, uterine: 8.2	Cell line enhanced		hTERT-HME1: 17.5;SCLC-21H: 16.1;SH-SY5Y: 27.5;SK-MEL-30: 23.8;WM-115: 17.1
ADCY10	HCA2, RP1-313L4.2, SAC, SACI, Sacy	ENSG00000143199	Adenylate cyclase 10, soluble	1	167809388-167914215	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015243, HPA017749	Approved					Tissue enhanced	Tissue enriched	11	testis: 33.1	liver: 3.1	Cell line enhanced		T-47d: 1.3
ADCY5	AC5	ENSG00000173175	Adenylate cyclase 5	3	123282296-123449758	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017730, HPA077682	Uncertain		Enhanced	Intermediate filaments	Renal cancer:7.46e-6 (favourable)	Mixed	Tissue enhanced		heart muscle: 69.1	prostate,seminal vesicle: 30.0	Cell line enhanced		MCF7: 11.9;RPTEC TERT1: 4.0
ADCY6	AC6	ENSG00000174233	Adenylate cyclase 6	12	48766194-48789037	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018365	Approved		Approved	Golgi apparatus	Liver cancer:8.23e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 44.6	Mixed		
ADGRG1	GPR56, TM7LN4, TM7XN1	ENSG00000205336	Adhesion G protein-coupled receptor G1	16	57610652-57665580	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046065	Uncertain				Renal cancer:5.52e-7 (favourable), Head and neck cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 349.0	Cell line enhanced		SK-MEL-30: 229.9
ADGRG2	EDDM6, GPR64, HE6, TM7LN2	ENSG00000173698	Adhesion G protein-coupled receptor G2	X	18989309-19122637	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001478, HPA050029	Enhanced		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	6	epididymis: 1494.8	parathyroid gland: 240.0	Cell line enhanced		A549: 5.4;BEWO: 7.0;NTERA-2: 6.3;SH-SY5Y: 6.9;U-2197: 13.5
ADGRG6	FLJ14937, GPR126	ENSG00000112414	Adhesion G protein-coupled receptor G6	6	142301854-142446266	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017346	Approved				Pancreatic cancer:2.78e-5 (unfavourable), Lung cancer:8.78e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 67.2	liver: 36.9	Cell line enhanced		HUVEC TERT2: 133.3;MCF7: 118.0
ADGRV1	DKFZp761P0710, FEB4, GPR98, KIAA0686, MASS1, USH2C, VLGR1	ENSG00000164199	Adhesion G protein-coupled receptor V1	5	90529344-91164437	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA067503	Approved		Approved	Lipid droplets		Mixed	Tissue enriched	11	adrenal gland: 261.4	kidney: 22.9	Cell line enhanced		AF22: 15.3;HAP1: 23.8;NTERA-2: 11.7;SCLC-21H: 13.1
ADSL		ENSG00000239900	Adenylosuccinate lyase	22	40346500-40390463	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000525, CAB019285	Enhanced		Enhanced	Cytosol	Liver cancer:5.81e-8 (unfavourable), Colorectal cancer:2.38e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 127.3	Expressed in all		
ADSSL1	FLJ38602	ENSG00000185100	Adenylosuccinate synthase like 1	14	104724186-104747325	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.99e-4 (unfavourable)	Mixed	Tissue enriched	7	skeletal muscle: 428.0	heart muscle: 63.0	Cell line enhanced		EFO-21: 13.7;MCF7: 10.4;SiHa: 23.7
AFG3L2	SCA28, SPAX5	ENSG00000141385	AFG3 like matrix AAA peptidase subunit 2	18	12328944-12377314	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA004479, HPA004480	Enhanced		Enhanced	Mitochondria	Renal cancer:6.05e-14 (favourable), Endometrial cancer:8.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 123.6	Expressed in all		
AGA	ASRG	ENSG00000038002	Aspartylglucosaminidase	4	177430770-177442503	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031415, HPA031417	Enhanced				Liver cancer:1.99e-4 (unfavourable), Head and neck cancer:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 35.3	Expressed in all		
AGBL1	CCP4, FLJ32310	ENSG00000273540	ATP/GTP binding protein like 1	15	86079973-87029052	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		lung: 1.3;skeletal muscle: 4.4	esophagus: 1.0	Not detected		
AGBL5	CCP5, FLJ21839	ENSG00000084693	ATP/GTP binding protein like 5	2	27042364-27070622	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030981	Uncertain		Supported	Microtubules<br>Cytokinetic bridge<br>Cytosol	Liver cancer:6.87e-5 (unfavourable)	Expressed in all	Tissue enriched	7	testis: 357.5	parathyroid gland: 50.4	Expressed in all		
AGK	FLJ10842, MULK	ENSG00000006530	Acylglycerol kinase	7	141551189-141655244	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020959, HPA053471	Supported		Supported	Vesicles<br>Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 26.9	Expressed in all		
AGL		ENSG00000162688	Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase	1	99850084-99924023	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA028498, HPA054340	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.73e-10 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 90.3	parathyroid gland: 35.1	Mixed		
AGPAT2	BSCL, LPAAT-beta	ENSG00000169692	1-acylglycerol-3-phosphate O-acyltransferase 2	9	136673143-136687423	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA019544	Uncertain		Approved	Centrosome		Expressed in all	Expressed in all			adipose tissue: 300.1	Mixed		
AGPS	ADAP-S, ADAS, ADHAPS, ADPS, ALDHPSY	ENSG00000018510	Alkylglycerone phosphate synthase	2	177392644-177559299	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030209, HPA030210, HPA030211	Supported		Enhanced	Peroxisomes	Liver cancer:8.62e-6 (unfavourable), Pancreatic cancer:8.35e-4 (unfavourable), Renal cancer:9.45e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 50.4	Mixed		
AGXT	AGT, AGT1, AGXT1, PH1, SPAT, SPT	ENSG00000172482	Alanine-glyoxylate aminotransferase	2	240868479-240880502	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035370, HPA035371	Enhanced		Supported	Vesicles	Liver cancer:5.92e-5 (favourable)	Tissue enriched	Tissue enriched	58	liver: 611.6	kidney: 10.4	Cell line enhanced		Hep G2: 5.6;SK-BR-3: 1.1
AHCY	SAHH	ENSG00000101444	Adenosylhomocysteinase	20	34280268-34311802	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041225, HPA044675	Approved		Supported	Cytosol		Expressed in all	Expressed in all			kidney: 159.4	Expressed in all		
AICDA	AID, ARP2, CDA2, HIGM2	ENSG00000111732	Activation induced cytidine deaminase	12	8602166-8612871	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	11	appendix: 4.9;lymph node: 18.7;tonsil: 11.0	spleen: 1.0	Group enriched	5	Daudi: 101.6;U-698: 81.2
AK1		ENSG00000106992	Adenylate kinase 1	9	127866480-127877743	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006456, CAB009893	Enhanced		Supported	Cytosol	Stomach cancer:7.31e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 774.9	Mixed		
AK2		ENSG00000004455	Adenylate kinase 2	1	33007940-33080996	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018479	Approved				Breast cancer:4.37e-4 (favourable), Pancreatic cancer:6.40e-4 (unfavourable), Endometrial cancer:8.65e-4 (unfavourable), Liver cancer:9.32e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 183.3	Expressed in all		
AKR1C4	3-alpha-HSD, C11, CDR, CHDR, DD4, HAKRA, MGC22581	ENSG00000198610	Aldo-keto reductase family 1 member C4	10	5195462-5218949	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044720, HPA068265	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol		Tissue enriched	Tissue enriched	6	liver: 360.3	gallbladder: 64.2	Cell line enriched	8	HDLM-2: 6.1
AKT1	AKT, PKB, PRKBA, RAC	ENSG00000142208	AKT serine/threonine kinase 1	14	104769349-104795751	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA002891, CAB003765	Enhanced		Supported	Nucleus<br>Microtubules	Renal cancer:2.12e-4 (favourable), Ovarian cancer:4.83e-4 (favourable)	Expressed in all	Expressed in all			prostate: 106.4	Expressed in all		
AKT2		ENSG00000105221	AKT serine/threonine kinase 2	19	40230317-40285536	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004204, HPA064521	Uncertain		Supported	Nucleus<br>Vesicles<br>Cytosol	Endometrial cancer:1.05e-6 (unfavourable), Prostate cancer:4.74e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 170.1	Expressed in all		
AKT3	PKBG, PRKBG, RAC-gamma	ENSG00000117020	AKT serine/threonine kinase 3	1	243488233-243851079	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB013090, HPA026441	Approved		Supported	Cytosol	Urothelial cancer:9.27e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 51.6	Mixed		
ALAS2	ASB	ENSG00000158578	5'-aminolevulinate synthase 2	X	55009055-55031064	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001638	Approved					Mixed	Tissue enriched	7	bone marrow: 335.6	placenta: 51.0	Group enriched	173	HEL: 42.0;K-562: 61.5
ALDH18A1	GSAS, P5CS, PYCS, SPG9	ENSG00000059573	Aldehyde dehydrogenase 18 family member A1	10	95605929-95656706	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008333, HPA012604	Approved		Enhanced	Mitochondria	Renal cancer:3.60e-9 (unfavourable), Endometrial cancer:4.20e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 89.5	Expressed in all		
ALDH1A3	ALDH6, RALDH3	ENSG00000184254	Aldehyde dehydrogenase 1 family member A3	15	100877714-100916626	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046271, HPA064749	Enhanced		Enhanced	Nucleus<br>Cytosol		Group enriched	Tissue enhanced		prostate: 217.5	adipose tissue: 74.8	Cell line enhanced		HaCaT: 383.6;HBEC3-KT: 772.3;U-2197: 565.6;U-87 MG: 467.6;WM-115: 498.3
ALDH3A2	ALDH10, FALDH, SLS	ENSG00000072210	Aldehyde dehydrogenase 3 family member A2	17	19648136-19677598	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014769, CAB020692	Approved				Renal cancer:3.85e-8 (favourable)	Expressed in all	Expressed in all			adrenal gland: 179.0	Cell line enhanced		A549: 115.6
ALDH4A1	ALDH4, P5CDh	ENSG00000159423	Aldehyde dehydrogenase 4 family member A1	1	18871430-18902781	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004645, HPA006401	Enhanced				Cervical cancer:5.06e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 185.7;liver: 108.1	adipose tissue: 63.8	Expressed in all		
ALDH5A1	SSADH, SSDH	ENSG00000112294	Aldehyde dehydrogenase 5 family member A1	6	24494852-24537207	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029715, HPA029716	Enhanced		Enhanced	Mitochondria	Liver cancer:7.61e-6 (favourable), Renal cancer:3.68e-4 (favourable), Ovarian cancer:6.20e-4 (favourable)	Expressed in all	Expressed in all			liver: 46.8	Cell line enhanced		Daudi: 88.4;U-698: 105.9
ALDH6A1	MMSDH	ENSG00000119711	Aldehyde dehydrogenase 6 family member A1	14	74056850-74084493	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029072, HPA029073, HPA029074, HPA029075	Enhanced		Enhanced	Mitochondria	Renal cancer:2.00e-15 (favourable), Lung cancer:4.22e-4 (favourable)	Expressed in all	Expressed in all			kidney: 389.6	Expressed in all		
ALDH7A1	ATQ1, EPD, PDE	ENSG00000164904	Aldehyde dehydrogenase 7 family member A1	5	126531200-126595418	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023296	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:3.08e-4 (favourable)	Expressed in all	Expressed in all			kidney: 120.6	Mixed		
ALDOA		ENSG00000149925	Aldolase, fructose-bisphosphate A	16	30053090-30070457	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004177, CAB006252	Enhanced		Supported	Cytosol	Liver cancer:5.79e-5 (unfavourable), Lung cancer:7.32e-5 (unfavourable)	Expressed in all	Tissue enriched	7	skeletal muscle: 9377.0	esophagus: 1428.8	Expressed in all		
ALDOB		ENSG00000136872	Aldolase, fructose-bisphosphate B	9	101420578-101435823	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002198, CAB020827	Enhanced					Tissue enriched	Group enriched	23	duodenum: 3705.7;kidney: 6574.8;liver: 5092.2;small intestine: 5611.2	gallbladder: 231.1	Cell line enhanced		BEWO: 16.8;NB-4: 10.8;RPMI-8226: 13.6;SH-SY5Y: 17.3
ALG1	CDG1K, HMAT1, HMT-1, Mat-1	ENSG00000033011	ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase	16	5033960-5087379	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA060392	Approved		Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum	Colorectal cancer:5.79e-4 (favourable), Testis cancer:6.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.4	Expressed in all		
ALG11	CDG1P, KIAA0266	ENSG00000253710	ALG11, alpha-1,2-mannosyltransferase	13	52012398-52029664	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047214	Approved					Mixed	Expressed in all			thyroid gland: 23.6	Expressed in all		
ALG12	CDG1G, ECM39	ENSG00000182858	ALG12, alpha-1,6-mannosyltransferase	22	49900229-49918458	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA003076, HPA051665	Approved		Approved	Endoplasmic reticulum	Renal cancer:3.60e-5 (favourable), Endometrial cancer:6.09e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.2	Expressed in all		
ALG13	CDG1S, CXorf45, FLJ23018, GLT28D1, MDS031, TDRD13, YGL047W	ENSG00000101901	ALG13, UDP-N-acetylglucosaminyltransferase subunit	X	111665811-111760649	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002853	Approved				Renal cancer:1.10e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 30.4	Expressed in all		
ALG2	CDG1I, CDGIi, FLJ14511, hALPG2, NET38	ENSG00000119523	ALG2, alpha-1,3/1,6-mannosyltransferase	9	99216426-99221956	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041512, HPA041601	Approved		Enhanced	Actin filaments<br>Cytosol	Renal cancer:2.28e-7 (favourable), Endometrial cancer:8.44e-5 (favourable), Head and neck cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 77.1	Expressed in all		
ALG3	CDGS4, D16Ertd36e, Not56, NOT56L	ENSG00000214160	ALG3, alpha-1,3- mannosyltransferase	3	184242301-184249548	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA045103	Approved				Liver cancer:1.58e-5 (unfavourable), Lung cancer:8.67e-5 (unfavourable), Renal cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.4	Expressed in all		
ALG6		ENSG00000088035	ALG6, alpha-1,3-glucosyltransferase	1	63367590-63438562	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA062536			Supported	Endoplasmic reticulum	Renal cancer:2.63e-6 (unfavourable), Colorectal cancer:4.86e-4 (favourable), Liver cancer:9.46e-4 (unfavourable)	Expressed in all	Mixed			placenta: 11.9	Expressed in all		
ALG8	MGC2840	ENSG00000159063	ALG8, alpha-1,3-glucosyltransferase	11	78100936-78139660	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA051898	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 86.2	Expressed in all		
ALG9	DIBD1	ENSG00000086848	ALG9, alpha-1,2-mannosyltransferase	11	111782195-111871581	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038575	Approved		Approved	Endoplasmic reticulum	Renal cancer:7.29e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
ALOX12	12S-LOX	ENSG00000108839	Arachidonate 12-lipoxygenase, 12S type	17	6996065-7010736	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA010691, CAB019287	Approved		Supported	Nuclear speckles<br>Cytosol		Mixed	Group enriched	8	esophagus: 50.3;skin: 25.9	gallbladder: 5.0	Group enriched	5	A-431: 22.4;HEL: 36.7
ALOX15	15-LOX-1	ENSG00000161905	Arachidonate 15-lipoxygenase	17	4630902-4642294	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004962, CAB004963, HPA013859	Approved					Mixed	Tissue enhanced		fallopian tube: 19.6;lung: 9.8	breast: 4.7	Group enriched	7	HMC-1: 13.6;MCF7: 10.8;T-47d: 3.9
ALOXE3	E-LOX, eLOX3	ENSG00000179148	Arachidonate lipoxygenase 3	17	8095900-8119047	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023120, HPA078597	Enhanced		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	16	skin: 36.5	breast: 2.2	Cell line enhanced		A-431: 5.5;HBEC3-KT: 7.2;hTCEpi: 5.2;hTERT-HME1: 10.5;T-47d: 4.1
ALPL	HOPS, TNSALP	ENSG00000162551	Alkaline phosphatase, liver/bone/kidney	1	21509372-21578412	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007105, HPA008765, CAB020829	Enhanced		Approved	Cytosol	Melanoma:7.08e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 78.8	kidney: 47.2	Group enriched	8	HAP1: 31.9;HSkMC: 126.3;hTEC/SVTERT24-B: 139.0;LHCN-M2: 85.3;NTERA-2: 40.7;SCLC-21H: 103.8
AMACR	P504S, RACE	ENSG00000242110	Alpha-methylacyl-CoA racemase	5	33986178-34008108	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB001809, HPA019527, HPA020912	Enhanced		Supported	Vesicles<br>Plasma membrane	Colorectal cancer:7.11e-4 (favourable)	Expressed in all	Expressed in all			kidney: 135.3	Expressed in all		
AMHR2	MISR2, MISRII	ENSG00000135409	Anti-Mullerian hormone receptor type 2	12	53423855-53431534	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		adrenal gland: 32.1;ovary: 40.9	testis: 10.1	Group enriched	19	HEL: 36.1;K-562: 19.9
AMPD1	MAD, MADA	ENSG00000116748	Adenosine monophosphate deaminase 1	1	114673090-114695618	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA026478, HPA028080	Enhanced					Mixed	Tissue enriched	12	skeletal muscle: 193.6	duodenum: 16.5	Cell line enriched	32	U-266/70: 6.6
AMPD2	SPG63	ENSG00000116337	Adenosine monophosphate deaminase 2	1	109616104-109632051	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027137, HPA045760, HPA050590	Approved	Approved	Enhanced	Cytosol	Renal cancer:3.78e-10 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 82.4	Expressed in all		
AMPD3		ENSG00000133805	Adenosine monophosphate deaminase 3	11	10308313-10507579	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038662, HPA047408	Uncertain		Enhanced	Nuclear membrane	Endometrial cancer:2.37e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 54.4	bone marrow: 41.4	Cell line enhanced		BJ hTERT+: 35.8
AMT	GCST, NKH	ENSG00000145020	Aminomethyltransferase	3	49416775-49422753	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005566	Supported		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.90e-8 (favourable)	Expressed in all	Mixed			parathyroid gland: 23.2	Group enriched	12	BEWO: 14.2;Hep G2: 30.0;NTERA-2: 7.6;SH-SY5Y: 11.8
ANK1	ANK, SPH1	ENSG00000029534	Ankyrin 1	8	41653220-41896762	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA004842, HPA056953	Supported					Mixed	Tissue enriched	5	skeletal muscle: 348.3	heart muscle: 63.9	Group enriched	5	HEL: 84.7;K-562: 96.3;RH-30: 157.8
ANK2	LQT4	ENSG00000145362	Ankyrin 2	4	112818109-113383740	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA008007, CAB015178, HPA035970	Enhanced		Supported	Plasma membrane	Renal cancer:2.41e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 184.4	kidney: 125.1	Cell line enhanced		RH-30: 60.5;SH-SY5Y: 33.1
ANKH	ANK, CCAL2, CMDJ, CPPDD, HANK	ENSG00000154122	ANKH inorganic pyrophosphate transport regulator	5	14704804-14871778	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA068104			Approved	Cytosol	Glioma:7.64e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 49.4	Mixed		
ANO3	C11orf25, DYT23, GENX-3947, TMEM16C	ENSG00000134343	Anoctamin 3	11	26309599-26663288	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041629	Uncertain					Not detected	Tissue enriched	6	epididymis: 62.2	cerebral cortex: 10.5	Cell line enhanced		HDLM-2: 5.9;U-2 OS: 1.7;U-2197: 4.2
ANO5	GDD1, LGMD2L, TMEM16E	ENSG00000171714	Anoctamin 5	11	22193176-22283357	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA058857	Uncertain				Renal cancer:2.50e-7 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 56.1	skeletal muscle: 23.6	Cell line enhanced		A549: 4.5;HAP1: 5.6;HEK93: 6.2
ANO6	DKFZp313M0720, TMEM16F	ENSG00000177119	Anoctamin 6	12	45215987-45440404	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038958	Approved		Approved	Plasma membrane<br>Cytosol	Breast cancer:7.56e-5 (unfavourable), Cervical cancer:3.82e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 91.1	Expressed in all		
ANXA5	ANX5, ENX2	ENSG00000164111	Annexin A5	4	121667955-121697113	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB003677, HPA035330	Approved		Approved	Nuclear membrane	Renal cancer:9.29e-7 (unfavourable), Liver cancer:1.64e-5 (unfavourable), Head and neck cancer:3.01e-5 (unfavourable), Urothelial cancer:1.26e-4 (unfavourable), Endometrial cancer:3.64e-4 (favourable), Stomach cancer:7.19e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 616.2	Expressed in all		
APCS	MGC88159, PTX2, SAP	ENSG00000132703	Amyloid P component, serum	1	159587825-159588865	Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	CAB007817, HPA053294	Supported					Tissue enriched	Tissue enriched	25	liver: 1851.8	gallbladder: 73.5	Cell line enhanced		RH-30: 1.1
APRT		ENSG00000198931	Adenine phosphoribosyltransferase	16	88809339-88811944	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026681	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skin: 112.4	Expressed in all		
AQP2		ENSG00000167580	Aquaporin 2	12	49950741-49958881	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046834	Enhanced					Group enriched	Group enriched	132	kidney: 435.9;seminal vesicle: 302.5	testis: 2.8	Cell line enhanced		EFO-21: 3.0;HMC-1: 1.7
AQP5		ENSG00000161798	Aquaporin 5	12	49961870-49965681	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA065008	Enhanced		Approved	Plasma membrane	Head and neck cancer:1.75e-5 (favourable)	Tissue enhanced	Group enriched	8	salivary gland: 255.6;stomach: 53.3;testis: 176.4	breast: 21.1	Group enriched	9	CAPAN-2: 7.6;REH: 9.2
ARG1		ENSG00000118520	Arginase 1	6	131573144-131584332	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003595, CAB009434, HPA024006, CAB056159	Enhanced					Tissue enriched	Tissue enhanced		bone marrow: 171.2;liver: 566.2	skin: 78.2	Not detected		
ARSA		ENSG00000100299	Arylsulfatase A	22	50622754-50628173	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005554, CAB025183	Enhanced		Uncertain	Golgi apparatus<br>Cytosol	Endometrial cancer:2.96e-5 (favourable)	Expressed in all	Expressed in all			testis: 37.4	Cell line enhanced		Karpas-707: 58.2
ARSB		ENSG00000113273	Arylsulfatase B	5	78777209-78986087	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA037770, HPA037771	Enhanced		Approved	Golgi apparatus	Urothelial cancer:3.42e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 18.2	Expressed in all		
ARV1		ENSG00000173409	ARV1 homolog, fatty acid homeostasis modulator	1	230978981-231000595	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035709	Approved		Approved	Vesicles	Lung cancer:3.27e-5 (favourable), Colorectal cancer:1.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 61.9	Expressed in all		
ASAH1	AC, ACDase, ASAH, FLJ21558, PHP32	ENSG00000104763	N-acylsphingosine amidohydrolase 1	8	18055992-18084998	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005468	Supported				Renal cancer:3.08e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 547.6	Expressed in all		
ASL		ENSG00000126522	Argininosuccinate lyase	7	66075798-66093558	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003696, HPA016646	Supported		Approved	Cytosol	Cervical cancer:4.05e-6 (unfavourable)	Expressed in all	Expressed in all			liver: 97.5	Expressed in all		
ASNS		ENSG00000070669	Asparagine synthetase (glutamine-hydrolyzing)	7	97852118-97872542	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004924, HPA029318, HPA064737	Approved		Enhanced	Cytosol	Renal cancer:6.21e-7 (unfavourable), Liver cancer:9.42e-6 (unfavourable), Head and neck cancer:8.79e-5 (unfavourable), Endometrial cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.0	Expressed in all		
ASPA	ACY2, ASP	ENSG00000108381	Aspartoacylase	17	3472374-3503419	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022142, HPA022145	Enhanced		Uncertain	Cytosol		Tissue enhanced	Tissue enhanced		kidney: 39.8	cerebral cortex: 24.7	Cell line enhanced		ASC diff: 3.7;HSkMC: 5.5
ASPH	BAH, CASQ2BP1, HAAH, JCTN	ENSG00000198363	Aspartate beta-hydroxylase	8	61500556-61714640	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA055161, HPA059303	Uncertain		Supported	Endoplasmic reticulum	Renal cancer:1.57e-5 (unfavourable), Cervical cancer:8.07e-5 (unfavourable), Pancreatic cancer:1.75e-4 (unfavourable), Lung cancer:3.61e-4 (unfavourable), Thyroid cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 403.5	Mixed		
ASS1	ASS, CTLN1	ENSG00000130707	Argininosuccinate synthase 1	9	130444929-130501274	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020896, HPA020934	Enhanced		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:8.14e-9 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 1259.9;liver: 1027.3	fallopian tube: 261.5	Cell line enhanced		BJ hTERT+: 709.0;HaCaT: 734.6;RPMI-8226: 956.8;THP-1: 690.3
ATM	ATA, ATC, ATD, ATDC, TEL1, TELO1	ENSG00000149311	ATM serine/threonine kinase	11	108222484-108369102	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000102, HPA067142	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 40.8	Expressed in all		
ATP10A	ATP10C, ATPVA, ATPVC, KIAA0566	ENSG00000206190	ATPase phospholipid transporting 10A (putative)	15	25677273-25865172	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA041496, HPA042509	Uncertain				Renal cancer:6.60e-5 (unfavourable)	Expressed in all	Mixed			lung: 10.6	Cell line enhanced		BJ: 16.3;fHDF/TERT166: 22.1;HMC-1: 16.2;SK-MEL-30: 20.1
ATP13A2	CLN12, HSA9947, PARK9	ENSG00000159363	ATPase 13A2	1	16985958-17011928	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB037038, CAB037111, HPA050910, HPA054717	Approved				Liver cancer:3.33e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.8	Expressed in all		
ATP1A2	FHM2, MHP2	ENSG00000018625	ATPase Na+/K+ transporting subunit alpha 2	1	160115759-160143591	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022230	Approved					Tissue enriched	Group enriched	6	cerebral cortex: 434.2;skeletal muscle: 307.0	heart muscle: 57.5	Cell line enhanced		AF22: 50.7;HHSteC: 12.3;RH-30: 16.2;U-87 MG: 10.1
ATP1A3	DYT12	ENSG00000105409	ATPase Na+/K+ transporting subunit alpha 3	19	41966582-41997497	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB033630, HPA045367, HPA056446	Enhanced				Renal cancer:3.02e-6 (unfavourable), Pancreatic cancer:6.15e-5 (favourable), Ovarian cancer:3.44e-4 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 378.4;heart muscle: 86.0	testis: 54.5	Cell line enhanced		Daudi: 39.5;SCLC-21H: 148.3;SH-SY5Y: 57.8
ATP2A1	ATP2A, SERCA1	ENSG00000196296	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1	16	28878405-28904509	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002310, CAB032706	Enhanced		Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enriched	96	skeletal muscle: 2781.9	esophagus: 29.1	Mixed		
ATP2A2	ATP2B, DAR, SERCA2	ENSG00000174437	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2	12	110280756-110351093	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA062605, HPA067892	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			skeletal muscle: 1006.4	Expressed in all		
ATP2B3	CFAP39, CLA2, PMCA3, SCAX1	ENSG00000067842	ATPase plasma membrane Ca2+ transporting 3	X	153517676-153582939	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001583	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane		Not detected	Group enriched	8	adrenal gland: 12.1;cerebral cortex: 19.0	fallopian tube: 2.0	Cell line enhanced		SCLC-21H: 11.7;SH-SY5Y: 3.1;THP-1: 1.7;U-937: 1.9
ATP6AP2	APT6M8-9, ATP6IP2, ATP6M8-9, M8-9, PRR, RENR	ENSG00000182220	ATPase H+ transporting accessory protein 2	X	40579372-40606848	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA003156	Approved				Renal cancer:2.01e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 893.4	Expressed in all		
ATP6V0A4	a4, ATP6N1B, ATP6N2, RDRTA2, RTA1C, RTADR, Stv1, Vph1, VPP2	ENSG00000105929	ATPase H+ transporting V0 subunit a4	7	138706295-138799560	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018029, HPA064555	Enhanced		Approved	Cytosol	Renal cancer:1.32e-6 (favourable)	Tissue enriched	Group enriched	9	kidney: 69.6;salivary gland: 31.6	breast: 5.5	Cell line enriched	12	SK-BR-3: 42.2
ATP7A	MNK	ENSG00000165240	ATPase copper transporting alpha	X	77910656-78050395	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012887, HPA048107	Approved		Supported	Golgi apparatus<br>Vesicles	Renal cancer:8.38e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.3	Mixed		
ATP7B	WND	ENSG00000123191	ATPase copper transporting beta	13	51930436-52012125	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA009137, HPA013187	Supported		Supported	Golgi apparatus	Endometrial cancer:5.01e-4 (unfavourable)	Mixed	Mixed			testis: 13.9	Cell line enhanced		BEWO: 31.8;HEL: 46.9;RPTEC TERT1: 22.2
ATP8A2	ATPIB, ML-1	ENSG00000132932	ATPase phospholipid transporting 8A2	13	25372071-26025851	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA039926, HPA040033	Approved		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Group enriched	6	cerebral cortex: 26.4;testis: 10.7	adrenal gland: 2.9	Cell line enhanced		HMC-1: 19.3;SCLC-21H: 3.9
ATP8B1	ATPIC, BRIC, FIC1, PFIC, PFIC1	ENSG00000081923	ATPase phospholipid transporting 8B1	18	57646426-57803101	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018673, HPA018674	Enhanced				Colorectal cancer:2.60e-4 (favourable), Renal cancer:6.35e-4 (favourable)	Expressed in all	Expressed in all			colon: 94.6	Cell line enhanced		RT4: 171.8
ATR	FRP1, MEC1, SCKL, SCKL1	ENSG00000175054	ATR serine/threonine kinase	3	142449235-142578826	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054320			Supported	Nucleoplasm<br>Golgi apparatus	Pancreatic cancer:1.23e-5 (unfavourable), Liver cancer:8.39e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.4	Expressed in all		
ATRX	JMS, MRX52, RAD54, XH2, XNP	ENSG00000085224	ATRX, chromatin remodeler	X	77504878-77786269	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001906, CAB009372, HPA064684, CAB068176	Supported		Supported	Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 54.4	Expressed in all		
ATXN3	ATX3, JOS, MJD, SCA3	ENSG00000066427	Ataxin 3	14	92038652-92106621	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB021976, HPA024123, HPA069338	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane		Mixed	Mixed			testis: 18.6	Expressed in all		
AUH		ENSG00000148090	AU RNA binding methylglutaconyl-CoA hydratase	9	91213815-91361913	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA004171	Enhanced				Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			kidney: 65.4	Expressed in all		
AURKB	Aik2, AIM-1, ARK2, AurB, IPL1, PPP1R48, STK12, STK5	ENSG00000178999	Aurora kinase B	17	8204733-8210600	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005862, HPA037708	Enhanced		Enhanced	Nucleoplasm<br>Midbody	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.24e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 44.4	tonsil: 33.8	Mixed		
AURKC	ARK3, AurC, STK13	ENSG00000105146	Aurora kinase C	19	57230802-57235548	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034859	Uncertain					Mixed	Tissue enriched	11	testis: 73.7	spleen: 6.9	Cell line enriched	7	NTERA-2: 39.0
AXL	ARK, JTK11, Tyro7, UFO	ENSG00000167601	AXL receptor tyrosine kinase	19	41219203-41261766	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB032501, HPA037422, HPA037423	Uncertain				Renal cancer:2.53e-7 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 54.6	Mixed		
B3GALT6	beta3GalT6	ENSG00000176022	Beta-1,3-galactosyltransferase 6	1	1232265-1235041	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Expressed in all	Expressed in all			cerebral cortex: 12.0	Expressed in all		
B3GAT3	GlcAT-I	ENSG00000149541	Beta-1,3-glucuronyltransferase 3	11	62615296-62622175	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051328	Approved				Liver cancer:5.11e-6 (unfavourable), Glioma:5.96e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 36.9	Expressed in all		
B4GALNT1	beta1-4GalNAc-T, GALGT, SPG26	ENSG00000135454	Beta-1,4-N-acetyl-galactosaminyltransferase 1	12	57623410-57633355	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008968, HPA015128	Enhanced				Renal cancer:3.18e-14 (unfavourable)	Tissue enriched	Tissue enriched	6	cerebral cortex: 26.2	seminal vesicle: 4.0	Cell line enhanced		EFO-21: 33.8;HDLM-2: 29.7
B4GALT1	beta4Gal-T1, GGTB2	ENSG00000086062	Beta-1,4-galactosyltransferase 1	9	33104082-33167356	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA010806, HPA010807	Enhanced		Enhanced	Golgi apparatus	Endometrial cancer:6.85e-7 (favourable), Lung cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 140.5	Expressed in all		
B4GALT7	beta4Gal-T7, XGALT-1	ENSG00000027847	Beta-1,4-galactosyltransferase 7	5	177600100-177610347	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042330	Supported				Glioma:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 27.3	Expressed in all		
BAAT	BAT	ENSG00000136881	Bile acid-CoA:amino acid N-acyltransferase	9	101360417-101383519	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021251, HPA021330	Supported		Uncertain	Vesicles	Renal cancer:4.24e-7 (unfavourable), Liver cancer:4.97e-4 (favourable)	Tissue enriched	Tissue enriched	16	liver: 340.4	gallbladder: 21.1	Cell line enhanced		A549: 1.8
BAP1	hucep-6, KIAA0272, UCHL2	ENSG00000163930	BRCA1 associated protein 1	3	52401013-52410350	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004322, HPA028814, HPA028815, HPA055560	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.29e-7 (favourable)	Expressed in all	Expressed in all			testis: 118.2	Expressed in all		
BAZ1B	WBSCR10, WBSCR9, WSTF	ENSG00000009954	Bromodomain adjacent to zinc finger domain 1B	7	73440398-73522278	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037081, CAB037158, HPA067010	Supported		Supported	Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 54.8	Expressed in all		
BCAP31	6C6-Ag, BAP31, CDM, DXS1357E	ENSG00000185825	B-cell receptor-associated protein 31	X	153700497-153724697	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003906, CAB015350, CAB015424	Enhanced	Approved	Enhanced	Endoplasmic reticulum	Head and neck cancer:9.87e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 273.7	Expressed in all		
BCKDHA	MSU, OVD1A	ENSG00000248098	Branched chain keto acid dehydrogenase E1, alpha polypeptide	19	41397460-41425005	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036640	Supported				Renal cancer:5.33e-10 (favourable), Thyroid cancer:3.27e-5 (unfavourable), Head and neck cancer:9.37e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 56.0	Expressed in all		
BCKDHB		ENSG00000083123	Branched chain keto acid dehydrogenase E1 subunit beta	6	80106647-80346270	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA031580	Approved				Renal cancer:5.54e-9 (favourable)	Expressed in all	Expressed in all			liver: 39.9	Expressed in all		
BCKDK		ENSG00000103507	Branched chain ketoacid dehydrogenase kinase	16	31106107-31112791	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017995, HPA056067	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 34.3	Expressed in all		
BCO1	BCDO, BCDO1, BCMO, BCMO1, FLJ10730	ENSG00000135697	Beta-carotene oxygenase 1	16	81238448-81291142	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043811			Uncertain	Actin filaments<br>Microtubule organizing center		Mixed	Tissue enhanced		duodenum: 8.7;small intestine: 14.8	kidney: 3.3	Cell line enhanced		A549: 9.9;EFO-21: 7.6;HAP1: 3.2;NTERA-2: 4.4;RPTEC TERT1: 6.2
BEST1	BEST, BMD, RP50, VMD2	ENSG00000167995	Bestrophin 1	11	61949821-61965515	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA057464	Supported					Group enriched	Mixed			cerebral cortex: 17.0	Cell line enhanced		SK-MEL-30: 40.9;U-266/70: 10.4
BIRC3	API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49	ENSG00000023445	Baculoviral IAP repeat containing 3	11	102317450-102339403	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002317	Enhanced	Approved	Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.66e-6 (unfavourable), Pancreatic cancer:3.03e-4 (unfavourable), Breast cancer:3.60e-4 (favourable), Colorectal cancer:9.35e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 138.1	appendix: 117.5	Cell line enhanced		CAPAN-2: 106.1;Daudi: 77.5;HDLM-2: 96.2;hTERT-HME1: 79.1
BLK	MGC10442	ENSG00000136573	BLK proto-oncogene, Src family tyrosine kinase	8	11494001-11564604	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005093, HPA069571	Approved		Approved	Nucleoplasm		Mixed	Group enriched	10	appendix: 22.0;lymph node: 61.2;spleen: 40.6;tonsil: 51.4	urinary bladder: 4.3	Group enriched	6	Daudi: 99.9;REH: 39.4;RPMI-8226: 47.4;U-698: 55.4;U-87 MG: 29.9
BLM	BS, RECQ2, RECQL3	ENSG00000197299	Bloom syndrome RecQ like helicase	15	90717327-90816165	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005689	Approved		Supported	Nucleus<br>Cytosol		Mixed	Mixed			lymph node: 3.8	Mixed		
BLVRA	BLVR	ENSG00000106605	Biliverdin reductase A	7	43758680-43807342	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019709, HPA042865, HPA054322	Approved		Supported	Cytosol	Lung cancer:8.65e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 158.1	Mixed		
BMP1	PCOLC	ENSG00000168487	Bone morphogenetic protein 1	8	22164736-22212326	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA014572	Enhanced				Renal cancer:3.37e-9 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 21.1	smooth muscle: 10.5	Mixed		
BMPR1A	ACVRLK3, ALK3, CD292	ENSG00000107779	Bone morphogenetic protein receptor type 1A	10	86756601-86932838	Cancer-related genes, CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB019398	Approved		Approved	Cytosol	Liver cancer:8.93e-4 (unfavourable), Glioma:9.38e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 19.6	Mixed		
BMPR1B	ALK6, CDw293	ENSG00000138696	Bone morphogenetic protein receptor type 1B	4	94757968-95158448	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:2.84e-4 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 37.2;prostate: 37.0	seminal vesicle: 21.0	Cell line enhanced		A549: 21.1;SH-SY5Y: 20.1
BMPR2	BMPR-II, BMPR3, BRK-3, PPH1, T-ALK	ENSG00000204217	Bone morphogenetic protein receptor type 2	2	202376936-202567751	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA017385, HPA049014	Approved		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			placenta: 44.9	Mixed		
BPGM		ENSG00000172331	Bisphosphoglycerate mutase	7	134646808-134679813	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016493, HPA028735	Enhanced		Approved	Nucleoli	Renal cancer:1.54e-8 (favourable), Cervical cancer:7.95e-4 (favourable)	Expressed in all	Expressed in all			placenta: 65.1	Expressed in all		
BRCA1	BRCC1, FANCS, PPP1R53, RNF53	ENSG00000012048	BRCA1, DNA repair associated	17	43044295-43170245	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB001946, HPA034966, HPA057371	Enhanced					Expressed in all	Mixed			testis: 23.9	Expressed in all		
BRCC3	BRCC36, C6.1A, CXorf53	ENSG00000185515	BRCA1/BRCA2-containing complex subunit 3	X	155071420-155123074	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048737			Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 21.2	Expressed in all		
BRIP1	BACH1, FANCJ, OF	ENSG00000136492	BRCA1 interacting protein C-terminal helicase 1	17	61681266-61863521	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005474	Approved		Supported	Nucleus<br>Nuclear membrane	Colorectal cancer:3.45e-5 (favourable), Head and neck cancer:3.62e-4 (favourable)	Mixed	Tissue enhanced		testis: 14.4	bone marrow: 5.0	Cell line enhanced		MCF7: 77.7
BSND	BART, DFNB73	ENSG00000162399	Barttin CLCNK type accessory beta subunit	1	54998933-55010883	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA053836, HPA060617	Enhanced					Tissue enriched	Tissue enriched	7	kidney: 10.2	salivary gland: 1.5	Cell line enriched	15	RPMI-8226: 8.0
BTD		ENSG00000169814	Biotinidase	3	15601341-15645822	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052275	Uncertain				Renal cancer:2.60e-9 (favourable)	Expressed in all	Expressed in all			epididymis: 53.0	Mixed		
BUB1B	Bub1A, BUBR1, MAD3L, SSK1	ENSG00000156970	BUB1 mitotic checkpoint serine/threonine kinase B	15	40161023-40221136	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008419			Supported	Cytosol	Liver cancer:7.43e-6 (unfavourable), Pancreatic cancer:1.79e-4 (unfavourable), Lung cancer:3.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 40.3	lymph node: 14.9	Mixed		
C2		ENSG00000166278	Complement C2	6	31897785-31945672	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016775	Supported				Renal cancer:2.64e-7 (unfavourable)	Tissue enriched	Tissue enhanced		liver: 86.3;lung: 42.6	placenta: 21.9	Group enriched	5	Hep G2: 30.0;Karpas-707: 94.7
C6		ENSG00000039537	Complement C6	5	41142234-41261438	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	HPA043823, CAB069427	Enhanced				Renal cancer:4.31e-4 (favourable)	Group enriched	Group enriched	9	fallopian tube: 73.5;liver: 358.3	heart muscle: 23.4	Group enriched	11	ASC diff: 3.2;ASC TERT1: 4.5;HSkMC: 12.3
C8A		ENSG00000157131	Complement C8 alpha chain	1	56854806-56918221	Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	63	liver: 328.8	gallbladder: 5.2	Not detected		
CA12	HsT18816	ENSG00000074410	Carbonic anhydrase 12	15	63321378-63382161	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA008773, CAB025181, CAB062549, CAB068179, HPA073203	Enhanced		Approved	Nucleus<br>Vesicles	Pancreatic cancer:3.80e-6 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 308.4;skin: 168.3	rectum: 102.9	Cell line enhanced		A549: 191.8;RT4: 180.0;T-47d: 269.1;U-138 MG: 295.7;U-87 MG: 352.6
CA5A	CA5, CAV, CAVA	ENSG00000174990	Carbonic anhydrase 5A	16	87881546-87936529	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		liver: 1.3	bone marrow: 0.8	Cell line enhanced		Hep G2: 1.4
CACNG2	MGC138502, MGC138504, stargazin	ENSG00000166862	Calcium voltage-gated channel auxiliary subunit gamma 2	22	36563921-36703558	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	13	cerebral cortex: 15.3	adrenal gland: 1.2	Group enriched	11	SCLC-21H: 3.3;SH-SY5Y: 1.3
CAD		ENSG00000084774	Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase	2	27217390-27243943	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB007781, HPA057266, HPA069341	Supported		Supported	Nucleoplasm	Liver cancer:1.72e-11 (unfavourable), Renal cancer:1.82e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 22.0	Expressed in all		
CANT1	SCAN-1, SHAPY	ENSG00000171302	Calcium activated nucleotidase 1	17	78991717-79009867	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019627, HPA019639, HPA022818	Enhanced				Liver cancer:1.41e-4 (unfavourable), Lung cancer:2.90e-4 (unfavourable), Renal cancer:6.21e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 115.7	Expressed in all		
CAPN1	CANP, CANPL1, muCANP, muCL	ENSG00000014216	Calpain 1	11	65180566-65212006	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005992	Enhanced		Supported	Cytosol	Renal cancer:7.06e-8 (favourable), Pancreatic cancer:4.30e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 243.9	Expressed in all		
CAPN10		ENSG00000142330	Calpain 10	2	240586716-240617705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004170, HPA056098	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:4.78e-6 (unfavourable), Pancreatic cancer:7.94e-5 (favourable), Head and neck cancer:8.47e-5 (favourable)	Expressed in all	Mixed			skin,spleen: 14.5	Expressed in all		
CAPN3	CANP3, LGMD2, LGMD2A, nCL-1, p94	ENSG00000092529	Calpain 3	15	42359500-42412318	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040052	Enhanced					Tissue enriched	Tissue enhanced		epididymis: 217.3;skeletal muscle: 336.8	skin: 92.9	Cell line enriched	27	SK-MEL-30: 202.7
CAPN5	ADNIV, HTRA3, nCL-3, VRNI	ENSG00000149260	Calpain 5	11	77066932-77126155	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033237	Uncertain				Endometrial cancer:2.16e-6 (unfavourable)	Expressed in all	Mixed			colon: 61.0	Mixed		
CARS	CARS1	ENSG00000110619	Cysteinyl-tRNA synthetase	11	3000922-3057613	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737	Enhanced		Enhanced	Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.16e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.2	Mixed		
CARS2	FLJ12118	ENSG00000134905	Cysteinyl-tRNA synthetase 2, mitochondrial (putative)	13	110641412-110713603	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041776	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:2.49e-5 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Endometrial cancer:1.84e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 28.4	Expressed in all		
CASK	CAGH39, FGS4, LIN2, TNRC8	ENSG00000147044	Calcium/calmodulin dependent serine protein kinase	X	41514934-41923463	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB001949, HPA023857	Enhanced		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:6.11e-5 (unfavourable)	Expressed in all	Expressed in all			small intestine: 34.5	Mixed		
CASP10	MCH4	ENSG00000003400	Caspase 10	2	201182881-201229406	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003780, HPA017059	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:6.05e-7 (unfavourable), Liver cancer:8.54e-4 (unfavourable)	Expressed in all	Mixed			spleen: 24.1	Cell line enhanced		HUVEC TERT2: 21.4
CASP14	MGC119078, MGC119079, MICE	ENSG00000105141	Caspase 14	19	15049384-15058293	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010059, HPA027062	Enhanced		Approved	Nucleus<br>Mitochondria<br>Cytosol	Pancreatic cancer:5.96e-4 (unfavourable), Lung cancer:7.59e-4 (unfavourable)	Tissue enhanced	Tissue enriched	55	skin: 558.6	breast: 10.1	Cell line enriched	6	hTCEpi: 34.2
CASP8	Casp-8, FLICE, MACH, MCH5	ENSG00000064012	Caspase 8	2	201233443-201287711	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001302, CAB002047, HPA005688, HPA006191	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.27e-6 (unfavourable), Ovarian cancer:1.25e-4 (favourable), Liver cancer:3.02e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 44.8	Expressed in all		
CASQ1	CASQ, PDIB1	ENSG00000143318	Calsequestrin 1	1	160190556-160201886	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA007845, CAB015170, HPA026823	Enhanced		Uncertain	Nucleoplasm<br>Mitochondria	Urothelial cancer:8.93e-5 (favourable)	Mixed	Tissue enriched	33	skeletal muscle: 1514.0	esophagus: 45.3	Group enriched	9	BEWO: 18.6;HDLM-2: 35.6;RT4: 53.5
CATSPER2		ENSG00000166762	Cation channel sperm associated 2	15	43628503-43668118	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enhanced		testis: 30.8	parathyroid gland: 6.5	Mixed		
CAV1	CAV	ENSG00000105974	Caveolin 1	7	116524785-116561184	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB003791, HPA049326	Enhanced		Supported	Golgi apparatus	Lung cancer:7.17e-5 (unfavourable), Renal cancer:1.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 859.9	adipose tissue: 640.4	Cell line enhanced		LHCN-M2: 1943.1
CAV3	LGMD1C, LQT9, VIP-21, VIP21	ENSG00000182533	Caveolin 3	3	8733800-8841808	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB017518, CAB018557, HPA054488	Enhanced		Supported	Vesicles<br>Plasma membrane		Tissue enhanced	Group enriched	6	heart muscle: 14.0;skeletal muscle: 63.3	esophagus: 6.0	Group enriched	15	LHCN-M2: 19.0;RH-30: 91.1
CBL	c-Cbl, CBL2, RNF55	ENSG00000110395	Cbl proto-oncogene	11	119206276-119313926	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004350, HPA027956	Enhanced		Supported	Cytosol		Expressed in all	Mixed			testis: 33.9	Expressed in all		
CBS	HIP4	ENSG00000160200	Cystathionine-beta-synthase	21	43053191-43076943	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001223	Supported		Approved	Nucleoli<br>Vesicles		Mixed	Tissue enhanced		liver: 56.6;ovary: 31.1	cerebral cortex: 19.8	Cell line enhanced		HAP1: 171.2;HHSteC: 181.6
CD151	PETA-3, RAPH, SFA-1, TSPAN24	ENSG00000177697	CD151 molecule (Raph blood group)	11	832843-839831	Blood group antigen proteins, CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002428, HPA011906	Supported				Liver cancer:5.58e-4 (unfavourable), Thyroid cancer:6.92e-4 (favourable), Lung cancer:9.46e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 361.3	Mixed		
CD36	FAT, GP3B, GP4, GPIV, SCARB3	ENSG00000135218	CD36 molecule	7	80369575-80679277	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002018, CAB025866, HPA071026	Enhanced		Enhanced	Golgi apparatus	Stomach cancer:4.47e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 1617.9	Cell line enhanced		ASC diff: 218.9;HEL: 144.7
CD81	TAPA-1, TAPA1, TSPAN28	ENSG00000110651	CD81 molecule	11	2376177-2397419	CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002507, HPA007234	Supported		Supported	Plasma membrane	Glioma:5.12e-5 (unfavourable), Pancreatic cancer:3.86e-4 (favourable), Colorectal cancer:7.56e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 2273.0	Cell line enhanced		ASC diff: 2031.3
CDC14A	cdc14, Cdc14A1, Cdc14A2, DFNB105	ENSG00000079335	Cell division cycle 14A	1	100345025-100520277	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023783	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Tissue enhanced		testis: 56.3	fallopian tube: 19.8	Cell line enhanced		K-562: 25.8
CDK12	CRK7, CRKR, CRKRS, KIAA0904	ENSG00000167258	Cyclin dependent kinase 12	17	39461511-39564907	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008038	Supported		Supported	Nucleus		Expressed in all	Expressed in all			testis: 33.8	Expressed in all		
CDK5	PSSALRE	ENSG00000164885	Cyclin dependent kinase 5	7	151053812-151058530	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB008909, HPA064535	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 49.9	Expressed in all		
CDK9	C-2k, CDC2L4, PITALRE, TAK	ENSG00000136807	Cyclin dependent kinase 9	9	127785679-127790787	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004216, HPA006738	Supported		Approved	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:8.92e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 60.5	Expressed in all		
CDKAL1	FLJ20342	ENSG00000145996	CDK5 regulatory subunit associated protein 1 like 1	6	20534457-21232404	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057474			Uncertain	Vesicles	Endometrial cancer:1.03e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 16.0	Cell line enriched	6	SCLC-21H: 222.3
CDKL5	CFAP247, EIEE2, STK9	ENSG00000008086	Cyclin dependent kinase like 5	X	18425583-18653629	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002847, CAB011577	Supported		Enhanced	Nucleoplasm	Renal cancer:5.54e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 31.0	testis: 14.4	Mixed		
CDKN3	CDI1, KAP	ENSG00000100526	Cyclin dependent kinase inhibitor 3	14	54396849-54420218	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005285, HPA039311, HPA058874			Enhanced	Cytosol	Renal cancer:0.00e+0 (unfavourable), Lung cancer:4.52e-4 (unfavourable), Pancreatic cancer:7.46e-4 (unfavourable)	Expressed in all	Tissue enriched	11	testis: 342.6	lymph node: 31.7	Expressed in all		
CECR1	ADGF, IDGFL	ENSG00000093072	Cat eye syndrome chromosome region, candidate 1	22	17178790-17221989	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007888	Approved				Pancreatic cancer:8.91e-4 (favourable), Ovarian cancer:9.26e-4 (favourable)	Expressed in all	Expressed in all			spleen: 161.4	Cell line enhanced		CAPAN-2: 22.2;Karpas-707: 30.5;MOLT-4: 33.3;U-937: 32.1
CELSR1	ADGRC1, CDHF9, FMI2, HFMI2, ME2	ENSG00000075275	Cadherin EGF LAG seven-pass G-type receptor 1	22	46360834-46537170	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052976, HPA060521			Supported	Plasma membrane		Expressed in all	Mixed			fallopian tube: 15.5	Cell line enhanced		A549: 38.6;T-47d: 28.3
CERS3	LASS3, MGC27091	ENSG00000154227	Ceramide synthase 3	15	100400395-100544995	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006092, HPA024356	Approved		Approved	Nucleoplasm		Tissue enhanced	Group enriched	9	esophagus: 48.1;skin: 60.5;testis: 32.3;tonsil: 14.3	breast: 4.3	Cell line enriched	6	hTCEpi: 47.1
CETP	BPIFF	ENSG00000087237	Cholesteryl ester transfer protein	16	56961850-56983845	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Mixed	Group enriched	6	adipose tissue: 36.9;liver: 21.7;lymph node: 46.3;placenta: 50.4;spleen: 77.7	thyroid gland: 8.4	Cell line enhanced		HEL: 2.4;HUVEC TERT2: 3.6;TIME: 2.1
CFB	BF, BFD, H2-Bf	ENSG00000243649	Complement factor B	6	31945650-31952084	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000951, HPA001817, HPA001832, CAB016381	Supported		Approved	Endoplasmic reticulum<br>Vesicles<br>Cell Junctions	Renal cancer:1.53e-5 (unfavourable), Breast cancer:2.76e-5 (favourable)	Expressed in all	Tissue enriched	21	liver: 285.9	stomach: 13.8	Cell line enhanced		CAPAN-2: 6.6;fHDF/TERT166: 9.6;HSkMC: 14.1
CFD	ADN, DF, PFD	ENSG00000197766	Complement factor D	19	859643-863630	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA052799			Uncertain	Plasma membrane	Pancreatic cancer:1.77e-4 (favourable), Renal cancer:7.09e-4 (unfavourable)	Expressed in all	Tissue enriched	7	adipose tissue: 378.5	breast: 52.5	Group enriched	6	ASC diff: 82.6;THP-1: 121.6
CFI	C3b-INA, FI, IF, KAF	ENSG00000205403	Complement factor I	4	109740694-109802179	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA001143, CAB016777, HPA024061	Supported				Urothelial cancer:6.06e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 524.7	kidney: 221.8	Cell line enhanced		CAPAN-2: 112.1;Hep G2: 117.9;HSkMC: 48.7;RPTEC TERT1: 139.4
CHAT		ENSG00000070748	Choline O-acetyltransferase	10	49609095-49665104	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002313, HPA048547	Supported					Not detected	Tissue enriched	8	placenta: 7.2	duodenum: 0.8	Cell line enriched	9	NB-4: 7.2
CHD2	DKFZp547I1315, DKFZp686E01200, DKFZp781D1727, FLJ38614	ENSG00000173575	Chromodomain helicase DNA binding protein 2	15	92900189-93028005	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060744, HPA060960	Enhanced		Enhanced	Nucleus		Expressed in all	Expressed in all			bone marrow: 48.3	Mixed		
CHD4	Mi-2b, Mi2-BETA	ENSG00000111642	Chromodomain helicase DNA binding protein 4	12	6570083-6607476	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA012008	Supported		Enhanced	Nucleus	Liver cancer:6.03e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 119.0	Expressed in all		
CHD5		ENSG00000116254	Chromodomain helicase DNA binding protein 5	1	6101793-6180123	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015809, HPA055477	Supported		Supported	Nucleoplasm<br>Nuclear speckles<br>Cytosol		Mixed	Tissue enriched	7	cerebral cortex: 42.1	testis: 6.2	Cell line enhanced		SCLC-21H: 16.0;U-2 OS: 6.3
CHD6	CHD5, dJ620E11.1, FLJ22369, KIAA1335, RIGB	ENSG00000124177	Chromodomain helicase DNA binding protein 6	20	41402101-41618494	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015543			Approved	Nucleus	Lung cancer:3.42e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 31.5	Expressed in all		
CHD7	CRG, FLJ20357, FLJ20361, KIAA1416	ENSG00000171316	Chromodomain helicase DNA binding protein 7	8	60678778-60868028	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA053075			Supported	Nucleoplasm<br>Nucleoli	Endometrial cancer:5.34e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 14.6	Cell line enhanced		AF22: 50.9;SCLC-21H: 55.1
CHD8	DUPLIN, HELSNF1, KIAA1564	ENSG00000100888	Chromodomain helicase DNA binding protein 8	14	21385194-21456126	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA052186			Supported	Nucleoplasm	Liver cancer:4.94e-4 (unfavourable), Ovarian cancer:8.35e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.1	Expressed in all		
CHEK2	bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53	ENSG00000183765	Checkpoint kinase 2	22	28687743-28742422	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001878, CAB002030	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:7.80e-9 (unfavourable)	Expressed in all	Mixed			testis: 13.4	Expressed in all		
CHRNB1	CHRNB	ENSG00000170175	Cholinergic receptor nicotinic beta 1 subunit	17	7445061-7457707	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005822, CAB011200	Approved					Expressed in all	Expressed in all			skeletal muscle: 21.9	Cell line enhanced		LHCN-M2: 28.7;RH-30: 68.7
CHRND	ACHRD	ENSG00000135902	Cholinergic receptor nicotinic delta subunit	2	232525993-232536667	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA056404, HPA065404			Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	12	skeletal muscle: 9.6	prostate: 0.8	Cell line enriched	76	RH-30: 79.9
CHRNE	ACHRE	ENSG00000108556	Cholinergic receptor nicotinic epsilon subunit	17	4897774-4903074	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enriched	26	heart muscle: 33.9	epididymis: 1.3	Group enriched	15	HEL: 3.9;HMC-1: 9.2
CHRNG	ACHRG	ENSG00000196811	Cholinergic receptor nicotinic gamma subunit	2	232539727-232546403	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	17	skeletal muscle: 8.2	prostate: 0.4	Group enriched	21	HSkMC: 2.3;RH-30: 8.7
CHST11	C4ST, C4St-1, C4ST1, HSA269537	ENSG00000171310	Carbohydrate sulfotransferase 11	12	104455295-104762014	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052828	Approved		Approved	Golgi apparatus	Renal cancer:7.59e-11 (unfavourable), Urothelial cancer:8.42e-4 (unfavourable)	Expressed in all	Mixed			appendix: 27.6	Mixed		
CHST14	D4ST-1, D4ST1, HD4ST	ENSG00000169105	Carbohydrate sulfotransferase 14	15	40470998-40474571	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA057697, HPA071601	Approved		Approved	Vesicles		Expressed in all	Expressed in all			placenta: 38.8	Expressed in all		
CHST3	C6ST, C6ST1	ENSG00000122863	Carbohydrate sulfotransferase 3	10	71964365-72013564	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA047523, HPA055704	Enhanced		Approved	Golgi apparatus<br>Cytosol		Expressed in all	Mixed			testis: 30.7	Mixed		
CHSY1	CSS1, KIAA0990	ENSG00000131873	Chondroitin sulfate synthase 1	15	101175723-101251932	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA048902	Uncertain				Renal cancer:6.33e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 64.8	Expressed in all		
CHUK	IkBKA, IKK-alpha, IKK1, IKKA, NFKBIKA, TCF16	ENSG00000213341	Conserved helix-loop-helix ubiquitous kinase	10	100188298-100229619	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001402, CAB004240, CAB018564	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
CIITA	C2TA, MHC2TA, NLRA	ENSG00000179583	Class II major histocompatibility complex transactivator	16	10866222-10932281	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB016084	Enhanced		Approved	Nucleoplasm		Expressed in all	Mixed			lymph node,spleen: 59.2	Cell line enhanced		HDLM-2: 44.9;REH: 81.4
CIT	CITK, CRIK, KIAA0949, STK21	ENSG00000122966	Citron rho-interacting serine/threonine kinase	12	119685790-119877291	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019082, HPA048812, HPA075506	Uncertain		Approved	Cytosol		Mixed	Mixed			cerebral cortex: 10.4	Mixed		
CLCN1	ClC-1, CLC1	ENSG00000188037	Chloride voltage-gated channel 1	7	143316126-143352083	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enriched	17	skeletal muscle: 22.9	testis: 1.3	Cell line enhanced		HSkMC: 1.1;PC-3: 1.0
CLCN4	ClC-4, CLC4	ENSG00000073464	Chloride voltage-gated channel 4	X	10156945-10237660	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031313, HPA063637	Enhanced		Approved	Vesicles	Endometrial cancer:2.13e-5 (unfavourable), Pancreatic cancer:9.55e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 49.1;epididymis: 28.1	skeletal muscle: 14.6	Cell line enhanced		HEL: 21.9;SCLC-21H: 28.6
CLCN7	CLC-7, CLC7, OPTA2, PPP1R63	ENSG00000103249	Chloride voltage-gated channel 7	16	1444934-1475580	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043019, HPA043586	Supported		Supported	Nucleoplasm	Testis cancer:3.21e-4 (unfavourable), Head and neck cancer:5.23e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 41.2	Expressed in all		
CLDN1	ILVASC, SEMP1	ENSG00000163347	Claudin 1	3	190305701-190322475	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002602, HPA048319	Enhanced				Endometrial cancer:2.00e-4 (unfavourable), Pancreatic cancer:5.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 306.2;smooth muscle: 186.0	liver: 158.4	Cell line enhanced		EFO-21: 613.4;HaCaT: 206.6;hTCEpi: 206.7;RPTEC TERT1: 310.7;RT4: 210.1
CLDN16	HOMG3, PCLN1	ENSG00000113946	Claudin 16	3	190322541-190412143	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA056020	Enhanced				Endometrial cancer:1.99e-5 (unfavourable)	Group enriched	Tissue enriched	6	kidney: 51.7	thyroid gland: 8.7	Group enriched	135	EFO-21: 435.6;RPTEC TERT1: 123.6
CLDN19		ENSG00000164007	Claudin 19	1	42733093-42740254	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Group enriched	12	kidney: 19.7;placenta: 14.5	breast: 1.4	Cell line enhanced		CACO-2: 2.4;Hep G2: 4.3
CLDN3	C7orf1, CPE-R2, CPETR2, HRVP1, RVP1	ENSG00000165215	Claudin 3	7	73768997-73770270	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002702, HPA014361	Supported		Supported	Cell Junctions	Renal cancer:3.39e-5 (favourable)	Mixed	Tissue enhanced		colon: 87.7;small intestine: 119.5	duodenum: 55.0	Cell line enhanced		MCF7: 175.3;PC-3: 44.1;SCLC-21H: 68.2;T-47d: 98.9
CLDN4	CPE-R, CPETR, CPETR1, hCPE-R, WBSCR8	ENSG00000189143	Claudin 4	7	73799542-73832693	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002610	Enhanced		Supported	Plasma membrane	Renal cancer:3.46e-10 (favourable), Ovarian cancer:3.28e-4 (unfavourable)	Mixed	Mixed			colon: 208.6	Cell line enhanced		A-431: 285.9;BEWO: 354.2;CAPAN-2: 613.4;MCF7: 279.4;PC-3: 419.8;SK-BR-3: 439.0
CLIC2	XAP121	ENSG00000155962	Chloride intracellular channel 2	X	155276211-155334657	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA047381, HPA060101	Uncertain		Approved	Plasma membrane	Renal cancer:1.74e-5 (unfavourable)	Expressed in all	Mixed			spleen: 62.8	Cell line enhanced		HDLM-2: 85.0;K-562: 44.8;Karpas-707: 31.6;RPMI-8226: 54.1
CLIC5	DFNB102	ENSG00000112782	Chloride intracellular channel 5	6	45898451-46080395	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA074371			Supported	Nuclear speckles<br>Plasma membrane		Tissue enhanced	Tissue enhanced		lung: 116.1;skeletal muscle: 119.2	heart muscle: 76.0	Group enriched	7	CAPAN-2: 13.3;EFO-21: 10.0;HDLM-2: 5.7;REH: 13.6;U-266/70: 10.5
CLP1	hClp1, HEAB	ENSG00000172409	Cleavage and polyadenylation factor I subunit 1	11	57648992-57661868	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057770	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 17.0	Expressed in all		
CLPB	ANKCLB, FLJ13152, HSP78, SKD3	ENSG00000162129	ClpB homolog, mitochondrial AAA ATPase chaperonin	11	72292425-72434680	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039005, HPA039006, HPA064571	Enhanced				Renal cancer:8.36e-8 (favourable)	Expressed in all	Tissue enriched	10	testis: 176.6	parathyroid gland: 18.5	Expressed in all		
CLPP		ENSG00000125656	Caseinolytic mitochondrial matrix peptidase proteolytic subunit	19	6361452-6368908	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA010649	Supported		Enhanced	Mitochondria	Pancreatic cancer:6.50e-4 (favourable)	Expressed in all	Expressed in all			appendix: 48.3	Expressed in all		
CLRN1	RP61, USH3, USH3A	ENSG00000163646	Clarin 1	3	150926163-150972999	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA054636	Uncertain					Not detected	Group enriched	5	adrenal gland: 6.7;duodenum: 1.5	testis: 0.7	Cell line enriched	31	NTERA-2: 3.5
CNGA1	CNCG, CNCG1, CNG1, RCNC1, RCNCa, RP49	ENSG00000198515	Cyclic nucleotide gated channel alpha 1	4	47935977-48016672	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Mixed			liver: 14.2	Cell line enhanced		CAPAN-2: 9.1;RT4: 6.7;U-2 OS: 3.3
CNGA3	ACHM2, CCNC1, CCNCa, CNCG3, CNG3	ENSG00000144191	Cyclic nucleotide gated channel alpha 3	2	98346155-98398601	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA049378, CAB079025	Approved	Approved				Tissue enriched	Mixed			esophagus: 1.9	Cell line enriched	7	U-87 MG: 6.9
CNGB1	CNCG2, CNCG3L, CNGB1B, GAR1, GARP, RCNC2, RCNCb, RP45	ENSG00000070729	Cyclic nucleotide gated channel beta 1	16	57882340-57971116	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039159, HPA060355			Approved	Vesicles<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 1.6	appendix,cerebral cortex: 1.5	Cell line enhanced		SCLC-21H: 2.6;SiHa: 3.1
CNGB3	ACHM1, ACHM3, RMCH	ENSG00000170289	Cyclic nucleotide gated channel beta 3	8	86553977-86743675	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA057244	Enhanced					Not detected	Tissue enhanced		bone marrow: 2.7;testis: 3.9	fallopian tube: 2.1	Cell line enriched	19	SCLC-21H: 23.7
CNNM4	ACDP4, KIAA1592	ENSG00000158158	Cyclin and CBS domain divalent metal cation transport mediator 4	2	96760902-96811891	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017732	Enhanced		Uncertain	Plasma membrane<br>Actin filaments	Ovarian cancer:8.75e-4 (unfavourable), Endometrial cancer:9.14e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 36.9	Expressed in all		
CNTN2	AXT, TAG-1, TAX, TAX1	ENSG00000184144	Contactin 2	1	205042937-205078284	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA001397, HPA012497	Approved					Tissue enriched	Tissue enriched	7	cerebral cortex: 81.7	testis: 11.2	Group enriched	7	NTERA-2: 3.8;SCLC-21H: 11.1
COASY	CoASY, DPCK, NBP, PPAT	ENSG00000068120	Coenzyme A synthase	17	42561467-42566277	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022875, HPA022912, HPA023273	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:7.54e-5 (unfavourable), Endometrial cancer:2.15e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 60.1	Expressed in all		
COCH	COCH-5B2, DFNA31, DFNA9	ENSG00000100473	Cochlin	14	30874514-30895065	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA065086			Approved	Vesicles		Mixed	Group enriched	6	pancreas: 94.8;prostate: 79.0;seminal vesicle: 99.1	cervix, uterine: 15.4	Cell line enhanced		HEK93: 92.9;K-562: 114.9;NB-4: 71.8;SCLC-21H: 130.1
COQ2	CL640, FLJ26072	ENSG00000173085	Coenzyme Q2, polyprenyltransferase	4	83261536-83284914	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA056599, HPA068727	Approved		Approved	Cytosol		Expressed in all	Expressed in all			adrenal gland: 18.4	Expressed in all		
COQ8A	ADCK3, CABC1, COQ8, SCAR9	ENSG00000163050	Coenzyme Q8A	1	226897536-226987545	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA061662			Supported	Mitochondria		Expressed in all	Tissue enriched	6	skeletal muscle: 401.8	adrenal gland: 68.1	Cell line enhanced		HEK93: 75.6
COQ8B	ADCK4, COQ8, FLJ12229	ENSG00000123815	Coenzyme Q8B	19	40691529-40718207	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027229, HPA027277, HPA027279, HPA028303	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			fallopian tube: 41.1	Expressed in all		
CORIN	ATC2, CRN, Lrp4, PRSC, TMPRSS10	ENSG00000145244	Corin, serine peptidase	4	47593998-47838106	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA070941			Approved	Nuclear bodies<br>Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		heart muscle: 38.6	skin: 9.4	Group enriched	6	ASC diff: 7.2;ASC TERT1: 31.6
COX4I2	COX4-2, COX4B, COX4L2, COXIV-2, dJ857M17.2	ENSG00000131055	Cytochrome c oxidase subunit 4I2	20	31637888-31645006	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Head and neck cancer:6.04e-5 (favourable), Renal cancer:9.78e-4 (unfavourable)	Expressed in all	Group enriched	5	lung: 42.8;placenta: 157.5	thyroid gland: 19.3	Cell line enriched	5	SH-SY5Y: 1.8
COX5A		ENSG00000178741	Cytochrome c oxidase subunit 5A	15	74919791-74938168	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA027526	Supported				Renal cancer:6.06e-7 (favourable), Cervical cancer:2.15e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 548.4	Expressed in all		
CP		ENSG00000047457	Ceruloplasmin	3	149162410-149222055	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001834, CAB008591	Supported				Renal cancer:1.14e-7 (unfavourable)	Tissue enhanced	Tissue enriched	9	liver: 916.0	cervix, uterine: 99.1	Cell line enriched	12	EFO-21: 273.0
CPA6	CPAH	ENSG00000165078	Carboxypeptidase A6	8	67422038-67746385	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		prostate: 4.9;rectum: 2.9	colon: 1.7	Cell line enhanced		CACO-2: 2.9;EFO-21: 1.8;Hep G2: 3.6
CPN1		ENSG00000120054	Carboxypeptidase N subunit 1	10	100042193-100081877	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040323			Approved	Nucleus<br>Nucleoli		Group enriched	Tissue enriched	22	liver: 37.1	testis: 1.7	Cell line enriched	16	SK-MEL-30: 110.4
CPOX	CPO, CPX, HCP	ENSG00000080819	Coproporphyrinogen oxidase	3	98521132-98593723	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA015736, HPA054448			Enhanced	Mitochondria	Renal cancer:1.04e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 25.5	Expressed in all		
CPT1C	CPT1P, CPTIC, FLJ23809	ENSG00000169169	Carnitine palmitoyltransferase 1C	19	49690898-49713731	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014529, HPA063621	Approved		Approved	Centrosome	Pancreatic cancer:1.84e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 34.2	adrenal gland: 7.0	Cell line enhanced		AF22: 39.0;SH-SY5Y: 74.9
CREBBP	CBP, KAT3A, RSTS, RTS	ENSG00000005339	CREB binding protein	16	3725054-3880726	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004212, HPA055861	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:6.24e-5 (favourable)	Expressed in all	Expressed in all			testis: 61.7	Expressed in all		
CRYM	DFNA40	ENSG00000103316	Crystallin mu	16	21238874-21303083	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019086, HPA030619	Enhanced		Supported	Cytosol		Tissue enhanced	Group enriched	6	cerebral cortex: 51.1;heart muscle: 47.8;kidney: 28.4;prostate: 24.7;urinary bladder: 14.8	lung: 5.7	Cell line enhanced		HEL: 9.4;RPTEC TERT1: 32.9;U-87 MG: 8.7
CSNK1D	CKID, CKIdelta, HCKID	ENSG00000141551	Casein kinase 1 delta	17	82239023-82273731	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015410	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:2.38e-6 (unfavourable), Pancreatic cancer:9.62e-5 (favourable), Endometrial cancer:7.04e-4 (unfavourable), Renal cancer:8.34e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 66.9	Expressed in all		
CSNK2A1		ENSG00000101266	Casein kinase 2 alpha 1	20	473591-543821	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB020680, HPA059206, HPA061698, CAB069395	Enhanced		Supported	Nucleoplasm	Liver cancer:4.11e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 129.5	Expressed in all		
CSTB	CST6, EPM1, PME, STFB	ENSG00000160213	Cystatin B	21	43772511-43776445	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA017380, CAB047320, HPA058557	Enhanced		Supported	Nucleoli<br>Cytosol	Liver cancer:6.66e-5 (unfavourable), Renal cancer:2.10e-4 (unfavourable)	Expressed in all	Tissue enriched	8	esophagus: 1822.8	tonsil: 228.0	Expressed in all		
CTDP1	FCP1	ENSG00000060069	CTD phosphatase subunit 1	18	79679801-79756623	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB032641, HPA040394, HPA070389	Supported		Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.51e-5 (favourable), Endometrial cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			testis: 19.6	Expressed in all		
CTH		ENSG00000116761	Cystathionine gamma-lyase	1	70411218-70439851	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021591, HPA023300	Enhanced				Liver cancer:8.69e-4 (favourable)	Group enriched	Expressed in all			liver: 73.2	Cell line enhanced		Karpas-707: 52.3;SK-MEL-30: 75.8
CTNS	CTNS-LSB, PQLC4	ENSG00000040531	Cystinosin, lysosomal cystine transporter	17	3636468-3661542	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA046947			Supported	Vesicles<br>Intermediate filaments	Pancreatic cancer:6.39e-5 (favourable), Head and neck cancer:7.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 42.6	Expressed in all		
CTPS1	CTPS	ENSG00000171793	CTP synthase 1	1	40979335-41012565	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017111, HPA051322	Enhanced		Supported	Actin filaments<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 80.2	Expressed in all		
CTRC	CLCR, ELA4	ENSG00000162438	Chymotrypsin C	1	15438439-15449242	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA046920	Enhanced					Tissue enriched	Tissue enriched	361	pancreas: 18186.4	ovary: 50.3	Not detected		
CTSA	GSL, PPGB	ENSG00000064601	Cathepsin A	20	45890144-45898820	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB024930, HPA031068	Enhanced		Enhanced	Vesicles	Liver cancer:1.95e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 243.4	Expressed in all		
CTSC	DPP1, PALS, PLS	ENSG00000109861	Cathepsin C	11	88293592-88337787	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025364, HPA066610, HPA068434	Enhanced		Supported	Vesicles	Liver cancer:9.30e-5 (unfavourable), Renal cancer:4.80e-4 (favourable)	Expressed in all	Expressed in all			lung: 390.4	Expressed in all		
CTSD	CLN10, CPSD	ENSG00000117984	Cathepsin D	11	1752752-1764573	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000109, HPA003001	Enhanced				Renal cancer:4.93e-5 (favourable), Colorectal cancer:2.46e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 1026.9	Expressed in all		
CTSF	CATSF, CLN13	ENSG00000174080	Cathepsin F	11	66563463-66568841	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002141, HPA031431, HPA055610	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:8.92e-7 (favourable)	Expressed in all	Expressed in all			ovary: 140.6	Cell line enhanced		SK-MEL-30: 123.6
CTSK	CTSO, CTSO2, PKND, PYCD	ENSG00000143387	Cathepsin K	1	150796208-150808323	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050346			Supported	Vesicles	Renal cancer:7.12e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 575.0	Group enriched	6	ASC diff: 1592.3;ASC TERT1: 590.6;BJ hTERT+: 1576.7
CX3CR1	CCRL1, CMKBRL1, CMKDR1, GPR13, V28	ENSG00000168329	C-X3-C motif chemokine receptor 1	3	39263494-39281735	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA030311, CAB032478, HPA046587, HPA077743	Approved		Approved	Nucleus		Tissue enhanced	Tissue enhanced		cerebral cortex: 59.2	spleen: 16.6	Cell line enriched	18	RPMI-8226: 409.2
CYB5R3	DIA1	ENSG00000100243	Cytochrome b5 reductase 3	22	42617840-42649568	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001566	Approved		Enhanced	Endoplasmic reticulum	Liver cancer:2.13e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 339.4	Expressed in all		
CYBA	p22-PHOX	ENSG00000051523	Cytochrome b-245 alpha chain	16	88643283-88651152	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009492	Enhanced				Endometrial cancer:4.75e-5 (favourable), Renal cancer:1.83e-4 (unfavourable), Breast cancer:8.19e-4 (favourable)	Expressed in all	Expressed in all			spleen: 466.1	Cell line enhanced		RPMI-8226: 1035.0
CYBB	CGD, GP91-PHOX, NOX2	ENSG00000165168	Cytochrome b-245 beta chain	X	37780011-37813461	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051227	Enhanced					Expressed in all	Tissue enhanced		appendix: 215.6	lung: 132.2	Group enriched	5	Daudi: 37.3;NB-4: 40.0;REH: 49.1;RPMI-8226: 143.6
CYLD	CYLD1, KIAA0849, USPL2	ENSG00000083799	CYLD lysine 63 deubiquitinase	16	50742050-50801935	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011713, HPA050095	Approved		Supported	Nucleoplasm<br>Microtubule organizing center		Expressed in all	Expressed in all			testis: 70.2	Expressed in all		
CYP11B2	ALDOS, CPN2, CYP11B, CYP11BL, P-450C18, P450aldo	ENSG00000179142	Cytochrome P450 family 11 subfamily B member 2	8	142910559-142917843	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049171, HPA056348, HPA057752	Supported					Not detected	Tissue enriched	1057	adrenal gland: 126.3	testis: 0.1	Not detected		
CYP1B1	CP1B, GLC3A	ENSG00000138061	Cytochrome P450 family 1 subfamily B member 1	2	38066973-38109902	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB011705, HPA026863	Approved		Uncertain	Mitochondria	Renal cancer:4.39e-6 (unfavourable), Urothelial cancer:2.76e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 76.1	Cell line enhanced		HSkMC: 400.2;SiHa: 283.9;U-87 MG: 138.5
CYP21A2	CA21H, CAH1, CPS1, CYP21, CYP21B, P450c21B	ENSG00000231852	Cytochrome P450 family 21 subfamily A member 2	6	32038265-32041670	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA048979, HPA053371	Enhanced					Tissue enhanced	Tissue enriched	257	adrenal gland: 266.4	epididymis: 1.0	Group enriched	5	HDLM-2: 6.1;Karpas-707: 1.2
CYP24A1	CP24, CYP24, P450-CC24	ENSG00000019186	Cytochrome P450 family 24 subfamily A member 1	20	54153449-54173973	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022261, HPA063771	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Mitochondria		Mixed	Tissue enhanced		endometrium: 24.8;urinary bladder: 50.8	placenta: 14.1	Group enriched	13	A549: 372.2;Hep G2: 83.4
CYP27A1	CP27, CTX, CYP27	ENSG00000135929	Cytochrome P450 family 27 subfamily A member 1	2	218781749-218815293	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059155	Enhanced		Enhanced	Mitochondria	Liver cancer:8.62e-6 (favourable), Breast cancer:1.05e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 279.5	lung: 98.4	Cell line enhanced		Hep G2: 187.0;RPTEC TERT1: 50.8;SK-MEL-30: 86.7;WM-115: 42.3
CYP27B1	CYP1, P450c1, PDDR, VDD1	ENSG00000111012	Cytochrome P450 family 27 subfamily B member 1	12	57762334-57768986	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Thyroid cancer:6.79e-4 (unfavourable)	Mixed	Tissue enhanced		kidney: 4.3;thyroid gland: 3.9	appendix: 1.2	Cell line enriched	8	RH-30: 47.8
CYP2R1		ENSG00000186104	Cytochrome P450 family 2 subfamily R member 1	11	14877440-14892252	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042949	Approved				Renal cancer:2.86e-4 (unfavourable)	Expressed in all	Mixed			skin: 8.1	Cell line enhanced		Karpas-707: 18.6
CYP2U1	SPG49	ENSG00000155016	Cytochrome P450 family 2 subfamily U member 1	4	107931369-107953457	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA041622, HPA046754, HPA064827	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:2.75e-5 (favourable), Stomach cancer:6.97e-4 (unfavourable)	Expressed in all	Mixed			prostate: 15.7	Mixed		
CYP4F2		ENSG00000186115	Cytochrome P450 family 4 subfamily F member 2	19	15878023-15898120	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014048, HPA017265, HPA058960	Supported					Tissue enriched	Group enriched	6	duodenum: 78.2;epididymis: 28.0;kidney: 39.3;liver: 84.6;small intestine: 84.3	prostate: 10.4	Cell line enhanced		Hep G2: 2.5
CYP4V2	CYP4AH1	ENSG00000145476	Cytochrome P450 family 4 subfamily V member 2	4	186191520-186213456	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA029122	Approved		Approved	Nuclear speckles	Renal cancer:1.49e-7 (favourable), Liver cancer:1.85e-4 (favourable), Endometrial cancer:5.86e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 65.1	liver: 47.4	Cell line enhanced		SK-MEL-30: 19.3
CYP7B1	SPG5A	ENSG00000172817	Cytochrome P450 family 7 subfamily B member 1	8	64587763-64798761	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA017761	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 40.3	thyroid gland: 22.4	Cell line enhanced		HSkMC: 11.3;SH-SY5Y: 6.2;WM-115: 11.7
DARS		ENSG00000115866	Aspartyl-tRNA synthetase	2	135906677-135986100	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020451, HPA029804, HPA029805	Enhanced		Enhanced	Cytosol	Liver cancer:2.39e-6 (unfavourable), Renal cancer:1.24e-5 (unfavourable), Pancreatic cancer:6.54e-4 (unfavourable), Melanoma:7.57e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 91.0	Expressed in all		
DARS2	FLJ10514	ENSG00000117593	Aspartyl-tRNA synthetase 2, mitochondrial	1	173824503-173858546	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026506, HPA026528	Enhanced		Supported	Nucleus<br>Mitochondria	Renal cancer:1.74e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 24.9	Expressed in all		
DBT		ENSG00000137992	Dihydrolipoamide branched chain transacylase E2	1	100186919-100249834	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026481, HPA026485, HPA026533	Enhanced		Supported	Mitochondria	Renal cancer:8.79e-12 (favourable)	Expressed in all	Expressed in all			kidney: 19.7	Expressed in all		
DCPS	HINT-5, HSL1, HSPC015	ENSG00000110063	Decapping enzyme, scavenger	11	126303752-126345749	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039632, HPA058597	Supported		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			lymph node: 24.5	Expressed in all		
DCXR	DCR, KIDCR, SDR20C1	ENSG00000169738	Dicarbonyl and L-xylulose reductase	17	82035136-82037732	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023371, HPA023863	Enhanced		Uncertain	Nucleoli<br>Microtubules	Renal cancer:2.13e-4 (favourable), Pancreatic cancer:4.70e-4 (favourable)	Expressed in all	Group enriched	6	epididymis: 297.5;kidney: 217.3;liver: 640.9;prostate: 137.5	adipose tissue: 56.7	Expressed in all		
DDX11	CHL1, CHLR1, KRG2, WABS	ENSG00000013573	DEAD/H-box helicase 11	12	31073845-31104791	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA065197	Supported		Supported	Nucleus<br>Nucleoli fibrillar center<br>Centrosome	Renal cancer:5.23e-8 (unfavourable), Liver cancer:2.40e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 19.3	Expressed in all		
DDX3X	DBX, DDX14, DDX3, HLP2	ENSG00000215301	DEAD-box helicase 3, X-linked	X	41333348-41364472	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001648, HPA005631, HPA059585	Supported	Approved	Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 274.6	Expressed in all		
DDX3Y	DBY	ENSG00000067048	DEAD-box helicase 3, Y-linked	Y	12904108-12920478	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001648, HPA005631	Uncertain	Approved	Supported	Nucleus<br>Cytosol	Head and neck cancer:4.70e-5 (favourable)	Mixed	Tissue enhanced		testis: 128.6	prostate: 54.0	Cell line enhanced		HEL: 139.0
DDX41	ABS, MGC8828	ENSG00000183258	DEAD-box helicase 41	5	177511577-177517469	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017911, HPA048803	Enhanced		Supported	Nucleus	Renal cancer:2.21e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 52.6	Expressed in all		
DDX58	DKFZp434J1111, FLJ13599, RIG-I	ENSG00000107201	DExD/H-box helicase 58	9	32455705-32526324	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB012643, HPA047193	Uncertain		Supported	Cytosol	Renal cancer:4.66e-4 (unfavourable), Endometrial cancer:5.46e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 19.8	Group enriched	6	BJ hTERT+ SV40 Large T+: 118.2;BJ hTERT+ SV40 Large T+ RasG12V: 128.1
DDX59	DKFZP564B1023, ZNHIT5	ENSG00000118197	DEAD-box helicase 59	1	200623896-200669969	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047166	Approved		Approved	Nucleus<br>Actin filaments	Renal cancer:9.02e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 33.4	Expressed in all		
DDX6	HLR2, RCK	ENSG00000110367	DEAD-box helicase 6	11	118747766-118791149	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004668, HPA024201, HPA026644	Approved		Supported	Cytosol<br>Cytoplasmic bodies	Liver cancer:6.56e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.6	Expressed in all		
DECR1	DECR, SDR18C1	ENSG00000104325	2,4-dienoyl-CoA reductase 1	8	90001405-90052092	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023160, HPA023162, HPA023238	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:1.79e-7 (favourable), Breast cancer:1.49e-4 (unfavourable), Urothelial cancer:6.06e-4 (favourable)	Expressed in all	Expressed in all			liver: 262.9	Expressed in all		
DFNA5	ICERE-1	ENSG00000105928	DFNA5, deafness associated tumor suppressor	7	24698353-24758113	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA011326, CAB019306	Approved		Enhanced	Cytosol	Liver cancer:2.49e-5 (unfavourable)	Mixed	Mixed			placenta: 58.7	Mixed		
DFNB59	pejvakin	ENSG00000204311	Deafness, autosomal recessive 59	2	178451436-178461390	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA042621			Supported	Mitochondria	Renal cancer:8.92e-4 (unfavourable)	Mixed	Tissue enriched	6	testis: 32.4	ovary: 5.4	Mixed		
DGAT1	ARGP1, DGAT	ENSG00000185000	Diacylglycerol O-acyltransferase 1	8	144314584-144326910	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB032853	Enhanced		Approved	Nucleoli<br>Endoplasmic reticulum		Expressed in all	Tissue enhanced		duodenum: 71.3;small intestine: 75.1	adipose tissue: 20.0	Cell line enhanced		PC-3: 35.6
DGKE	DAGK6, DGK	ENSG00000153933	Diacylglycerol kinase epsilon	17	56834099-56869567	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017167	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:3.92e-5 (favourable)	Mixed	Mixed			testis: 12.1	Cell line enhanced		Karpas-707: 61.4
DGUOK	dGK	ENSG00000114956	Deoxyguanosine kinase	2	73926826-73958961	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034766, HPA057246	Approved				Renal cancer:8.69e-7 (unfavourable), Urothelial cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			testis: 56.6	Expressed in all		
DHCR24	DCE, KIAA0018, seladin-1	ENSG00000116133	24-dehydrocholesterol reductase	1	54849633-54887218	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017981, CAB037247, HPA063005	Approved				Endometrial cancer:1.05e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 1094.6	Mixed		
DHCR7	SLOS	ENSG00000172893	7-dehydrocholesterol reductase	11	71428193-71452868	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA044280	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:6.93e-7 (favourable), Urothelial cancer:5.67e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 115.2	Expressed in all		
DHDDS	DS, FLJ13102, HDS, RP59	ENSG00000117682	Dehydrodolichyl diphosphate synthase subunit	1	26432282-26471294	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026721, HPA026727	Uncertain		Uncertain	Plasma membrane	Renal cancer:4.08e-7 (favourable)	Expressed in all	Expressed in all			adipose tissue: 54.5	Expressed in all		
DHTKD1	CMT2Q, DKFZP762M115, KIAA1630, MGC3090	ENSG00000181192	Dehydrogenase E1 and transketolase domain containing 1	10	12068972-12123225	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037949, HPA037950, HPA066098	Approved		Supported	Mitochondria	Renal cancer:3.43e-4 (favourable)	Expressed in all	Expressed in all			liver: 66.5	Expressed in all		
DICER1	Dicer, HERNA, K12H4.8-LIKE, KIAA0928, MNG1	ENSG00000100697	Dicer 1, ribonuclease III	14	95086228-95158010	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000694, CAB068185	Approved		Supported	Cytosol		Expressed in all	Expressed in all			placenta: 32.6	Expressed in all		
DIRC2	FLJ14784, RCC4	ENSG00000138463	Disrupted in renal carcinoma 2	3	122794795-122881139	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA072579			Supported	Vesicles	Renal cancer:8.81e-11 (favourable), Pancreatic cancer:5.81e-5 (unfavourable), Liver cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 16.2	Mixed		
DLAT	DLTA, PDC-E2	ENSG00000150768	Dihydrolipoamide S-acetyltransferase	11	112024814-112064390	Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003782, HPA040786, HPA062766	Enhanced		Enhanced	Mitochondria	Renal cancer:1.95e-14 (favourable), Colorectal cancer:6.19e-6 (favourable), Liver cancer:7.49e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.0	Expressed in all		
DLD	DLDH, GCSL, LAD	ENSG00000091140	Dihydrolipoamide dehydrogenase	7	107890970-107931730	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044849	Enhanced		Supported	Mitochondria	Renal cancer:7.58e-9 (favourable)	Expressed in all	Expressed in all			heart muscle: 174.7	Expressed in all		
DMD	BMD, DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272, MRX85	ENSG00000198947	Dystrophin	X	31097677-33339441	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000119, HPA002725, HPA023885	Enhanced					Mixed	Mixed			seminal vesicle: 54.6	Cell line enhanced		AF22: 25.1;RH-30: 31.0
DMGDH		ENSG00000132837	Dimethylglycine dehydrogenase	5	78997606-79236038	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036441, HPA036442, HPA077849	Enhanced		Supported	Mitochondria	Renal cancer:1.17e-5 (favourable), Liver cancer:5.32e-5 (favourable)	Group enriched	Group enriched	11	kidney: 179.1;liver: 146.2	epididymis: 14.9	Cell line enhanced		BJ hTERT+: 2.9;Hep G2: 5.2
DMPK	DM, DM1, DM1PK, DMK, MDPK, MT-PK	ENSG00000104936	Dystrophia myotonica protein kinase	19	45769717-45782552	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007164, HPA008905	Enhanced		Approved	Vesicles<br>Cytosol	Pancreatic cancer:9.39e-5 (favourable)	Expressed in all	Expressed in all			smooth muscle: 97.3	Cell line enhanced		RH-30: 99.0
DNA2	DNA2L, KIAA0083	ENSG00000138346	DNA replication helicase/nuclease 2	10	68414064-68472121	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037487, HPA057526	Approved		Supported	Mitochondria		Mixed	Mixed			lymph node: 6.3	Mixed		
DNAJC6	KIAA0473, PARK19	ENSG00000116675	DnaJ heat shock protein family (Hsp40) member C6	1	65248219-65415869	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031182, HPA054917	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.81e-4 (favourable)	Tissue enhanced	Tissue enriched	10	cerebral cortex: 162.8	adrenal gland: 15.6	Cell line enhanced		HDLM-2: 58.7;HEL: 150.3;K-562: 59.3
DNASE1	DNL1	ENSG00000213918	Deoxyribonuclease 1	16	3611728-3680143	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA010703	Enhanced		Supported	Vesicles	Urothelial cancer:1.14e-4 (favourable)	Expressed in all	Tissue enhanced		small intestine: 37.8	duodenum: 29.9	Mixed		
DNM1	DNM	ENSG00000106976	Dynamin 1	9	128191655-128255248	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005920, HPA049910, HPA061801	Enhanced		Supported	Nucleoplasm		Mixed	Tissue enriched	14	cerebral cortex: 364.2	cervix, uterine: 25.6	Cell line enhanced		A549: 114.8
DNM1L	DRP1, DVLP, DYMPLE, HDYNIV, VPS1	ENSG00000087470	Dynamin 1 like	12	32679200-32745650	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009952, HPA039324	Enhanced		Enhanced	Vesicles<br>Cytosol	Liver cancer:6.27e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 88.1	Expressed in all		
DNM2	CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII	ENSG00000079805	Dynamin 2	19	10718079-10833488	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA054246	Enhanced		Approved	Golgi apparatus<br>Cytosol	Liver cancer:3.63e-4 (unfavourable), Head and neck cancer:8.91e-4 (favourable)	Expressed in all	Expressed in all			colon: 103.9	Expressed in all		
DNMT3A		ENSG00000119772	DNA methyltransferase 3 alpha	2	25227855-25342590	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009469, HPA026588	Approved		Supported	Nucleoplasm	Pancreatic cancer:1.18e-4 (favourable), Endometrial cancer:1.55e-4 (unfavourable), Liver cancer:1.58e-4 (unfavourable), Renal cancer:2.49e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 22.8	Cell line enhanced		NTERA-2: 59.7;SH-SY5Y: 76.5
DNMT3B		ENSG00000088305	DNA methyltransferase 3 beta	20	32762385-32809356	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001595, CAB069896	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.87e-7 (unfavourable), Endometrial cancer:5.04e-4 (unfavourable)	Tissue enriched	Tissue enhanced		testis: 9.2	skin: 4.5	Cell line enhanced		BEWO: 236.9;NTERA-2: 333.3
DOLK	DK1, KIAA1094, TMEM15	ENSG00000175283	Dolichol kinase	9	128945530-128947619	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA066767, HPA068706			Supported	Nucleus<br>Nucleoli	Thyroid cancer:6.88e-5 (favourable), Renal cancer:5.53e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 24.7	Expressed in all		
DPAGT1	ALG7, CDG-Ij, D11S366, DGPT, DPAGT, DPAGT2, GPT	ENSG00000172269	Dolichyl-phosphate N-acetylglucosaminephosphotransferase 1	11	119096503-119108331	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA053878	Approved				Liver cancer:2.03e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 25.5	Expressed in all		
DPH1	DPH2L, DPH2L1, OVCA1	ENSG00000108963	Diphthamide biosynthesis 1	17	2030110-2043430	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA069750			Approved	Nucleoplasm<br>Cell Junctions	Pancreatic cancer:1.78e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 31.5	Expressed in all		
DPM1	CDGIE, MPDS	ENSG00000000419	Dolichyl-phosphate mannosyltransferase subunit 1, catalytic	20	50934867-50958555	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051818	Approved				Liver cancer:1.94e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 80.5	Expressed in all		
DPP10	DPL2, DPPY, DPRP3	ENSG00000175497	Dipeptidyl peptidase like 10	2	114442299-115845752	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048767	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol		Mixed	Group enriched	7	adrenal gland: 14.1;cerebral cortex: 34.7	pancreas: 3.6	Cell line enhanced		AF22: 4.1;HAP1: 6.4;HMC-1: 3.8;NTERA-2: 3.7;RT4: 5.3;SCLC-21H: 11.4;SH-SY5Y: 4.1
DPP6	DPL1, DPPX	ENSG00000130226	Dipeptidyl peptidase like 6	7	153887097-154894285	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050509	Enhanced	Supported				Tissue enriched	Tissue enhanced		cerebral cortex: 51.1;endometrium: 27.6	smooth muscle: 15.4	Cell line enriched	9	NTERA-2: 5.5
DPYD	DPD	ENSG00000188641	Dihydropyrimidine dehydrogenase	1	97077743-97921049	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033241, HPA045210	Uncertain				Pancreatic cancer:6.27e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 44.1	Mixed		
DPYS	DHPase	ENSG00000147647	Dihydropyrimidinase	8	104330324-104467053	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024785	Enhanced					Group enriched	Group enriched	22	kidney: 200.4;liver: 246.2	gallbladder: 10.1	Not detected		
DSE	DSEPI, SART2	ENSG00000111817	Dermatan sulfate epimerase	6	116254173-116444860	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014764, HPA052151	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.50e-4 (unfavourable), Cervical cancer:3.36e-4 (unfavourable), Ovarian cancer:6.34e-4 (unfavourable)	Mixed	Mixed			appendix: 36.2	Mixed		
DSTYK	DustyPK, KIAA0472, RIP5, RIPK5	ENSG00000133059	Dual serine/threonine and tyrosine protein kinase	1	205142505-205211566	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044140	Uncertain		Uncertain	Nuclear speckles<br>Intermediate filaments	Urothelial cancer:8.73e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 28.8	Expressed in all		
DUOX2	LNOX2, P138-TOX, P138(TOX), THOX2	ENSG00000140279	Dual oxidase 2	15	45092650-45114344	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enhanced		gallbladder: 446.7;thyroid gland: 124.8	urinary bladder: 87.1	Cell line enriched	8	HaCaT: 5.5
DUSP6	MKP-3, PYST1	ENSG00000139318	Dual specificity phosphatase 6	12	89347232-89353271	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017566, HPA053188	Approved		Uncertain	Nucleoplasm<br>Cytosol	Endometrial cancer:7.21e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 141.2	Cell line enhanced		AN3-CA: 428.0
DUX4		ENSG00000260596	Double homeobox 4	4	190173774-190185942	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	HPA058451			Supported	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol		Not detected	Tissue enhanced		testis: 1.4	prostate: 0.4	Cell line enhanced		A549: 1.3;U-2 OS: 2.2;U-266/70: 3.6;U-266/84: 4.6
DYRK1A	DYRK, DYRK1, MNBH	ENSG00000157540	Dual specificity tyrosine phosphorylation regulated kinase 1A	21	37365790-37517450	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015323, HPA015810	Approved		Approved	Nucleoli fibrillar center<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 61.3	Expressed in all		
DYRK1B	MIRK	ENSG00000105204	Dual specificity tyrosine phosphorylation regulated kinase 1B	19	39825350-39834201	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028522, HPA028786	Uncertain		Approved	Nucleus	Renal cancer:8.83e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 37.4	testis: 33.6	Cell line enhanced		SCLC-21H: 15.0;SH-SY5Y: 15.3
DYSF	FER1L1, LGMD2B	ENSG00000135636	Dysferlin	2	71453722-71686768	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002510, HPA017071, HPA021945	Enhanced		Supported	Plasma membrane<br>Microtubule organizing center		Expressed in all	Mixed			skeletal muscle: 32.8	Group enriched	6	HUVEC TERT2: 69.0;LHCN-M2: 62.5;RH-30: 75.9;TIME: 44.6
EARS2	KIAA1970, MSE1	ENSG00000103356	Glutamyl-tRNA synthetase 2, mitochondrial	16	23522014-23557731	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043289, HPA043633	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.16e-6 (favourable), Pancreatic cancer:7.20e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 32.9	Expressed in all		
EBP	CDPX2, CHO2, CPX, CPXD	ENSG00000147155	Emopamil binding protein (sterol isomerase)	X	48521158-48528716	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA003130	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			liver: 91.3	Expressed in all		
ECE1	ECE	ENSG00000117298	Endothelin converting enzyme 1	1	21217247-21345504	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001490, HPA013616	Approved					Expressed in all	Expressed in all			parathyroid gland: 436.1	Expressed in all		
ECEL1	DINE, XCE	ENSG00000171551	Endothelin converting enzyme like 1	2	232479827-232487828	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067560, HPA069756		Supported	Approved	Nucleoplasm<br>Nuclear membrane<br>Nucleoli		Tissue enhanced	Tissue enriched	25	ovary: 111.9	spleen: 4.4	Group enriched	7	AN3-CA: 40.8;HeLa: 15.2
ECHS1	SCEH	ENSG00000127884	Enoyl-CoA hydratase, short chain 1	10	133362480-133373689	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003783, HPA021995, HPA022476	Enhanced		Enhanced	Mitochondria	Renal cancer:8.57e-5 (favourable)	Expressed in all	Expressed in all			liver: 438.0	Expressed in all		
EGLN1	C1orf12, HIFPH2, PHD2, SM-20, ZMYND6	ENSG00000135766	Egl-9 family hypoxia inducible factor 1	1	231363751-231425044	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022129	Approved		Approved	Cytosol	Cervical cancer:2.99e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.9	Expressed in all		
EHHADH	ECHD	ENSG00000113790	Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase	3	185190624-185281990	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036401, HPA042021	Enhanced				Renal cancer:1.28e-5 (favourable)	Group enriched	Group enriched	7	kidney: 148.6;liver: 173.1	duodenum: 21.4	Mixed		
EHMT1	bA188C12.1, Eu-HMTase1, FLJ12879, KIAA1876, KMT1D	ENSG00000181090	Euchromatic histone lysine methyltransferase 1	9	137618963-137870016	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA060022			Supported	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:6.56e-4 (favourable), Head and neck cancer:8.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 65.0	Expressed in all		
EI24	EPG4, PIG8, TP53I8	ENSG00000149547	EI24, autophagy associated transmembrane protein	11	125569216-125584687	Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047165, HPA051029	Approved		Supported	Endoplasmic reticulum<br>Golgi apparatus<br>Cytosol	Pancreatic cancer:9.28e-4 (unfavourable)	Expressed in all	Tissue enriched	9	parathyroid gland: 1120.1	liver: 125.1	Expressed in all		
EIF2AK3	PEK, PERK	ENSG00000172071	Eukaryotic translation initiation factor 2 alpha kinase 3	2	88556741-88627576	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB009204, HPA015737	Enhanced					Expressed in all	Mixed			parathyroid gland: 37.3	Expressed in all		
EIF2AK4	GCN2, KIAA1338	ENSG00000128829	Eukaryotic translation initiation factor 2 alpha kinase 4	15	39934146-40035591	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA011811	Approved		Approved	Cytosol		Expressed in all	Expressed in all			endometrium: 54.3	Expressed in all		
EIF4A3	DDX48, EIF4AIII, KIAA0111	ENSG00000141543	Eukaryotic translation initiation factor 4A3	17	80135214-80147183	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA021878	Enhanced		Supported	Nucleoplasm	Liver cancer:1.68e-5 (unfavourable), Colorectal cancer:3.57e-5 (favourable), Lung cancer:1.87e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 112.1	Expressed in all		
ELAC2	FLJ10530, HPC2	ENSG00000006744	ElaC ribonuclease Z 2	17	12992391-13018187	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019535	Approved		Enhanced	Nucleoplasm	Endometrial cancer:3.24e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 55.1	Expressed in all		
ELOVL4	CT118, SCA34, STGD2, STGD3	ENSG00000118402	ELOVL fatty acid elongase 4	6	79914812-79947580	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Urothelial cancer:6.27e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 24.0;skin: 50.7	parathyroid gland: 15.7	Cell line enhanced		MOLT-4: 25.9
ELOVL5	dJ483K16.1, HELO1, SCA38	ENSG00000012660	ELOVL fatty acid elongase 5	6	53267398-53349179	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017042, HPA047752, HPA054197	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:1.94e-6 (unfavourable), Thyroid cancer:6.80e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 257.0	Expressed in all		
ENO3		ENSG00000108515	Enolase 3	17	4948092-4957131	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000793, HPA068284, HPA068721	Enhanced		Supported	Plasma membrane<br>Cytosol	Colorectal cancer:7.33e-4 (unfavourable)	Expressed in all	Tissue enriched	17	skeletal muscle: 5974.6	heart muscle: 350.1	Expressed in all		
ENPP1	M6S1, NPPS, PC-1, PCA1, PDNP1	ENSG00000197594	Ectonucleotide pyrophosphatase/phosphodiesterase 1	6	131808016-131895155	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB032904, HPA062066	Enhanced					Expressed in all	Tissue enhanced		parathyroid gland: 54.3;placenta: 62.9	thyroid gland: 34.1	Cell line enhanced		ASC diff: 23.4;U-138 MG: 27.3
ENTPD1	ATPDase, CD39, NTPDase-1, SPG64	ENSG00000138185	Ectonucleoside triphosphate diphosphohydrolase 1	10	95711779-95869695	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB002494, HPA014067	Enhanced		Uncertain	Microtubules	Renal cancer:5.33e-5 (unfavourable), Thyroid cancer:7.89e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 98.8	Group enriched	7	HDLM-2: 179.7;Karpas-707: 112.9
EOGT	AER61, C3orf64, FLJ33770	ENSG00000163378	EGF domain specific O-linked N-acetylglucosamine transferase	3	68975214-69013961	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019460	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Renal cancer:8.97e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 50.3	Mixed		
EP300	KAT3B, p300	ENSG00000100393	E1A binding protein p300	22	41091786-41180079	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000146, HPA003128, HPA004112	Supported		Enhanced	Nucleoplasm	Renal cancer:7.45e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.2	Expressed in all		
EPB41	4.1R, EL1	ENSG00000159023	Erythrocyte membrane protein band 4.1	1	28887091-29120046	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA028076, HPA028412, HPA028414	Supported		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.75e-6 (unfavourable), Endometrial cancer:4.58e-4 (unfavourable), Head and neck cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 50.6	Mixed		
EPHA3	ETK, ETK1, HEK, HEK4, TYRO4	ENSG00000044524	EPH receptor A3	3	89107524-89482134	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010462	Approved		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:3.28e-7 (unfavourable)	Mixed	Tissue enhanced		prostate: 51.9	gallbladder: 29.8	Cell line enriched	7	AF22: 192.5
EPHB2	DRT, EPHT3, ERK, Hek5, Tyro5	ENSG00000133216	EPH receptor B2	1	22710839-22921500	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013647, HPA071200	Approved		Supported	Nucleus<br>Plasma membrane	Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable)	Tissue enhanced	Mixed			rectum: 27.3	Cell line enhanced		HUVEC TERT2: 71.2;TIME: 69.5
EPHB4	HTK, Tyro11	ENSG00000196411	EPH receptor B4	7	100802565-100827521	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013537	Uncertain				Colorectal cancer:4.33e-4 (unfavourable), Breast cancer:8.56e-4 (unfavourable), Urothelial cancer:8.84e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 50.6	Mixed		
EPHX1	EPHX	ENSG00000143819	Epoxide hydrolase 1	1	225810092-225845563	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020593, HPA048847	Enhanced				Lung cancer:7.02e-5 (favourable), Prostate cancer:1.32e-4 (favourable)	Tissue enriched	Expressed in all			adrenal gland: 1085.6	Cell line enhanced		ASC diff: 821.1;SiHa: 629.7
EPM2A	LD, LDE	ENSG00000112425	EPM2A, laforin glucan phosphatase	6	145382535-145736023	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA053643, HPA055468			Enhanced	Nucleoplasm	Renal cancer:4.08e-7 (favourable)	Expressed in all	Mixed			skeletal muscle: 26.8	Mixed		
EPX	EPO, EPP, EPX-PEN	ENSG00000121053	Eosinophil peroxidase	17	58192737-58205174	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA050507	Approved					Not detected	Tissue enriched	24	bone marrow: 20.5	cerebral cortex: 0.8	Cell line enriched	55	NB-4: 157.0
ERBB3	HER3, LCCS2	ENSG00000065361	Erb-b2 receptor tyrosine kinase 3	12	56079857-56103505	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025331, HPA045396	Uncertain		Approved	Plasma membrane<br>Actin filaments		Expressed in all	Mixed			small intestine: 86.8	Cell line enhanced		Hep G2: 79.5;SK-BR-3: 77.6;SK-MEL-30: 109.7;T-47d: 108.2;WM-115: 145.7
ERCC2	EM9, MAG, MGC102762, MGC126218, MGC126219, TFIIH, XPD	ENSG00000104884	ERCC excision repair 2, TFIIH core complex helicase subunit	19	45349837-45370918	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005375, HPA038057, HPA069266	Approved		Supported	Nucleoplasm	Pancreatic cancer:3.26e-4 (favourable)	Expressed in all	Expressed in all			testis: 16.1	Expressed in all		
ERCC3	BTF2, GTF2H, RAD25, TFIIH, XPB	ENSG00000163161	ERCC excision repair 3, TFIIH core complex helicase subunit	2	127257290-127294176	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037153, HPA046077	Approved		Enhanced	Nucleoplasm	Liver cancer:1.62e-7 (unfavourable), Renal cancer:4.30e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 55.1	Expressed in all		
ETFDH	ETFQO	ENSG00000171503	Electron transfer flavoprotein dehydrogenase	4	158672125-158709623	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041978	Enhanced				Renal cancer:5.76e-10 (favourable)	Expressed in all	Expressed in all			liver: 99.7	Expressed in all		
ETHE1	HSCO, YF13H12	ENSG00000105755	ETHE1, persulfide dioxygenase	19	43506719-43527244	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028360, HPA029028, HPA029029	Enhanced		Enhanced	Mitochondria	Lung cancer:9.58e-4 (unfavourable)	Expressed in all	Expressed in all			colon: 240.2	Mixed		
EXT1	LGCR, LGS, ttv	ENSG00000182197	Exostosin glycosyltransferase 1	8	117794490-118111853	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044394	Uncertain				Lung cancer:1.20e-5 (unfavourable), Thyroid cancer:4.64e-4 (unfavourable), Cervical cancer:7.04e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 31.6	Cell line enhanced		BJ hTERT+: 193.5;fHDF/TERT166: 189.8
EXT2	SOTV	ENSG00000151348	Exostosin glycosyltransferase 2	11	44095549-44245429	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA078409			Supported	Golgi apparatus	Renal cancer:5.36e-6 (unfavourable), Head and neck cancer:2.50e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 90.7	Expressed in all		
EYA1	BOR	ENSG00000104313	EYA transcriptional coactivator and phosphatase 1	8	71197433-71362232	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028917			Supported	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		parathyroid gland: 81.7;prostate: 21.2	cerebral cortex: 10.7	Cell line enhanced		AN3-CA: 28.1;RH-30: 23.1;SH-SY5Y: 57.2
EYA4	CMD1J, DFNA10	ENSG00000112319	EYA transcriptional coactivator and phosphatase 4	6	133240598-133532120	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004805, HPA038771, HPA038772	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		seminal vesicle: 16.0	fallopian tube: 11.5	Cell line enhanced		A549: 22.1;HeLa: 45.5;RH-30: 22.5;U-87 MG: 23.4
EZH2	ENX-1, EZH1, KMT6, KMT6A	ENSG00000106462	Enhancer of zeste 2 polycomb repressive complex 2 subunit	7	148807383-148884321	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009589	Enhanced		Supported	Nucleoplasm	Renal cancer:8.18e-12 (unfavourable), Liver cancer:2.11e-6 (unfavourable), Melanoma:1.96e-4 (unfavourable), Stomach cancer:6.97e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 50.5	bone marrow: 30.0	Expressed in all		
F13A1	F13A	ENSG00000124491	Coagulation factor XIII A chain	6	6144085-6321013	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001804, CAB002155	Enhanced				Renal cancer:6.61e-6 (unfavourable)	Expressed in all	Expressed in all			placenta: 670.5	Cell line enhanced		AF22: 22.5;LHCN-M2: 7.1;RH-30: 41.4
FAH		ENSG00000103876	Fumarylacetoacetate hydrolase	15	80152490-80186946	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041370, HPA044093	Enhanced		Approved	Cytosol	Head and neck cancer:8.51e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 151.9	Cell line enhanced		HHSteC: 261.9
FAM20C	DKFZp547D065, DMP4, G-CK, IMAGE:4942737	ENSG00000177706	FAM20C, golgi associated secretory pathway kinase	7	192969-260745	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA019823			Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Ovarian cancer:9.40e-6 (unfavourable), Cervical cancer:8.89e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 38.3	Cell line enhanced		HSkMC: 118.8;U-87 MG: 99.8
FAN1	KIAA1018, MTMR15	ENSG00000198690	FANCD2 and FANCI associated nuclease 1	15	30903852-30943108	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048198			Supported	Nucleoplasm<br>Cytokinetic bridge<br>Cytosol	Renal cancer:1.42e-6 (favourable)	Expressed in all	Expressed in all			epididymis: 11.4	Expressed in all		
FANCL	FAAP43, FLJ10335, PHF9, Pog	ENSG00000115392	Fanconi anemia complementation group L	2	58159243-58241372	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033842, HPA036685, HPA036686	Supported		Approved	Nuclear bodies<br>Vesicles	Renal cancer:1.12e-7 (unfavourable), Liver cancer:2.81e-7 (unfavourable), Urothelial cancer:7.80e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 44.6	Expressed in all		
FAR1	FLJ22728, MLSTD2, SDR10E1	ENSG00000197601	Fatty acyl-CoA reductase 1	11	13668670-13732346	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017322	Approved		Enhanced	Peroxisomes	Colorectal cancer:2.27e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 58.9	Mixed		
FARS2	dJ236A3.1, FARS1	ENSG00000145982	Phenylalanyl-tRNA synthetase 2, mitochondrial	6	5261044-5771580	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018148, HPA028836	Approved		Approved	Plasma membrane	Renal cancer:1.24e-6 (favourable), Colorectal cancer:5.14e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 24.5	Expressed in all		
FBP1	FBP	ENSG00000165140	Fructose-bisphosphatase 1	9	94603133-94640249	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005857, HPA012513, CAB033869	Enhanced		Uncertain	Mitochondria	Renal cancer:6.86e-7 (favourable), Urothelial cancer:1.64e-5 (favourable), Liver cancer:1.79e-4 (favourable), Endometrial cancer:5.16e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 443.9	duodenum: 329.6	Cell line enhanced		HaCaT: 66.7;MCF7: 184.8;RT4: 124.5;U-698: 78.4
FBXO18	FBH1, Fbx18, FLJ14590	ENSG00000134452	F-box protein, helicase, 18	10	5890203-5937594	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA002844	Supported				Liver cancer:7.73e-7 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 46.8	Expressed in all		
FECH		ENSG00000066926	Ferrochelatase	18	57548283-57586772	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044100, HPA048177	Approved				Renal cancer:2.38e-10 (favourable)	Expressed in all	Expressed in all			bone marrow: 93.3	Expressed in all		
FES	FPS	ENSG00000182511	FES proto-oncogene, tyrosine kinase	15	90883695-90895776	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001376	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol	Colorectal cancer:5.78e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 96.5	Cell line enhanced		HEL: 56.3;HL-60: 45.0;HMC-1: 100.9;NB-4: 46.6;THP-1: 73.8
FGR	c-fgr, p55c-fgr, SRC2	ENSG00000000938	FGR proto-oncogene, Src family tyrosine kinase	1	27612064-27635277	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002024	Enhanced		Approved	Plasma membrane<br>Aggresome		Expressed in all	Tissue enhanced		appendix: 85.6;bone marrow: 137.0;spleen: 90.6	lung: 56.3	Cell line enhanced		Daudi: 61.4;HMC-1: 25.8;U-266/70: 116.7
FH	fumarase	ENSG00000091483	Fumarate hydratase	1	241497603-241519761	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017785, HPA025770, HPA025948, HPA027341	Enhanced	Approved	Enhanced	Mitochondria	Renal cancer:2.76e-7 (favourable)	Expressed in all	Expressed in all			liver: 142.2	Expressed in all		
FHIT	AP3Aase, FRA3B	ENSG00000189283	Fragile histidine triad	3	59749310-61251459	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002684, HPA018840, HPA018909	Enhanced		Approved	Nucleoli fibrillar center<br>Plasma membrane	Renal cancer:1.36e-4 (favourable)	Mixed	Expressed in all			kidney: 26.8	Cell line enhanced		U-266/70: 27.6
FKBP10	FKBP6, FLJ20683, FLJ22041, FLJ23833, hFKBP65	ENSG00000141756	FK506 binding protein 10	17	41812680-41823217	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051171, HPA057021	Enhanced		Approved	Vesicles	Renal cancer:0.00e+0 (unfavourable), Thyroid cancer:3.43e-5 (unfavourable), Cervical cancer:4.16e-4 (unfavourable), Urothelial cancer:4.99e-4 (unfavourable)	Expressed in all	Mixed			placenta: 84.7	Mixed		
FKBP14	FKBP22, FLJ20731	ENSG00000106080	FK506 binding protein 14	7	30010587-30026684	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA013329, HPA026829	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Breast cancer:1.60e-4 (unfavourable), Urothelial cancer:4.25e-4 (unfavourable), Stomach cancer:4.57e-4 (unfavourable), Liver cancer:6.87e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 20.3	Mixed		
FLAD1	FAD1, PP591	ENSG00000160688	Flavin adenine dinucleotide synthetase 1	1	154983338-154993111	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028476, HPA028486, HPA028563	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:2.55e-6 (unfavourable), Liver cancer:3.04e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 28.5	Expressed in all		
FLNA	ABP-280, FLN, FLN1, OPD1, OPD2	ENSG00000196924	Filamin A	X	154348524-154374638	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000356, HPA000368, HPA001016, HPA001115, HPA002925	Enhanced	Approved	Enhanced	Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:1.54e-6 (unfavourable), Urothelial cancer:3.88e-4 (unfavourable), Colorectal cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1051.0	Expressed in all		
FLNB	ABP-278, FH1, FLN1L, LRS1, TABP, TAP	ENSG00000136068	Filamin B	3	58008400-58172251	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA004747, HPA004886, CAB019322	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:3.45e-6 (favourable), Pancreatic cancer:8.45e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 148.3	Expressed in all		
FLNC	ABP-280, ABPL, FLN2	ENSG00000128591	Filamin C	7	128830377-128859274	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA006135	Enhanced		Supported	Plasma membrane<br>Cytosol	Lung cancer:2.17e-5 (unfavourable), Urothelial cancer:3.73e-5 (unfavourable), Glioma:2.14e-4 (unfavourable), Renal cancer:5.69e-4 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 384.7	smooth muscle: 160.7	Cell line enhanced		BJ: 331.0;hTEC/SVTERT24-B: 190.2;U-2 OS: 169.5
FLVCR1	AXPC1, FLVCR, MFSD7B, PCA	ENSG00000162769	Feline leukemia virus subgroup C cellular receptor 1	1	212858255-212899363	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046646	Approved		Approved	Cell Junctions	Renal cancer:1.06e-5 (unfavourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:3.50e-4 (favourable)	Expressed in all	Tissue enhanced		small intestine: 21.4	duodenum: 9.8	Expressed in all		
FLVCR2	C14orf58, FLJ20371, MFSD7C	ENSG00000119686	Feline leukemia virus subgroup C cellular receptor family member 2	14	75578617-75663214	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037984	Enhanced				Renal cancer:2.53e-5 (favourable)	Expressed in all	Tissue enhanced		testis: 38.8	small intestine: 26.9	Cell line enhanced		ASC diff: 37.0;BEWO: 71.0
FMO3		ENSG00000007933	Flavin containing monooxygenase 3	1	171090877-171117819	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013750	Enhanced				Lung cancer:5.60e-5 (favourable), Renal cancer:1.13e-4 (unfavourable), Liver cancer:3.46e-4 (favourable)	Tissue enriched	Tissue enriched	24	liver: 556.7	fallopian tube: 22.8	Group enriched	13	ASC diff: 23.4;ASC TERT1: 17.9;HSkMC: 5.1
FOLR1	FOLR	ENSG00000110195	Folate receptor 1	11	72189558-72196323	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA077030			Approved	Nuclear membrane	Liver cancer:2.50e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 166.6;fallopian tube: 275.8;lung: 267.5	kidney: 152.7	Group enriched	6	HeLa: 298.2;RPTEC TERT1: 350.8
FTCD		ENSG00000160282	Formimidoyltransferase cyclodeaminase	21	46136262-46155567	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020073, HPA030928, HPA030929, HPA036114	Enhanced		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:6.78e-5 (favourable), Liver cancer:1.70e-4 (favourable), Renal cancer:5.78e-4 (favourable)	Tissue enriched	Group enriched	18	kidney: 100.2;liver: 184.7	testis: 7.7	Cell line enriched	24	Hep G2: 62.7
FTSJ1	CDLIV, JM23, MRX44, MRX9, SPB1, TRM7, TRMT7	ENSG00000068438	FtsJ RNA methyltransferase homolog 1 (E. coli)	X	48476021-48486364	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002718	Approved		Approved	Cytosol	Renal cancer:5.24e-10 (unfavourable), Liver cancer:1.74e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 24.7	Expressed in all		
FUCA1		ENSG00000179163	Fucosidase, alpha-L- 1, tissue	1	23845077-23868294	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA046542, HPA056371	Enhanced				Renal cancer:5.70e-13 (favourable), Endometrial cancer:2.45e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 185.6	Cell line enhanced		CAPAN-2: 144.5
FXN	CyaY, FA, FARR, FRDA, X25	ENSG00000165060	Frataxin	9	69035259-69100178	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022164, HPA068304	Supported		Supported	Mitochondria<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 34.1	Expressed in all		
FXYD6		ENSG00000137726	FXYD domain containing ion transport regulator 6	11	117836976-117877486	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041334, HPA042284	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:1.05e-5 (unfavourable), Renal cancer:4.38e-5 (favourable), Urothelial cancer:1.60e-4 (unfavourable), Liver cancer:5.87e-4 (favourable), Pancreatic cancer:5.97e-4 (favourable)	Tissue enriched	Expressed in all			cerebral cortex: 696.9	Cell line enhanced		AF22: 128.6;HAP1: 89.7;SCLC-21H: 231.1;SH-SY5Y: 118.8
FZD4	CD344, EVR1	ENSG00000174804	Frizzled class receptor 4	11	86945679-86955391	CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA042328, HPA074833	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.60e-5 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 127.3	seminal vesicle: 42.3	Cell line enhanced		ASC diff: 43.7;Hep G2: 57.9;HUVEC TERT2: 78.0;TIME: 37.7
FZD6	Hfz6	ENSG00000164930	Frizzled class receptor 6	8	103298433-103332866	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA017991	Approved		Approved	Plasma membrane	Pancreatic cancer:1.20e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 45.5	Mixed		
G6PC	G6PT, GSD1a	ENSG00000131482	Glucose-6-phosphatase catalytic subunit	17	42900797-42913369	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA052324	Enhanced				Renal cancer:3.79e-5 (favourable), Liver cancer:5.42e-5 (favourable)	Tissue enriched	Tissue enhanced		kidney: 89.1;liver: 147.3	small intestine: 33.2	Not detected		
G6PC3	UGRP	ENSG00000141349	Glucose-6-phosphatase catalytic subunit 3	17	44070735-44076344	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067052			Supported	Endoplasmic reticulum	Endometrial cancer:1.11e-4 (favourable), Liver cancer:9.61e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 84.3	Expressed in all		
G6PD	G6PD1	ENSG00000160211	Glucose-6-phosphate dehydrogenase	X	154531391-154547572	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000247, HPA000834	Enhanced		Approved	Vesicles<br>Microtubule organizing center<br>Cytosol	Liver cancer:9.45e-13 (unfavourable)	Expressed in all	Expressed in all			testis: 107.0	Expressed in all		
GAD1	GAD	ENSG00000128683	Glutamate decarboxylase 1	2	170813213-170861151	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004415, HPA031949, HPA058412, CAB078176	Enhanced	Supported	Approved	Vesicles	Cervical cancer:7.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable)	Tissue enhanced	Tissue enriched	6	cerebral cortex: 75.3	parathyroid gland: 11.8	Cell line enhanced		HEL: 55.7
GALC		ENSG00000054983	Galactosylceramidase	14	87837820-87993665	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB022196	Approved					Expressed in all	Expressed in all			testis: 44.0	Cell line enhanced		CAPAN-2: 72.3;HMC-1: 67.2
GALE	SDR1E1	ENSG00000117308	UDP-galactose-4-epimerase	1	23795599-23800804	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007340	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Thyroid cancer:2.68e-4 (favourable)	Expressed in all	Expressed in all			stomach: 112.8	Expressed in all		
GALK1	GALK	ENSG00000108479	Galactokinase 1	17	75751594-75765711	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007094, HPA016960	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.55e-6 (unfavourable), Urothelial cancer:1.62e-5 (unfavourable)	Expressed in all	Expressed in all			liver: 23.4	Expressed in all		
GALNS	GALNAC6S, GAS	ENSG00000141012	Galactosamine (N-acetyl)-6-sulfatase	16	88813734-88856970	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026404, HPA042433	Enhanced		Approved	Cytosol	Liver cancer:3.66e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 29.7	Expressed in all		
GALNT11	GalNAc-T11	ENSG00000178234	Polypeptide N-acetylgalactosaminyltransferase 11	7	152025674-152122347	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA039330	Uncertain				Renal cancer:2.24e-6 (favourable), Glioma:8.42e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 242.9	Mixed		
GALNT12	GalNAc-T12	ENSG00000119514	Polypeptide N-acetylgalactosaminyltransferase 12	9	98807699-98850081	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA048292	Enhanced				Renal cancer:3.24e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 92.1	rectum: 61.4	Cell line enhanced		U-2197: 151.4
GALNT3	GalNAc-T3, HFTC, HHS	ENSG00000115339	Polypeptide N-acetylgalactosaminyltransferase 3	2	165747591-165794682	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007613	Enhanced		Supported	Golgi apparatus	Cervical cancer:2.08e-4 (unfavourable), Head and neck cancer:4.10e-4 (unfavourable)	Expressed in all	Mixed			stomach: 86.1	Cell line enhanced		CAPAN-2: 92.9;HaCaT: 108.1;hTCEpi: 82.6
GALT		ENSG00000213930	Galactose-1-phosphate uridylyltransferase	9	34638133-34651035	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004868, HPA005729	Enhanced		Approved	Cytosol	Renal cancer:6.25e-6 (favourable), Pancreatic cancer:3.11e-5 (favourable)	Expressed in all	Expressed in all			liver: 25.7	Mixed		
GARS	CMT2D, DSMAV, GlyRS, SMAD1	ENSG00000106105	Glycyl-tRNA synthetase	7	30594681-30634033	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA017896, HPA019097	Enhanced		Supported	Cytosol	Renal cancer:1.70e-5 (unfavourable), Urothelial cancer:3.04e-5 (unfavourable), Liver cancer:8.95e-5 (unfavourable), Breast cancer:1.02e-4 (unfavourable), Endometrial cancer:8.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 96.0	Expressed in all		
GATM	AGAT	ENSG00000171766	Glycine amidinotransferase	15	45361124-45402327	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026077	Enhanced		Supported	Mitochondria	Renal cancer:1.38e-4 (favourable)	Expressed in all	Group enriched	6	kidney: 1904.2;liver: 1291.1;pancreas: 573.9	ovary: 195.7	Cell line enhanced		RH-30: 190.4;U-266/70: 92.4;U-266/84: 115.1
GBA	GBA1, GLUC	ENSG00000177628	Glucosylceramidase beta	1	155234452-155244699	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006667, CAB037171, CAB037289	Supported					Expressed in all	Expressed in all			parathyroid gland: 276.1	Expressed in all		
GBA2	AD035, DKFZp762K054, KIAA1605, SPG46	ENSG00000070610	Glucosylceramidase beta 2	9	35736866-35749228	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024026	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.24e-11 (favourable), Pancreatic cancer:6.00e-4 (favourable), Urothelial cancer:6.60e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 64.2	Expressed in all		
GBE1		ENSG00000114480	1,4-alpha-glucan branching enzyme 1	3	81489699-81762161	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038073, HPA038074, HPA038075	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			adipose tissue: 79.6	Expressed in all		
GCDH	ACAD5	ENSG00000105607	Glutaryl-CoA dehydrogenase	19	12891026-12914207	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043252, HPA048492	Enhanced		Supported	Mitochondria	Renal cancer:6.79e-8 (favourable), Liver cancer:7.28e-5 (favourable), Lung cancer:3.35e-4 (favourable)	Expressed in all	Expressed in all			liver: 42.9	Expressed in all		
GCH1	DYT14, DYT5, DYT5a, GCH, GTPCH1	ENSG00000131979	GTP cyclohydrolase 1	14	54842008-54902852	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028612	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Pancreatic cancer:1.41e-4 (favourable), Urothelial cancer:6.67e-4 (favourable), Ovarian cancer:8.69e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 22.6	liver: 18.8	Cell line enhanced		SH-SY5Y: 48.2
GCK	HK4, MODY2	ENSG00000106633	Glucokinase	7	44144271-44198170	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007034, HPA007093	Approved		Approved	Golgi apparatus<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 2.5	Cell line enriched	6	SCLC-21H: 7.7
GCLC	GCS, GLCL, GLCLC	ENSG00000001084	Glutamate-cysteine ligase catalytic subunit	6	53497341-53616970	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009569, HPA036359, HPA036360	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.83e-6 (favourable), Thyroid cancer:8.24e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 80.9	Expressed in all		
GCNT2	bA360O19.2, bA421M1.1, CCAT, GCNT5, IGNT, II, NACGT1, NAGCT1, ULG3	ENSG00000111846	Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)	6	10492223-10629368	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026776	Approved		Supported	Golgi apparatus		Mixed	Tissue enhanced		prostate: 55.7	breast: 13.9	Cell line enhanced		CACO-2: 39.6;EFO-21: 67.0
GFER	ALR, ERV1, HERV1, HPO1, HPO2, HSS	ENSG00000127554	Growth factor, augmenter of liver regeneration	16	1984207-1987749	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041227, HPA063553	Approved		Enhanced	Mitochondria<br>Cytosol	Renal cancer:4.06e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 50.0	Expressed in all		
GFPT1	GFA, GFAT, GFAT1, GFPT	ENSG00000198380	Glutamine--fructose-6-phosphate transaminase 1	2	69319769-69387254	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047240			Approved	Nucleus<br>Nucleoli	Colorectal cancer:7.13e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 81.8	Expressed in all		
GGT1	CD224, D22S672, D22S732, GGT	ENSG00000100031	Gamma-glutamyltransferase 1	22	24583750-24629005	Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045635, HPA047534, HPA065444	Supported		Approved	Vesicles	Renal cancer:4.83e-4 (favourable), Ovarian cancer:7.44e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 161.2	small intestine: 95.9	Cell line enhanced		HDLM-2: 148.2;Karpas-707: 162.6;RPMI-8226: 159.9;RPTEC TERT1: 155.8
GHSR		ENSG00000121853	Growth hormone secretagogue receptor	3	172445133-172448456	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			adrenal gland: 0.3	Not detected		
GJA3	CX46, CZP3	ENSG00000121743	Gap junction protein alpha 3	13	20138255-20161049	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014821	Supported					Tissue enhanced	Tissue enhanced		heart muscle: 5.1;parathyroid gland: 5.9;placenta: 3.5	testis: 2.4	Cell line enhanced		CAPAN-2: 6.8;HL-60: 5.2
GJA8	CAE, CAE1, CX50, CZP1	ENSG00000121634	Gap junction protein alpha 8	1	147907956-147909257	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014715, HPA062940	Enhanced					Not detected	Tissue enriched	86	testis: 11.4	kidney,smooth muscle: 0.1	Not detected		
GJB1	CMTX, CMTX1, CX32	ENSG00000169562	Gap junction protein beta 1	X	71215194-71225516	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB012994	Uncertain				Renal cancer:2.85e-6 (favourable)	Tissue enhanced	Tissue enhanced		liver: 159.4	gallbladder: 59.2	Group enriched	6	Hep G2: 94.2;SK-MEL-30: 123.7
GJB2	CX26, DFNA3, DFNB1, NSRD1	ENSG00000165474	Gap junction protein beta 2	13	20187470-20192898	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB013093, HPA014362	Uncertain		Approved	Mitochondria	Renal cancer:2.53e-6 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable), Glioma:5.98e-4 (unfavourable), Lung cancer:6.25e-4 (unfavourable)	Expressed in all	Tissue enriched	9	esophagus: 725.5	tonsil: 81.3	Cell line enhanced		CAPAN-2: 129.4;hTCEpi: 78.0;RT4: 137.8
GJB3	CX31, DFNA2, EKV	ENSG00000188910	Gap junction protein beta 3	1	34781189-34786369	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA074472			Supported	Vesicles<br>Cell Junctions	Pancreatic cancer:7.56e-5 (unfavourable), Lung cancer:4.56e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 33.6;skin: 77.3	tonsil: 11.6	Cell line enhanced		A-431: 76.8;CAPAN-2: 106.8;HaCaT: 87.5;HBEC3-KT: 60.8;hTCEpi: 98.5
GK	GK1, GKD	ENSG00000198814	Glycerol kinase	X	30653359-30731456	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060687	Supported				Renal cancer:3.24e-9 (favourable)	Expressed in all	Tissue enhanced		kidney: 111.0	small intestine: 98.6	Mixed		
GLA	GALA	ENSG00000102393	Galactosidase alpha	X	101397803-101407925	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA000237, HPA000966	Enhanced				Liver cancer:5.62e-5 (unfavourable), Stomach cancer:6.16e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 59.2	Expressed in all		
GLB1	EBP, ELNR1	ENSG00000170266	Galactosidase beta 1	3	32996608-33097230	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008382, HPA040610, HPA069503	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.14e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 122.5	Cell line enriched	5	BEWO: 804.9
GLDC	GCSP, NKH	ENSG00000178445	Glycine decarboxylase	9	6532464-6645783	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002318, HPA052887	Enhanced		Supported	Nucleus<br>Mitochondria	Endometrial cancer:5.24e-5 (unfavourable), Renal cancer:3.50e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 30.3;liver: 19.9;placenta: 20.1	cerebral cortex: 10.6	Cell line enhanced		BEWO: 206.9;RPTEC TERT1: 67.4
GLE1	GLE1L, hGLE1, LCCS1	ENSG00000119392	GLE1, RNA export mediator	9	128504700-128542288	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA041689, HPA043538, HPA061560	Supported		Supported	Nuclear membrane<br>Nucleoli	Stomach cancer:7.04e-4 (favourable), Endometrial cancer:7.49e-4 (favourable)	Expressed in all	Expressed in all			testis: 58.8	Expressed in all		
GLUD1	GDH, GLUD	ENSG00000148672	Glutamate dehydrogenase 1	10	87050486-87094866	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA042492, HPA044839, HPA061369	Approved		Supported	Mitochondria	Renal cancer:1.44e-6 (favourable), Pancreatic cancer:1.76e-5 (unfavourable), Glioma:5.08e-4 (favourable)	Expressed in all	Expressed in all			liver: 457.9	Expressed in all		
GLUL	GLNS	ENSG00000135821	Glutamate-ammonia ligase	1	182381704-182392206	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007316, HPA007571, CAB008636	Approved		Supported	Mitochondria<br>Cytosol	Breast cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 851.0	Cell line enhanced		ASC diff: 791.8;ASC TERT1: 567.1;HSkMC: 512.4
GLYCTK	HBEBP2, HBEBP4	ENSG00000168237	Glycerate kinase	3	52287089-52293476	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006913	Approved		Approved	Golgi apparatus<br>Cytosol<br>Rods & Rings	Head and neck cancer:1.64e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 38.3;liver: 60.6	small intestine: 31.8	Expressed in all		
GMPPB	KIAA1851	ENSG00000173540	GDP-mannose pyrophosphorylase B	3	49716844-49723951	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA014657	Uncertain		Supported	Nucleus	Endometrial cancer:6.19e-6 (favourable), Renal cancer:3.17e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 42.0	Expressed in all		
GMPS		ENSG00000163655	Guanine monophosphate synthase	3	155870536-155944026	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046630			Approved	Cytosol	Liver cancer:8.73e-7 (unfavourable), Endometrial cancer:5.54e-5 (unfavourable), Pancreatic cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 181.7	Expressed in all		
GNE	IBM2, Uae1	ENSG00000159921	Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	9	36214441-36277056	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007045, HPA027258	Approved		Supported	Cytosol	Renal cancer:9.28e-11 (favourable)	Expressed in all	Expressed in all			rectum: 53.4	Cell line enhanced		RPTEC TERT1: 82.9
GNMT		ENSG00000124713	Glycine N-methyltransferase	6	42960758-42963880	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027501	Enhanced		Approved	Cytosol	Liver cancer:1.86e-4 (favourable)	Group enriched	Group enriched	9	liver: 155.0;pancreas: 55.8;prostate: 32.7	breast: 9.4	Cell line enhanced		Hep G2: 5.7;SCLC-21H: 11.3;T-47d: 5.8
GNPAT	DAP-AT, DAPAT, DHAPAT	ENSG00000116906	Glyceronephosphate O-acyltransferase	1	231241207-231277973	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.29e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 59.7	Expressed in all		
GNPTAB	GNPTA, KIAA1208, MGC4170	ENSG00000111670	N-acetylglucosamine-1-phosphate transferase alpha and beta subunits	12	101745497-101830938	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014558, HPA042343	Approved		Supported	Golgi apparatus	Endometrial cancer:8.48e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.1	Expressed in all		
GNS		ENSG00000135677	Glucosamine (N-acetyl)-6-sulfatase	12	64713445-64759447	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013695, CAB026011, HPA048508	Enhanced				Liver cancer:1.94e-5 (unfavourable), Glioma:4.17e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 172.9	Expressed in all		
GPD1		ENSG00000167588	Glycerol-3-phosphate dehydrogenase 1	12	50103819-50111319	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044620	Enhanced					Mixed	Tissue enhanced		adipose tissue: 636.1;skeletal muscle: 195.7	kidney: 148.1	Cell line enhanced		ASC diff: 86.3;CACO-2: 22.1;Hep G2: 17.0;RPMI-8226: 20.7
GPD1L	KIAA0089	ENSG00000152642	Glycerol-3-phosphate dehydrogenase 1-like	3	32105689-32168713	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.33e-15 (favourable), Liver cancer:1.35e-5 (unfavourable), Lung cancer:5.71e-5 (favourable), Colorectal cancer:7.05e-4 (favourable)	Expressed in all	Expressed in all			prostate: 92.5	Expressed in all		
GPHN	KIAA1385	ENSG00000171723	Gephyrin	14	66507407-67181803	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003116, CAB004419, HPA024694	Enhanced		Uncertain	Cytoplasmic bodies	Renal cancer:5.25e-12 (favourable), Urothelial cancer:4.61e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.5	Mixed		
GPI	AMF, NLK	ENSG00000105220	Glucose-6-phosphate isomerase	19	34359480-34402156	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018655, HPA024305, CAB040563, HPA052171	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 314.1	Expressed in all		
GPR101		ENSG00000165370	G protein-coupled receptor 101	X	137030148-137031674	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001084	Uncertain					Not detected	Not detected			cerebral cortex: 0.1	Not detected		
GPR143	OA1	ENSG00000101850	G protein-coupled receptor 143	X	9725346-9786297	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003648	Enhanced				Renal cancer:2.45e-5 (favourable), Cervical cancer:8.73e-4 (favourable)	Tissue enriched	Mixed			skin: 10.3	Cell line enriched	7	SK-MEL-30: 119.4
GPR68	OGR1	ENSG00000119714	G protein-coupled receptor 68	14	91232532-91253925	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:3.06e-5 (favourable)	Mixed	Mixed			appendix: 8.1	Cell line enhanced		U-87 MG: 31.4
GPR88		ENSG00000181656	G protein-coupled receptor 88	1	100538137-100542018	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at transcript level	HPA007488		Approved				Tissue enriched	Group enriched	11	breast: 9.4;cerebral cortex: 3.1;liver: 4.9;ovary: 3.1;parathyroid gland: 4.9;spleen: 14.4	prostate: 0.6	Group enriched	8	HSkMC: 1.1;SCLC-21H: 2.3
GPT2	ALT2	ENSG00000166123	Glutamic--pyruvic transaminase 2	16	46884378-46931297	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051514	Approved		Approved	Mitochondria	Ovarian cancer:3.17e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 85.0	Mixed		
GPX4	MCSP, PHGPx	ENSG00000167468	Glutathione peroxidase 4	19	1103926-1106791	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008630, HPA047224, HPA058546	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Endometrial cancer:1.84e-5 (favourable), Cervical cancer:7.18e-4 (favourable), Pancreatic cancer:7.72e-4 (favourable), Renal cancer:8.61e-4 (favourable)	Expressed in all	Expressed in all			testis: 1140.7	Expressed in all		
GPX7	FLJ14777, GPX6, NPGPx	ENSG00000116157	Glutathione peroxidase 7	1	52602372-52609051	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA025829			Approved	Nucleoli	Renal cancer:2.26e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 42.1	Cell line enhanced		REH: 69.6;RPMI-8226: 89.3;THP-1: 68.1
GRHPR	GLXR, PH2	ENSG00000137106	Glyoxylate and hydroxypyruvate reductase	9	37422666-37436990	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022971	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.39e-9 (favourable), Breast cancer:7.00e-5 (favourable)	Expressed in all	Expressed in all			liver: 323.3	Expressed in all		
GRIA3	GluA3, GLUR3, GLURC, MRX94	ENSG00000125675	Glutamate ionotropic receptor AMPA type subunit 3	X	123184153-123490915	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA058659	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 56.6	adrenal gland: 11.3	Cell line enhanced		BJ: 20.3;BJ hTERT+: 28.1;fHDF/TERT166: 35.8;U-2197: 14.1
GRK1	GPRK1, RHOK, RK	ENSG00000185974	G protein-coupled receptor kinase 1	13	113667155-113737735	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035200, HPA059376	Enhanced					Tissue enhanced	Not detected			thyroid gland: 0.8	Not detected		
GRM1	GPRC1A, mGlu1, MGLUR1, PPP1R85	ENSG00000152822	Glutamate metabotropic receptor 1	6	146027646-146437598	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015701	Approved		Approved	Vesicles		Not detected	Group enriched	5	cerebral cortex: 7.0;heart muscle: 1.7	kidney: 0.8	Not detected		
GRM6	CSNB1B, GPRC1F, mGlu6, MGLUR6	ENSG00000113262	Glutamate metabotropic receptor 6	5	178978327-178996206	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA014511	Supported					Not detected	Not detected			testis: 0.7	Not detected		
GUCY1A3	GC-SA3, GUC1A3	ENSG00000164116	Guanylate cyclase 1 soluble subunit alpha	4	155666711-155732349	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010887, HPA056004, HPA058617	Uncertain		Supported	Nucleus	Lung cancer:2.38e-4 (favourable), Testis cancer:3.59e-4 (unfavourable), Renal cancer:7.59e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 136.7	smooth muscle: 43.8	Cell line enhanced		HAP1: 7.2;Karpas-707: 7.1;MOLT-4: 15.2;RPTEC TERT1: 9.3;RT4: 11.7;SH-SY5Y: 9.5
GUCY2D	CORD6, CYGD, GUC1A4, GUC2D, LCA, LCA1, retGC, RETGC-1, ROS-GC1	ENSG00000132518	Guanylate cyclase 2D, retinal	17	8002594-8020339	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enhanced		testis: 1.4	lymph node: 0.3	Cell line enriched	6	HMC-1: 1.1
GUSB		ENSG00000169919	Glucuronidase beta	7	65960684-65982314	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA036322, HPA036323	Approved		Supported	Vesicles		Expressed in all	Expressed in all			breast: 95.9	Expressed in all		
GYG1	GYG	ENSG00000163754	Glycogenin 1	3	148991341-149027668	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030497	Approved		Supported	Vesicles	Liver cancer:6.15e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 210.0	Mixed		
GYS1	GSY, GYS	ENSG00000104812	Glycogen synthase 1	19	48968125-48993310	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB007793, HPA041598	Enhanced		Approved	Microtubules<br>Cytosol	Renal cancer:3.46e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 109.7	Expressed in all		
GYS2		ENSG00000111713	Glycogen synthase 2	12	21536189-21604847	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039482	Approved				Liver cancer:7.62e-5 (favourable)	Tissue enriched	Tissue enriched	23	liver: 91.8	adipose tissue: 3.9	Cell line enhanced		CACO-2: 1.0
H6PD	GDH	ENSG00000049239	Hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	1	9234775-9271337	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA004824, HPA005440	Approved		Uncertain	Cytosol		Expressed in all	Expressed in all			ovary: 42.8	Mixed		
HABP2	FSAP, HABP, HGFAL, PHBP	ENSG00000148702	Hyaluronan binding protein 2	10	113550837-113589602	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019518	Approved					Tissue enriched	Group enriched	12	gallbladder: 55.8;liver: 225.6	stomach: 11.3	Cell line enriched	5	RPTEC TERT1: 38.3
HACD1	CAP, PTPLA	ENSG00000165996	3-hydroxyacyl-CoA dehydratase 1	10	17589032-17617377	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		heart muscle: 42.0	smooth muscle: 36.3	Mixed		
HACE1	KIAA1320	ENSG00000085382	HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1	6	104728093-104859919	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046071			Supported	Nuclear bodies<br>Endoplasmic reticulum	Renal cancer:1.17e-5 (unfavourable), Thyroid cancer:7.50e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 44.1	testis: 19.1	Mixed		
HADH	HADH1, HADHSC, SCHAD	ENSG00000138796	Hydroxyacyl-CoA dehydrogenase	4	107989714-108035175	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039588, HPA043888	Supported		Supported	Mitochondria	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			adipose tissue: 154.5	Expressed in all		
HADHA	GBP, LCEH, LCHAD, MTPA	ENSG00000084754	Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit	2	26190635-26244726	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015536, HPA056070	Approved		Enhanced	Mitochondria	Renal cancer:3.68e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 235.3	Expressed in all		
HADHB	MTPB	ENSG00000138029	Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit	2	26243170-26290468	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037539, HPA037540, HPA066099	Enhanced		Supported	Mitochondria	Renal cancer:1.37e-9 (favourable)	Expressed in all	Expressed in all			heart muscle: 300.8	Expressed in all		
HAL	HIS	ENSG00000084110	Histidine ammonia-lyase	12	95972662-95996365	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038547, HPA038548	Enhanced		Uncertain	Cytosol		Tissue enriched	Group enriched	8	liver: 51.2;skin: 72.5	bone marrow: 7.4	Cell line enhanced		BEWO: 2.1;THP-1: 7.4
HAMP	HEPC, HFE2B, LEAP-1, LEAP1	ENSG00000105697	Hepcidin antimicrobial peptide	19	35280716-35285143	Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level							Group enriched	Tissue enriched	12	liver: 259.1	heart muscle: 21.9	Cell line enriched	127	Hep G2: 135.7
HARS		ENSG00000170445	Histidyl-tRNA synthetase	5	140673173-140692024	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036539	Approved		Enhanced	Cytosol	Liver cancer:1.96e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 71.1	Expressed in all		
HARS2	HARSL, HARSR, HO3	ENSG00000112855	Histidyl-tRNA synthetase 2, mitochondrial	5	140691426-140699291	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA035941	Approved		Approved	Cytosol	Liver cancer:2.92e-4 (unfavourable), Colorectal cancer:6.19e-4 (favourable), Breast cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.5	Expressed in all		
HAS2		ENSG00000170961	Hyaluronan synthase 2	8	121612116-121641390	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA052060			Approved	Nuclear speckles		Mixed	Tissue enhanced		adipose tissue: 27.9	gallbladder: 12.7	Cell line enhanced		HBF TERT88: 154.7;hTEC/SVTERT24-B: 155.8;LHCN-M2: 174.3;U-138 MG: 396.2;U-251 MG: 103.0
HCCS	CCHL, MLS	ENSG00000004961	Holocytochrome c synthase	X	11111301-11123078	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA002946	Approved		Enhanced	Mitochondria	Renal cancer:6.17e-8 (favourable), Liver cancer:1.35e-5 (unfavourable), Breast cancer:8.69e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 31.5	Expressed in all		
HCK	JTK9	ENSG00000101336	HCK proto-oncogene, Src family tyrosine kinase	20	32052188-32101856	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005195, HPA063768	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:1.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 149.6;spleen: 113.2	lung: 74.1	Group enriched	8	THP-1: 48.4;U-937: 161.1
HCN1	BCNG-1, BCNG1, HAC-2	ENSG00000164588	Hyperpolarization activated cyclic nucleotide gated potassium channel 1	5	45254950-45696498	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA019195	Enhanced					Not detected	Tissue enriched	8	cerebral cortex: 4.9	heart muscle: 0.6	Cell line enhanced		WM-115: 1.0
HCN4		ENSG00000138622	Hyperpolarization activated cyclic nucleotide gated potassium channel 4	15	73319859-73369264	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Group enriched	Group enriched	6	cerebral cortex: 1.4;heart muscle: 1.5;testis: 6.7	adrenal gland: 0.5	Cell line enhanced		AF22: 1.2;CACO-2: 1.3;NTERA-2: 4.7;U-2 OS: 2.1
HECW2	KIAA1301, NEDL2	ENSG00000138411	HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2	2	196194370-196593692	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034609	Uncertain		Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum	Renal cancer:5.18e-5 (unfavourable)	Mixed	Mixed			placenta: 15.8	Cell line enhanced		HDLM-2: 59.6;HUVEC TERT2: 24.5;SCLC-21H: 45.1;TIME: 32.0
HEPACAM	FLJ25530, GLIALCAM, hepaCAM	ENSG00000165478	Hepatic and glial cell adhesion molecule	11	124919193-124936412	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017613, CAB025486	Enhanced		Approved	Vesicles		Tissue enriched	Tissue enriched	5	cerebral cortex: 80.7	adipose tissue: 15.1	Cell line enriched	27	Hep G2: 18.8
HERC1	p532, p619	ENSG00000103657	HECT and RLD domain containing E3 ubiquitin protein ligase family member 1	15	63608618-63833942	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049749	Uncertain				Renal cancer:1.36e-6 (favourable), Head and neck cancer:4.87e-5 (favourable), Pancreatic cancer:3.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 58.6	Expressed in all		
HERC2	D15F37S1, jdf2, p528	ENSG00000128731	HECT and RLD domain containing E3 ubiquitin protein ligase 2	15	28111040-28322152	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017188, HPA048389	Approved		Approved	Vesicles	Renal cancer:1.41e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.1	Cell line enhanced		HEL: 48.6
HEXA		ENSG00000213614	Hexosaminidase subunit alpha	15	72340919-72376476	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA054583	Supported				Endometrial cancer:5.63e-8 (favourable)	Expressed in all	Expressed in all			epididymis: 200.6	Mixed		
HEXB		ENSG00000049860	Hexosaminidase subunit beta	5	74640023-74722647	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA055409, HPA056010	Enhanced				Liver cancer:3.36e-8 (unfavourable)	Expressed in all	Expressed in all			placenta: 440.8	Mixed		
HFM1	FLJ36760, FLJ39011, MER3, SEC63D1	ENSG00000162669	HFM1, ATP dependent DNA helicase homolog	1	91260766-91404869	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035036, HPA035557			Supported	Golgi apparatus<br>Vesicles		Tissue enhanced	Tissue enriched	5	testis: 25.0	ovary: 4.7	Cell line enhanced		AF22: 5.1;AN3-CA: 2.6;K-562: 2.6;SCLC-21H: 2.1;SH-SY5Y: 2.3
HGD	AKU, HGO	ENSG00000113924	Homogentisate 1,2-dioxygenase	3	120628173-120682571	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047374, HPA052359	Enhanced		Supported	Golgi apparatus	Endometrial cancer:1.78e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 175.8;liver: 324.3	gallbladder: 87.1	Group enriched	10	CACO-2: 38.8;EFO-21: 75.8;Hep G2: 110.3;RPTEC TERT1: 153.1
HGF	DFNB39, F-TCF, HGFB, HPTA, SF	ENSG00000019991	Hepatocyte growth factor	7	81699006-81770438	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010333, HPA040360, HPA044088	Approved		Approved	Centrosome<br>Cytosol	Renal cancer:5.59e-4 (unfavourable)	Mixed	Tissue enriched	16	placenta: 438.8	gallbladder: 27.5	Cell line enhanced		ASC TERT1: 118.1;HHSteC: 111.7;HL-60: 63.0;hTEC/SVTERT24-B: 86.9;Karpas-707: 174.5;U-87 MG: 60.7
HGSNAT	FLJ32731, HGNAT, TMEM76	ENSG00000165102	Heparan-alpha-glucosaminide N-acetyltransferase	8	43140455-43202855	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA029578	Approved				Ovarian cancer:6.33e-5 (favourable), Glioma:7.02e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 49.2	Expressed in all		
HIBCH		ENSG00000198130	3-hydroxyisobutyryl-CoA hydrolase	2	190189735-190344193	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036540, HPA036541	Enhanced		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.04e-10 (favourable), Ovarian cancer:1.22e-4 (favourable)	Expressed in all	Expressed in all			kidney: 180.6	Expressed in all		
HK1		ENSG00000156515	Hexokinase 1	10	69269984-69401882	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007043, HPA007044, CAB010052, HPA011956	Supported		Enhanced	Mitochondria	Head and neck cancer:3.39e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 153.6	Cell line enhanced		K-562: 491.8
HLCS	HCS	ENSG00000159267	Holocarboxylase synthetase	21	36750888-36990236	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017379	Approved		Supported	Cytosol	Breast cancer:7.72e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.7	Expressed in all		
HMBS	PBGD, PORC, UPS	ENSG00000256269	Hydroxymethylbilane synthase	11	119084866-119093549	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006114, HPA050659	Enhanced		Approved	Lipid droplets		Expressed in all	Tissue enriched	5	bone marrow: 52.8	parathyroid gland: 9.8	Expressed in all		
HMGCL	HL	ENSG00000117305	3-hydroxymethyl-3-methylglutaryl-CoA lyase	1	23801885-23838620	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004727	Enhanced				Renal cancer:5.07e-8 (favourable), Colorectal cancer:7.67e-4 (favourable)	Expressed in all	Expressed in all			liver: 154.3	Expressed in all		
HMGCS2		ENSG00000134240	3-hydroxy-3-methylglutaryl-CoA synthase 2	1	119747996-119768905	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027423, HPA027442, CAB032906	Enhanced		Supported	Mitochondria	Liver cancer:2.43e-7 (favourable), Renal cancer:3.43e-5 (favourable), Ovarian cancer:2.17e-4 (favourable)	Tissue enhanced	Tissue enhanced		liver: 1270.5	colon: 363.4	Cell line enriched	15	RT4: 161.6
HMOX1	bK286B10, HO-1	ENSG00000100292	Heme oxygenase 1	22	35380361-35394214	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000635, CAB017444	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane	Liver cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 428.5	Cell line enhanced		BEWO: 701.9;U-138 MG: 414.7;U-87 MG: 399.9
HNMT		ENSG00000150540	Histamine N-methyltransferase	2	137964020-138016364	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035480, HPA035481	Approved				Pancreatic cancer:3.41e-4 (unfavourable), Urothelial cancer:4.68e-4 (favourable)	Expressed in all	Expressed in all			liver: 124.0	Cell line enhanced		Hep G2: 152.7;RT4: 91.6
HOGA1	C10orf65, DHDPS2, DHDPSL, FLJ37472, NPL2	ENSG00000241935	4-hydroxy-2-oxoglutarate aldolase 1	10	97584323-97612802	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039466	Approved				Renal cancer:9.08e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 53.4;liver: 20.7	heart muscle: 8.5	Cell line enhanced		EFO-21: 9.0;Hep G2: 17.6;RPTEC TERT1: 23.2
HP		ENSG00000257017	Haptoglobin	16	72054592-72061055	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB003787, HPA047750	Enhanced		Approved	Vesicles	Renal cancer:6.94e-13 (unfavourable)	Tissue enriched	Tissue enriched	182	liver: 28407.0	bone marrow: 155.8	Cell line enhanced		Hep G2: 153.5;HSkMC: 88.2
HPGD	SDR36C1	ENSG00000164120	Hydroxyprostaglandin dehydrogenase 15-(NAD)	4	174490177-174523154	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004919, HPA005679	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.20e-4 (favourable)	Tissue enhanced	Tissue enhanced		urinary bladder: 375.7	stomach: 181.5	Cell line enhanced		A549: 128.2;HEL: 282.4;RT4: 385.2
HSD11B1	HSD11, HSD11B, SDR26C1	ENSG00000117594	Hydroxysteroid 11-beta dehydrogenase 1	1	209686178-209734950	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047729	Enhanced				Renal cancer:1.97e-10 (unfavourable)	Tissue enriched	Group enriched	9	liver: 492.5;placenta: 105.1	ovary: 31.6	Group enriched	6	ASC diff: 678.2;HHSteC: 173.0
HSD17B10	17b-HSD10, ABAD, CAMR, ERAB, HADH2, MHBD, MRPP2, MRXS10, SDR5C1	ENSG00000072506	Hydroxysteroid 17-beta dehydrogenase 10	X	53431258-53434373	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001432	Approved				Cervical cancer:2.80e-4 (favourable)	Expressed in all	Expressed in all			liver: 126.6	Expressed in all		
HSD17B3	SDR12C2	ENSG00000130948	Hydroxysteroid 17-beta dehydrogenase 3	9	96235306-96302152	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056833	Enhanced		Supported	Vesicles		Mixed	Tissue enriched	15	testis: 74.9	thyroid gland: 4.8	Cell line enhanced		HBEC3-KT: 2.6;HEL: 3.2;U-2 OS: 5.8
HSD17B4	DBP, MFE-2, SDR8C1	ENSG00000133835	Hydroxysteroid 17-beta dehydrogenase 4	5	119452443-119637199	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021302, HPA021311, HPA021479	Enhanced		Enhanced	Peroxisomes	Renal cancer:6.31e-6 (favourable), Colorectal cancer:1.33e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 229.7	Expressed in all		
HSD3B7	C(27)-3BETA-HSD, SDR11E3	ENSG00000099377	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7	16	30985207-30989152	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050521, HPA060847	Uncertain		Supported	Lipid droplets	Renal cancer:1.60e-6 (unfavourable), Colorectal cancer:5.95e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 21.9	Cell line enhanced		HDLM-2: 83.9;HMC-1: 85.9;U-2197: 89.0
HSPD1	GroEL, HSP60, SPG13	ENSG00000144381	Heat shock protein family D (Hsp60) member 1	2	197486581-197516737	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001523, CAB002775, HPA050025, CAB072816	Supported		Enhanced	Mitochondria	Endometrial cancer:1.61e-4 (unfavourable), Liver cancer:2.25e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 834.1	Expressed in all		
HTRA1	ARMD7, HtrA, IGFBP5-protease, PRSS11	ENSG00000166033	HtrA serine peptidase 1	10	122461525-122514908	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036655	Enhanced		Supported	Plasma membrane	Renal cancer:7.90e-7 (unfavourable), Urothelial cancer:5.62e-6 (unfavourable), Glioma:8.66e-4 (unfavourable)	Expressed in all	Mixed			ovary: 503.4	Cell line enhanced		ASC diff: 1649.0;HSkMC: 1139.5;LHCN-M2: 1027.1;U-87 MG: 974.2
HTRA2	OMI, PARK13, PRSS25	ENSG00000115317	HtrA serine peptidase 2	2	74529377-74533348	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB004004, HPA006602, HPA027366	Uncertain		Supported	Mitochondria	Liver cancer:7.77e-8 (unfavourable)	Expressed in all	Mixed			spleen: 9.0	Expressed in all		
HUWE1	Ib772, KIAA0312, UREB1	ENSG00000086758	HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase	X	53532096-53686729	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002548, CAB022718	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 96.6	Expressed in all		
HYAL1	FUS2, HYAL-1, LUCA1, NAT6	ENSG00000114378	Hyaluronoglucosaminidase 1	3	50299889-50312381	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002112	Uncertain				Renal cancer:1.56e-11 (favourable), Colorectal cancer:2.07e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 71.1;spleen: 69.3	kidney: 43.5	Cell line enhanced		Hep G2: 66.6;SK-BR-3: 20.5
IARS	IARS1, ILRS	ENSG00000196305	Isoleucyl-tRNA synthetase	9	92210207-92293756	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029806	Approved		Supported	Cytosol	Liver cancer:4.98e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 141.8	Expressed in all		
IARS2	FLJ10326	ENSG00000067704	Isoleucyl-tRNA synthetase 2, mitochondrial	1	220094102-220148041	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024212, HPA024594, HPA024596	Enhanced		Enhanced	Mitochondria	Pancreatic cancer:9.24e-5 (unfavourable), Cervical cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 144.3	Expressed in all		
ICK	KIAA0936, LCK2, MGC46090, MRK	ENSG00000112144	Intestinal cell kinase	6	53001279-53061802	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000791, HPA001113	Approved		Approved	Nucleoli fibrillar center		Expressed in all	Mixed			adrenal gland: 23.1	Expressed in all		
IDH1		ENSG00000138413	Isocitrate dehydrogenase (NADP(+)) 1, cytosolic	2	208236227-208266074	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033218, HPA035248, HPA057936, CAB062556	Enhanced		Approved	Nuclear bodies<br>Cytosol	Renal cancer:2.45e-5 (unfavourable), Liver cancer:6.93e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 338.1	Expressed in all		
IDH2		ENSG00000182054	Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial	15	90083045-90102504	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007831	Enhanced		Supported	Mitochondria	Cervical cancer:5.15e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 450.0	Expressed in all		
IDH3B	RP46	ENSG00000101365	Isocitrate dehydrogenase 3 (NAD(+)) beta	20	2658395-2664219	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049387, HPA054180	Enhanced		Enhanced	Mitochondria	Renal cancer:6.78e-8 (favourable), Liver cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 100.5	Expressed in all		
IDS	SIDS	ENSG00000010404	Iduronate 2-sulfatase	X	149476990-149521096	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enriched	5	cerebral cortex: 435.8	epididymis: 86.8	Expressed in all		
IDUA	MPS1	ENSG00000127415	Iduronidase, alpha-L-	4	986997-1004506	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025901, HPA046979, HPA054254	Enhanced		Supported	Vesicles	Renal cancer:7.87e-5 (unfavourable), Urothelial cancer:8.04e-5 (favourable), Colorectal cancer:3.13e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 16.5	Cell line enhanced		U-266/70: 43.1
IFIH1	Hlcd, IDDM19, MDA-5, MDA5	ENSG00000115267	Interferon induced with helicase C domain 1	2	162267079-162318703	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002656	Approved					Expressed in all	Mixed			spleen: 31.1	Cell line enhanced		BJ hTERT+ SV40 Large T+: 72.5;BJ hTERT+ SV40 Large T+ RasG12V: 93.7
IGHMBP2	CATF1, CMT2S, HCSA, HMN6, SMARD1, SMUBP2, ZFAND7	ENSG00000132740	Immunoglobulin mu binding protein 2	11	68903842-68940602	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060994			Approved	Nucleus	Renal cancer:1.29e-8 (unfavourable), Pancreatic cancer:5.89e-4 (favourable)	Expressed in all	Expressed in all			testis: 27.9	Expressed in all		
IMMP2L	IMMP2L-IT1, IMP2	ENSG00000184903	Inner mitochondrial membrane peptidase subunit 2	7	110663051-111562517	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026711	Approved		Approved	Mitochondria	Head and neck cancer:1.89e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 39.4	Expressed in all		
IMPA1	IMPA	ENSG00000133731	Inositol monophosphatase 1	8	81657961-81686693	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037489	Approved		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			testis: 72.0	Expressed in all		
IMPAD1	FLJ20421, gPAPP, IMPA3	ENSG00000104331	Inositol monophosphatase domain containing 1	8	56957933-56993844	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009411	Supported		Supported	Nucleus<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 52.7	Expressed in all		
INPP5E	CORS1, JBTS1, pharbin, PPI5PIV	ENSG00000148384	Inositol polyphosphate-5-phosphatase E	9	136428619-136439823	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA065758	Approved				Pancreatic cancer:1.82e-4 (favourable)	Expressed in all	Expressed in all			testis: 15.9	Expressed in all		
INPPL1	SHIP2	ENSG00000165458	Inositol polyphosphate phosphatase like 1	11	72223701-72239105	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037601	Approved		Supported	Golgi apparatus<br>Cytosol	Liver cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 64.3	Expressed in all		
IRAK3	IRAK-M	ENSG00000090376	Interleukin 1 receptor associated kinase 3	12	66188879-66254622	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043097	Approved		Approved	Vesicles	Renal cancer:6.23e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 51.0	adipose tissue: 19.3	Cell line enhanced		HEL: 20.3;HL-60: 24.1;THP-1: 24.3;U-937: 20.5
IRAK4	NY-REN-64	ENSG00000198001	Interleukin 1 receptor associated kinase 4	12	43758944-43789543	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB016685, CAB022077	Uncertain		Approved	Nucleoli<br>Microtubules<br>Cytosol	Endometrial cancer:3.46e-5 (favourable), Urothelial cancer:4.42e-5 (favourable)	Expressed in all	Mixed			lymph node: 20.3	Expressed in all		
ITCH	AIP4	ENSG00000078747	Itchy E3 ubiquitin protein ligase	20	34363235-34511393	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021126, HPA049032	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 73.2	Expressed in all		
ITGA6	CD49f	ENSG00000091409	Integrin subunit alpha 6	2	172427354-172506282	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009009, HPA012696, HPA027582	Enhanced				Renal cancer:2.35e-11 (favourable), Head and neck cancer:1.03e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 114.9	Cell line enhanced		HaCaT: 319.9;HBEC3-KT: 511.4
ITK	EMT, LYK, PSCTK2	ENSG00000113263	IL2 inducible T-cell kinase	5	157142933-157255191	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 20.2;lymph node: 33.2;tonsil: 22.3	spleen: 14.0	Cell line enhanced		HDLM-2: 3.2;HEL: 3.4;HMC-1: 3.8;MOLT-4: 18.7
ITPA	C20orf37, dJ794I6.3, HLC14-06-P	ENSG00000125877	Inosine triphosphatase	20	3208868-3223870	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022824	Approved		Supported	Cytosol	Liver cancer:2.54e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 40.3	Expressed in all		
ITPKC	IP3-3KC, IP3KC	ENSG00000086544	Inositol-trisphosphate 3-kinase C	19	40717103-40740860	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050760, HPA053003	Approved		Supported	Nuclear speckles	Lung cancer:4.91e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 69.3	Mixed		
ITPR1	ACV, Insp3r1, IP3R1, PPP1R94, SCA15, SCA16, SCA29	ENSG00000150995	Inositol 1,4,5-trisphosphate receptor type 1	3	4493348-4847840	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014765, HPA016487	Approved		Approved	Vesicles	Thyroid cancer:3.43e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 106.8	thyroid gland: 47.4	Cell line enhanced		HDLM-2: 75.1;HeLa: 38.4;U-87 MG: 44.6
IVD	ACAD2	ENSG00000128928	Isovaleryl-CoA dehydrogenase	15	40405795-40435947	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041391, HPA044250	Enhanced		Enhanced	Nucleoplasm<br>Mitochondria	Renal cancer:2.91e-9 (favourable), Liver cancer:1.95e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 151.7	Mixed		
IYD	C6orf71, DEHAL1, dJ422F24.1	ENSG00000009765	Iodotyrosine deiodinase	6	150368892-150405969	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA059627	Enhanced		Supported	Plasma membrane	Liver cancer:6.22e-4 (favourable)	Tissue enriched	Tissue enriched	28	thyroid gland: 794.5	kidney: 27.9	Cell line enhanced		CACO-2: 1.1;SK-BR-3: 2.4
KALRN	ARHGEF24, DUET, duo, HAPIP, Hs.8004, Kalirin, TRAD	ENSG00000160145	Kalirin, RhoGEF kinase	3	124080023-124726325	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011913, CAB026456	Approved		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 51.3	spleen: 11.8	Cell line enhanced		CACO-2: 47.6;HEL: 31.9;SH-SY5Y: 16.9
KARS	DFNB89, KARS1, KARS2	ENSG00000065427	Lysyl-tRNA synthetase	16	75627474-75648643	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041345, HPA041550	Enhanced		Supported	Cytosol	Head and neck cancer:8.84e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 178.6	Expressed in all		
KAT6A	MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220	ENSG00000083168	Lysine acetyltransferase 6A	8	41929479-42051990	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017023, HPA063266, HPA065052	Supported		Approved	Nucleoli<br>Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 34.5	Expressed in all		
KAT6B	Morf, MOZ2, MYST4, qkf, querkopf, ZC2HC6B	ENSG00000156650	Lysine acetyltransferase 6B	10	74825582-75032622	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006104	Supported		Approved	Nucleus<br>Nuclear bodies	Renal cancer:4.82e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.3	Expressed in all		
KCNH1	eag, eag1, h-eag, Kv10.1	ENSG00000143473	Potassium voltage-gated channel subfamily H member 1	1	210676823-211134180	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014551, HPA019445	Enhanced		Approved	Vesicles		Not detected	Tissue enriched	6	cerebral cortex: 6.2	testis: 1.0	Cell line enhanced		RH-30: 4.9;SH-SY5Y: 6.8;SK-MEL-30: 4.8;T-47d: 4.3
KCNJ10	Kir1.2, Kir4.1	ENSG00000177807	Potassium voltage-gated channel subfamily J member 10	1	159998651-160070483	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA078302	Enhanced					Tissue enriched	Group enriched	5	cerebral cortex: 124.7;kidney: 30.6	spleen: 14.5	Cell line enhanced		Hep G2: 4.5;SK-MEL-30: 1.6;U-266/70: 1.6
KCNJ13	Kir1.4, Kir7.1, LCA16	ENSG00000115474	Potassium voltage-gated channel subfamily J member 13	2	232766464-232776568	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Tissue enriched	Group enriched	5	parathyroid gland: 25.8;small intestine: 112.2	thyroid gland: 12.5	Cell line enhanced		U-2197: 1.2
KCNJ2	IRK1, Kir2.1, LQT7	ENSG00000123700	Potassium voltage-gated channel subfamily J member 2	17	70168673-70180048	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA029109	Approved					Mixed	Tissue enhanced		parathyroid gland: 44.6	fallopian tube: 10.6	Cell line enhanced		REH: 6.8;RH-30: 28.3;U-138 MG: 10.5
KCNJ5	CIR, GIRK4, KATP1, Kir3.4, LQT13	ENSG00000120457	Potassium voltage-gated channel subfamily J member 5	11	128891356-128921035	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014722, HPA017353, CAB022569	Enhanced					Mixed	Tissue enhanced		adrenal gland: 84.8	spleen: 18.8	Cell line enriched	12	HBEC3-KT: 9.5
KCNJ6	BIR1, GIRK2, hiGIRK2, KATP2, KCNJ7, Kir3.2	ENSG00000157542	Potassium voltage-gated channel subfamily J member 6	21	37607376-37916446	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Not detected	Tissue enriched	9	cerebral cortex: 2.6	spleen,stomach,testis: 0.2	Cell line enhanced		LHCN-M2: 7.1;TIME: 1.8
KCNK18	K2p18.1, TRESK, TRESK-2, TRESK2, TRIK	ENSG00000186795	Potassium two pore domain channel subfamily K member 18	10	117197489-117210299	Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA044739	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
KCNQ4	DFNA2, Kv7.4	ENSG00000117013	Potassium voltage-gated channel subfamily Q member 4	1	40784012-40840452	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA018305	Uncertain					Mixed	Mixed			smooth muscle: 2.5	Cell line enhanced		HAP1: 1.9;HEK93: 2.5;K-562: 2.6
KCNT1	KCa4.1, KIAA1422, SLACK, Slo2.2	ENSG00000107147	Potassium sodium-activated channel subfamily T member 1	9	135702185-135795508	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA059880	Uncertain					Tissue enhanced	Group enriched	5	cerebral cortex: 11.6;ovary: 3.9;skeletal muscle: 3.8;spleen: 6.8	testis: 1.2	Cell line enhanced		RPMI-8226: 1.2;SCLC-21H: 3.0
KCNV2	Kv8.2	ENSG00000168263	Potassium voltage-gated channel modifier subfamily V member 2	9	2717502-2730037	Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA031131	Supported					Tissue enriched	Tissue enriched	44	testis: 6.6	skin: 0.1	Not detected		
KDSR	DHSR, FVT1, SDR35C1	ENSG00000119537	3-ketodihydrosphingosine reductase	18	63327726-63367510	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB003673, HPA044884	Approved				Renal cancer:9.53e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 45.5	Expressed in all		
KHK		ENSG00000138030	Ketohexokinase	2	27086747-27100772	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007040	Enhanced		Approved	Cytosol	Endometrial cancer:7.62e-8 (unfavourable)	Group enriched	Group enriched	11	duodenum: 113.1;kidney: 111.2;liver: 97.3;small intestine: 133.2	cerebral cortex: 10.1	Cell line enhanced		Hep G2: 32.5
KISS1R	AXOR12, GPR54, HOT7T175	ENSG00000116014	KISS1 receptor	19	917287-921015	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071913			Supported	Vesicles<br>Plasma membrane	Renal cancer:3.33e-6 (unfavourable)	Tissue enhanced	Tissue enriched	5	cerebral cortex: 1.2	appendix,lymph node,placenta: 0.2	Cell line enhanced		K-562: 14.0;RPMI-8226: 26.1;SCLC-21H: 8.9;SH-SY5Y: 21.3
KL		ENSG00000133116	Klotho	13	33016433-33066145	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.29e-9 (favourable), Pancreatic cancer:4.44e-4 (favourable)	Group enriched	Group enriched	5	kidney: 136.6;parathyroid gland: 346.4	placenta: 44.1	Cell line enhanced		HMC-1: 2.1;SK-BR-3: 3.4
KLK4	EMSP, EMSP1, KLK-L1, PRSS17, PSTS	ENSG00000167749	Kallikrein related peptidase 4	19	50906352-50910738	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051839	Enhanced					Tissue enriched	Tissue enriched	37	prostate: 406.5	skin: 10.8	Cell line enhanced		CAPAN-2: 5.7;HaCaT: 7.0
KMT2A	ALL-1, CXXC7, HRX, HTRX1, MLL, MLL1A, TRX1	ENSG00000118058	Lysine methyltransferase 2A	11	118436490-118526832	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017794, CAB024270, HPA044910	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 31.0	Expressed in all		
KMT2D	ALR, CAGL114, MLL2, MLL4, TNRC21	ENSG00000167548	Lysine methyltransferase 2D	12	49018975-49059774	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035977	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 46.6	Expressed in all		
KYNU		ENSG00000115919	Kynureninase	2	142877498-143055832	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031686	Enhanced		Supported	Nucleoplasm<br>Cytosol		Mixed	Mixed			liver: 45.9	Cell line enhanced		A549: 168.9;HeLa: 138.9;hTEC/SVTERT24-B: 106.9;SiHa: 109.4;U-87 MG: 309.1
L2HGDH	C14orf160, FLJ12618	ENSG00000087299	L-2-hydroxyglutarate dehydrogenase	14	50237563-50312548	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA065409, HPA069708	Approved		Enhanced	Mitochondria	Renal cancer:9.75e-10 (favourable)	Expressed in all	Mixed			kidney: 20.8	Expressed in all		
LAMP2	CD107b	ENSG00000005893	Lysosomal associated membrane protein 2	X	120427827-120469365	CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB005272, HPA029100	Enhanced					Expressed in all	Expressed in all			gallbladder: 223.2	Expressed in all		
LARS	FLJ10595, FLJ21788, HSPC192, LARS1, LEUS, RNTLS	ENSG00000133706	Leucyl-tRNA synthetase	5	146113038-146182660	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036424, HPA040881	Supported		Supported	Nuclear bodies<br>Cytosol	Liver cancer:3.78e-5 (unfavourable), Thyroid cancer:2.98e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 70.8	Expressed in all		
LARS2	KIAA0028, LEURS, MGC26121, mtLeuRS	ENSG00000011376	Leucyl-tRNA synthetase 2, mitochondrial	3	45388506-45549421	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035951, HPA045450, HPA066085	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:1.32e-11 (favourable), Colorectal cancer:1.71e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 19.2	Expressed in all		
LCAT		ENSG00000213398	Lecithin-cholesterol acyltransferase	16	67939750-67944131	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044767			Approved	Nucleoplasm	Liver cancer:4.21e-8 (favourable), Renal cancer:1.71e-4 (unfavourable), Colorectal cancer:8.50e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 105.7	Cell line enhanced		BEWO: 73.6
LCT		ENSG00000115850	Lactase	2	135787840-135837180	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Group enriched	631	duodenum: 223.1;small intestine: 142.8	appendix,lymph node: 0.2	Cell line enhanced		MOLT-4: 3.9;RPMI-8226: 6.7
LDHA		ENSG00000134333	Lactate dehydrogenase A	11	18394388-18408425	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015336, CAB069404	Uncertain		Supported	Vesicles<br>Cytosol	Renal cancer:9.69e-9 (unfavourable), Liver cancer:3.26e-8 (unfavourable), Lung cancer:2.27e-6 (unfavourable), Pancreatic cancer:8.09e-6 (unfavourable), Cervical cancer:2.78e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 503.4	Expressed in all		
LDHB		ENSG00000111716	Lactate dehydrogenase B	12	21635342-21757857	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004641, HPA019007	Enhanced		Enhanced	Cytosol	Renal cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			kidney: 1790.8	Expressed in all		
LFNG	SCDO3	ENSG00000106003	LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase	7	2512529-2529177	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA069130	Approved				Endometrial cancer:6.36e-4 (favourable)	Expressed in all	Expressed in all			skin: 68.5	Cell line enhanced		RH-30: 44.5;U-2 OS: 52.5
LGR4	GPR48	ENSG00000205213	Leucine rich repeat containing G protein-coupled receptor 4	11	27365961-27472775	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030267, HPA054350	Uncertain		Approved	Microtubule organizing center	Renal cancer:2.00e-7 (favourable)	Expressed in all	Expressed in all			kidney: 56.2	Cell line enhanced		HAP1: 86.6
LHFPL5	DFNB67, dJ510O8.8, MGC33835, Tmhs	ENSG00000197753	Lipoma HMGIC fusion partner-like 5	6	35805293-35833874	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA055110	Uncertain					Not detected	Tissue enhanced		epididymis: 10.8	bone marrow: 4.2	Mixed		
LIAS	LAS	ENSG00000121897	Lipoic acid synthetase	4	39458587-39485109	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018842, HPA019076	Approved	Approved	Approved	Nucleoplasm<br>Mitochondria	Renal cancer:4.11e-7 (favourable)	Expressed in all	Mixed			testis: 15.1	Expressed in all		
LIG4		ENSG00000174405	DNA ligase 4	13	108207439-108218368	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001334, HPA057325	Supported		Supported	Nucleoplasm<br>Cytoplasmic bodies		Expressed in all	Mixed			parathyroid gland: 20.2	Expressed in all		
LIMK1	LIMK	ENSG00000106683	LIM domain kinase 1	7	74082933-74122525	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028064, HPA028516	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:6.63e-8 (unfavourable), Liver cancer:7.79e-6 (unfavourable), Colorectal cancer:4.95e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.5	Expressed in all		
LIPA	CESD, LAL	ENSG00000107798	Lipase A, lysosomal acid type	10	89213569-89414557	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB034892, HPA057052	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			spleen: 496.6	Mixed		
LIPC	HL, HTGL	ENSG00000166035	Lipase C, hepatic type	15	58410569-58569843	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	14	liver: 86.4	kidney: 6.3	Cell line enhanced		CACO-2: 6.9;EFO-21: 5.7;Hep G2: 16.4;HMC-1: 6.0;U-2197: 17.2
LIPE	HSL	ENSG00000079435	Lipase E, hormone sensitive type	19	42401507-42427426	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006567, CAB017700	Enhanced		Supported	Cytosol	Pancreatic cancer:1.15e-4 (favourable)	Expressed in all	Tissue enriched	20	adipose tissue: 870.5	testis: 44.0	Cell line enriched	6	ASC diff: 94.1
LMBRD1	bA810I22.1, C6orf209, cblF, FLJ11240	ENSG00000168216	LMBR1 domain containing 1	6	69675802-69797111	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019547	Uncertain				Renal cancer:1.07e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 173.4	Expressed in all		
LONP1	hLON, LonHS, PIM1, PRSS15	ENSG00000196365	Lon peptidase 1, mitochondrial	19	5691834-5720572	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002034, HPA002192	Supported		Enhanced	Nucleus<br>Mitochondria		Expressed in all	Expressed in all			adrenal gland: 140.4	Expressed in all		
LOX		ENSG00000113083	Lysyl oxidase	5	122063195-122078360	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043930			Supported	Endoplasmic reticulum	Renal cancer:3.93e-8 (unfavourable), Urothelial cancer:3.32e-4 (unfavourable), Liver cancer:7.38e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 29.6	Cell line enhanced		BJ: 799.4;fHDF/TERT166: 1126.5;U-138 MG: 458.1
LOXL3		ENSG00000115318	Lysyl oxidase like 3	2	74532414-74555690	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035281	Approved				Renal cancer:7.97e-8 (unfavourable)	Tissue enhanced	Mixed			placenta: 21.6	Cell line enhanced		U-138 MG: 238.3;WM-115: 524.2
LPAR6	P2RY5, P2Y5	ENSG00000139679	Lysophosphatidic acid receptor 6	13	48389567-48444704	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA028934, HPA076273	Approved		Supported	Vesicles<br>Plasma membrane	Renal cancer:3.60e-4 (unfavourable), Lung cancer:6.22e-4 (favourable)	Expressed in all	Expressed in all			placenta: 100.9	Cell line enhanced		AF22: 19.1;HUVEC TERT2: 26.4
LPIN1	KIAA0188	ENSG00000134324	Lipin 1	2	11677595-11827409	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038021	Approved		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			testis: 102.1	Expressed in all		
LPIN2	KIAA0249	ENSG00000101577	Lipin 2	18	2916994-3013315	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015223, HPA017857, HPA030550	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol	Head and neck cancer:8.01e-4 (favourable)	Expressed in all	Mixed			liver: 87.3	Mixed		
LRAT	LCA14	ENSG00000121207	Lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase)	4	154626945-154753118	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA070726			Uncertain	Endoplasmic reticulum<br>Golgi apparatus		Mixed	Tissue enhanced		thyroid gland: 2.3	testis: 1.6	Cell line enriched	11	NTERA-2: 11.7
LRRC8A	FLJ10337, KIAA1437, LRRC8, SWELL1	ENSG00000136802	Leucine rich repeat containing 8 family member A	9	128882112-128918039	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:5.27e-5 (favourable), Pancreatic cancer:3.83e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 89.7	Expressed in all		
LRRK2	DKFZp434H2111, FLJ45829, PARK8, RIPK7, ROCO2	ENSG00000188906	Leucine rich repeat kinase 2	12	40196744-40369285	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA014293, CAB037160	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:3.02e-6 (favourable)	Group enriched	Expressed in all			lung: 95.4	Cell line enhanced		A549: 7.4;ASC TERT1: 5.6;RPTEC TERT1: 6.7
LRSAM1	CMT2P, FLJ31641	ENSG00000148356	Leucine rich repeat and sterile alpha motif containing 1	9	127451486-127503501	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021403, HPA021844, CAB037304	Supported		Approved	Cytosol	Pancreatic cancer:6.78e-6 (favourable), Renal cancer:5.72e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 20.8	Expressed in all		
LRTOMT	CFAP111, COMT2, DFNB63, LRRC51	ENSG00000184154	Leucine rich transmembrane and O-methyltransferase domain containing	11	72080331-72110782	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039949	Approved		Approved	Nucleoli<br>Microtubules	Ovarian cancer:5.36e-4 (favourable), Endometrial cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			testis: 136.6	Expressed in all		
LSS	OSC	ENSG00000160285	Lanosterol synthase	21	46188141-46228824	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA032060, HPA032062, CAB034116	Supported		Approved	Cytosol	Urothelial cancer:3.07e-4 (unfavourable), Stomach cancer:6.80e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 38.7	Expressed in all		
LTC4S	MGC33147	ENSG00000213316	Leukotriene C4 synthase	5	179793980-179796647	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		fallopian tube: 3.7	adipose tissue,adrenal gland: 2.0	Cell line enriched	6	HMC-1: 59.7
LTK	TYK1	ENSG00000062524	Leukocyte receptor tyrosine kinase	15	41503638-41513887	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059545	Uncertain		Approved	Vesicles		Mixed	Mixed			placenta: 15.2	Cell line enhanced		HEL: 4.4;NB-4: 6.1;RH-30: 4.4;THP-1: 9.9
LYN	JTK8	ENSG00000254087	LYN proto-oncogene, Src family tyrosine kinase	8	55879813-56014168	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001231, CAB004492	Enhanced		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane	Renal cancer:3.43e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 161.1	appendix: 130.6	Cell line enhanced		HEL: 215.0;HMC-1: 205.1
LYZ		ENSG00000090382	Lysozyme	12	69348341-69354234	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	CAB000055, HPA048284, HPA066182	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Actin filaments	Head and neck cancer:7.45e-4 (favourable)	Expressed in all	Expressed in all			stomach: 9651.4	Group enriched	5	Hep G2: 633.5;THP-1: 321.5;U-937: 404.3
MAGT1	DKFZp564K142, IAP, MRX95, OST3B	ENSG00000102158	Magnesium transporter 1	X	77826364-77895593	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049851	Approved				Breast cancer:1.30e-4 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable), Melanoma:8.98e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 137.3	Expressed in all		
MAK	dJ417M14.2, RP62	ENSG00000111837	Male germ cell associated kinase	6	10762723-10838555	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	9	fallopian tube: 9.7;parathyroid gland: 10.2;testis: 20.4	lung: 1.4	Cell line enhanced		HDLM-2: 1.4
MALT1	MLT, PCASP1	ENSG00000172175	MALT1 paracaspase	18	58671386-58754477	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004494, HPA048432	Enhanced		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 34.0	Expressed in all		
MAN1B1	ERManI, MANA-ER, MRT15	ENSG00000177239	Mannosidase alpha class 1B member 1	9	137086927-137109187	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051516	Approved		Uncertain	Vesicles	Liver cancer:1.45e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 33.4	Expressed in all		
MAN2B1	LAMAN, MANB	ENSG00000104774	Mannosidase alpha class 2B member 1	19	12646511-12666742	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA041530, HPA053404	Supported		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.94e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 95.1	Expressed in all		
MANBA		ENSG00000109323	Mannosidase beta	4	102631488-102760994	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA053478	Approved		Supported	Vesicles	Liver cancer:3.74e-6 (unfavourable), Glioma:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 37.4	Expressed in all		
MAP2K3	MAPKK3, MEK3, MKK3, PRKMK3	ENSG00000034152	Mitogen-activated protein kinase kinase 3	17	21284672-21315240	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB018548	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 129.9	Expressed in all		
MAP3K1	MAPKKK1, MEKK, MEKK1	ENSG00000095015	Mitogen-activated protein kinase kinase kinase 1	5	56815574-56896152	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB004500, HPA046509	Approved		Approved	Cytosol		Expressed in all	Mixed			spleen: 28.3	Cell line enhanced		SH-SY5Y: 55.9
MAP3K20	MLK7, MLTK, MLTKalpha, MLTKbeta, MRK, ZAK	ENSG00000091436	Mitogen-activated protein kinase kinase kinase 20	2	173075435-173268010	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017205	Approved		Supported	Cytosol	Renal cancer:3.41e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 133.3	Mixed		
MAP3K7	MEKK7, TAK1	ENSG00000135341	Mitogen-activated protein kinase kinase kinase 7	6	90513573-90587045	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007633	Approved		Approved	Nuclear speckles<br>Cytosol	Liver cancer:3.51e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.0	Expressed in all		
MAP3K9	MEKK9, MLK1, PRKE1	ENSG00000006432	Mitogen-activated protein kinase kinase kinase 9	14	70722526-70809534	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000942	Approved		Approved	Nucleus<br>Nucleoli		Mixed	Mixed			testis: 10.1	Cell line enhanced		A-431: 20.2
MAPK10	JNK3, p493F12, p54bSAPK, PRKM10	ENSG00000109339	Mitogen-activated protein kinase 10	4	86010395-86594131	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB022625	Approved				Renal cancer:3.11e-4 (favourable), Urothelial cancer:5.57e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 113.0	seminal vesicle: 38.6	Cell line enriched	16	AF22: 181.7
MAPK12	ERK6, p38gamma, PRKM12, SAPK-3, SAPK3	ENSG00000188130	Mitogen-activated protein kinase 12	22	50245450-50261825	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB025483, HPA054562	Enhanced		Approved	Nuclear speckles<br>Cytosol	Renal cancer:5.00e-6 (unfavourable)	Mixed	Tissue enriched	6	skeletal muscle: 91.5	cerebral cortex: 15.7	Mixed		
MAPKAPK3	3pK, MAPKAP3	ENSG00000114738	Mitogen-activated protein kinase-activated protein kinase 3	3	50611520-50649297	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058275			Supported	Nucleoplasm	Renal cancer:1.90e-8 (favourable), Colorectal cancer:8.08e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 117.6	Expressed in all		
MARK1	MARK, PAR-1C	ENSG00000116141	Microtubule affinity regulating kinase 1	1	220528183-220664461	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007421, HPA008061	Uncertain				Pancreatic cancer:2.23e-5 (favourable), Melanoma:2.63e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 21.1	Cell line enhanced		RT4: 50.7
MARS	CMT2U, MetRS, SPG70	ENSG00000166986	Methionyl-tRNA synthetase	12	57475445-57517569	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004125, CAB017097	Supported	Approved	Enhanced	Cytosol	Liver cancer:4.55e-7 (unfavourable), Renal cancer:1.59e-4 (unfavourable), Breast cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 66.7	Expressed in all		
MARS2	mtMetRS, SPAX3	ENSG00000247626	Methionyl-tRNA synthetase 2, mitochondrial	2	197705369-197708387	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035589, HPA035590	Uncertain		Approved	Intermediate filaments<br>Cytosol	Renal cancer:6.14e-5 (favourable), Glioma:1.49e-4 (favourable), Endometrial cancer:3.50e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 7.5	Expressed in all		
MARVELD2	DFNB49, FLJ30532, MRVLDC2, TRIC	ENSG00000152939	MARVEL domain containing 2	5	69415112-69444330	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018119, HPA061726	Uncertain		Supported	Cell Junctions	Renal cancer:2.84e-13 (favourable)	Mixed	Tissue enhanced		thyroid gland: 19.7	small intestine: 8.7	Cell line enhanced		BEWO: 30.0;CAPAN-2: 22.9;HaCaT: 17.6;RT4: 17.7;SCLC-21H: 32.0;T-47d: 18.4
MAS1		ENSG00000130368	MAS1 proto-oncogene, G protein-coupled receptor	6	159906690-159916530	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 1.8	cervix, uterine: 0.7	Cell line enriched	9	HMC-1: 6.7
MASP1	CRARF, MASP, PRSS5	ENSG00000127241	Mannan binding lectin serine peptidase 1	3	187217285-187292022	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001617, HPA009641	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.20e-4 (favourable)	Group enriched	Tissue enhanced		cervix, uterine: 135.4	endometrium: 94.8	Group enriched	8	BJ: 107.2;BJ hTERT+: 389.0
MASP2	MASP1P1	ENSG00000009724	Mannan binding lectin serine peptidase 2	1	11026523-11047233	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA029313, HPA029314	Approved		Supported	Golgi apparatus	Liver cancer:1.60e-4 (favourable)	Tissue enriched	Tissue enriched	18	liver: 105.5	skin: 5.7	Cell line enhanced		Hep G2: 12.9
MASTL	FLJ14813, Gwl, THC2	ENSG00000120539	Microtubule associated serine/threonine kinase like	10	27154824-27186924	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027175, HPA054273	Approved		Enhanced	Nucleoplasm	Renal cancer:1.71e-6 (unfavourable), Liver cancer:2.52e-6 (unfavourable), Pancreatic cancer:4.81e-5 (unfavourable)	Expressed in all	Mixed			testis: 12.6	Expressed in all		
MAT1A	MAT, MATA1, SAMS, SAMS1	ENSG00000151224	Methionine adenosyltransferase 1A	10	80271820-80289684	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048627	Supported					Tissue enriched	Tissue enriched	10	liver: 689.6	epididymis: 68.4	Cell line enriched	11	Hep G2: 64.0
MBOAT7	BB1, hMBOA-7, LENG4, LPIAT	ENSG00000125505	Membrane bound O-acyltransferase domain containing 7	19	54173412-54189882	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA055967	Approved		Approved	Cytosol	Liver cancer:5.55e-6 (unfavourable), Renal cancer:6.62e-5 (unfavourable), Urothelial cancer:4.31e-4 (favourable), Lung cancer:5.13e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 24.3	Cell line enhanced		HMC-1: 150.7
MBTPS2	KFSD, S2P	ENSG00000012174	Membrane bound transcription factor peptidase, site 2	X	21839636-21885424	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA005494, CAB009486	Approved		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 19.3	Expressed in all		
MC1R	MSH-R	ENSG00000258839	Melanocortin 1 receptor	16	89912119-89920977	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:7.88e-4 (favourable)	Tissue enhanced	Tissue enhanced		testis: 13.7	skin: 6.9	Cell line enhanced		SK-MEL-30: 28.3
MC4R		ENSG00000166603	Melanocortin 4 receptor	18	60371110-60372775	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016719	Uncertain					Tissue enhanced	Group enriched	10	cerebral cortex: 2.9;fallopian tube: 5.0	epididymis: 0.4	Cell line enriched	64	fHDF/TERT166: 75.8
MCCC1	MCCA	ENSG00000078070	Methylcrotonoyl-CoA carboxylase 1	3	183015218-183116075	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008310	Approved		Enhanced	Mitochondria	Renal cancer:3.68e-4 (favourable)	Expressed in all	Expressed in all			kidney: 57.9	Expressed in all		
MCCC2	MCCB	ENSG00000131844	Methylcrotonoyl-CoA carboxylase 2	5	71587288-71658704	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038300, HPA038301, HPA061546	Enhanced		Enhanced	Mitochondria	Renal cancer:6.43e-8 (favourable), Liver cancer:1.70e-4 (favourable), Colorectal cancer:3.62e-4 (favourable)	Expressed in all	Expressed in all			prostate: 77.2	Mixed		
MCEE	GLOD2	ENSG00000124370	Methylmalonyl-CoA epimerase	2	71109684-71130239	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035196			Approved	Nucleoli	Head and neck cancer:4.76e-4 (favourable), Liver cancer:5.78e-4 (favourable)	Expressed in all	Expressed in all			breast: 41.2	Expressed in all		
MCM2	BM28, CCNL1, cdc19, CDCL1, D3S3194, KIAA0030	ENSG00000073111	Minichromosome maintenance complex component 2	3	127598223-127622436	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000303, HPA031495, HPA031496	Enhanced		Supported	Nucleoplasm	Liver cancer:1.51e-7 (unfavourable), Cervical cancer:4.66e-4 (favourable)	Expressed in all	Mixed			bone marrow: 38.5	Expressed in all		
MCM4	CDC21, CDC54, hCdc21, MGC33310, P1-Cdc21	ENSG00000104738	Minichromosome maintenance complex component 4	8	47960185-47978160	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004497, HPA004873, HPA031052	Supported		Enhanced	Nucleoplasm	Endometrial cancer:2.84e-5 (unfavourable), Melanoma:1.15e-4 (unfavourable), Liver cancer:1.23e-4 (unfavourable), Colorectal cancer:2.19e-4 (favourable), Pancreatic cancer:2.38e-4 (unfavourable), Renal cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 78.6	Expressed in all		
MCM8	C20orf154, dJ967N21.5, MGC119522, MGC119523, MGC12866, MGC4816, REC	ENSG00000125885	Minichromosome maintenance 8 homologous recombination repair factor	20	5950652-5998977	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045141			Supported	Nucleoplasm	Liver cancer:9.30e-8 (unfavourable), Pancreatic cancer:7.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 27.6	lymph node: 10.2	Expressed in all		
MCM9	C6orf61, dJ329L24.3, FLJ20170, MCMDC1, MGC35304	ENSG00000111877	Minichromosome maintenance 9 homologous recombination repair factor	6	118813442-118935162	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031137	Approved		Approved	Nucleoplasm		Expressed in all	Mixed			epididymis: 15.5	Expressed in all		
MCOLN1	ML4, MLIV, MST080, MSTP080, TRPM-L1, TRPML1	ENSG00000090674	Mucolipin 1	19	7522626-7534009	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA031763, CAB032637	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:5.60e-5 (favourable), Renal cancer:5.67e-4 (favourable)	Expressed in all	Expressed in all			spleen: 48.2	Expressed in all		
MDH2		ENSG00000146701	Malate dehydrogenase 2	7	76048051-76067508	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019714, HPA019716, HPA019848, HPA026720	Enhanced		Enhanced	Mitochondria	Renal cancer:1.49e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 233.2	Expressed in all		
MDM2	HDM2, MGC5370	ENSG00000135679	MDM2 proto-oncogene	12	68808176-68850686	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000086, CAB016303	Supported		Supported	Nucleus	Endometrial cancer:4.51e-7 (favourable), Cervical cancer:3.23e-4 (favourable)	Expressed in all	Expressed in all			rectum: 33.9	Expressed in all		
MECR	CGI-63, ETR1, FASN2B, NRBF1	ENSG00000116353	Mitochondrial trans-2-enoyl-CoA reductase	1	29192873-29230942	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022018, HPA022030, HPA028740	Enhanced		Supported	Mitochondria	Renal cancer:5.81e-6 (favourable), Urothelial cancer:5.29e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 18.4	Expressed in all		
MELK	KIAA0175	ENSG00000165304	Maternal embryonic leucine zipper kinase	9	36572862-36677683	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017214	Uncertain				Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.91e-7 (unfavourable), Lung cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.58e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 16.9	lymph node: 11.7	Expressed in all		
MERTK	c-Eyk, mer, RP38, Tyro12	ENSG00000153208	MER proto-oncogene, tyrosine kinase	2	111898479-112029561	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036196, HPA075622	Approved		Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:4.43e-5 (favourable), Lung cancer:4.74e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 77.2	Cell line enhanced		CACO-2: 31.5;Hep G2: 27.2;HUVEC TERT2: 32.3
MEX3C	FLJ38871, RKHD2, RNF194	ENSG00000176624	Mex-3 RNA binding family member C	18	51174550-51218304	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040603	Uncertain		Approved	Vesicles	Liver cancer:8.49e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 81.7	Expressed in all		
MFN2	CMT2A2, CPRP1, KIAA0214, MARF	ENSG00000116688	Mitofusin 2	1	11980181-12013514	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030554	Uncertain				Renal cancer:2.36e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 200.3	Expressed in all		
MFSD2A	FLJ14490, MFSD2	ENSG00000168389	Major facilitator superfamily domain containing 2A	1	39955112-39969968	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043107	Uncertain		Approved	Plasma membrane<br>Cytosol<br>Cytoplasmic bodies	Renal cancer:4.22e-6 (unfavourable), Urothelial cancer:2.33e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 116.7;seminal vesicle: 110.9	testis: 63.4	Cell line enhanced		THP-1: 112.5
MFSD8	CLN7, MGC33302	ENSG00000164073	Major facilitator superfamily domain containing 8	4	127917805-127965995	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044802	Approved		Supported	Nucleoplasm<br>Vesicles	Urothelial cancer:2.21e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 12.5	Mixed		
MGAT2	GNT-II	ENSG00000168282	Mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase	14	49620795-49623481	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043721, HPA056824	Approved		Supported	Golgi apparatus	Cervical cancer:3.22e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 45.0	Expressed in all		
MIB1	DIP-1, KIAA1323, MIB, ZZANK2, ZZZ6	ENSG00000101752	Mindbomb E3 ubiquitin protein ligase 1	18	21704957-21870957	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019100, CAB037044	Approved		Approved	Nuclear membrane<br>Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 24.2	Expressed in all		
MICU1	CALC, CBARA1, EFHA3, FLJ12684	ENSG00000107745	Mitochondrial calcium uptake 1	10	72367327-72626191	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA037479, HPA037480	Uncertain		Supported	Mitochondria	Renal cancer:4.66e-7 (favourable)	Expressed in all	Expressed in all			kidney: 107.8	Expressed in all		
MID1	FXY, OS, RNF59, TRIM18	ENSG00000101871	Midline 1	X	10445310-10833654	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003715	Approved				Liver cancer:3.06e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 20.7	Cell line enhanced		A549: 168.3;AF22: 136.2
MID2	FXY2, MRX101, RNF60, TRIM1	ENSG00000080561	Midline 2	X	107825755-107927193	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Stomach cancer:3.73e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 23.4	Cell line enhanced		HUVEC TERT2: 34.7;Karpas-707: 25.8
MINPP1	MIPP	ENSG00000107789	Multiple inositol-polyphosphate phosphatase 1	10	87504875-87553460	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026859	Approved				Renal cancer:6.98e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 27.6	Mixed		
MIPEP	MIP	ENSG00000027001	Mitochondrial intermediate peptidase	13	23730189-23889419	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030676, HPA031669, HPA031670	Approved		Enhanced	Mitochondria	Renal cancer:7.66e-12 (favourable)	Expressed in all	Expressed in all			fallopian tube: 27.4	Expressed in all		
MKRN3	D15S9, MGC88288, RNF63, ZFP127, ZNF127	ENSG00000179455	Makorin ring finger protein 3	15	23565678-23630075	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029494	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Glioma:9.23e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 5.9;placenta: 4.1;testis: 3.6	epididymis: 1.1	Cell line enhanced		K-562: 22.8
MLC1	KIAA0027, LVM, MLC, VL	ENSG00000100427	Megalencephalic leukoencephalopathy with subcortical cysts 1	22	50059391-50085902	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003040, HPA067533	Enhanced					Tissue enriched	Tissue enriched	8	cerebral cortex: 180.8	bone marrow: 23.0	Cell line enhanced		HL-60: 182.4;NB-4: 133.9;THP-1: 267.0;U-266/70: 101.9;U-266/84: 85.6
MLYCD	hMCD, MCD	ENSG00000103150	Malonyl-CoA decarboxylase	16	83899126-83927026	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031625	Enhanced				Renal cancer:2.61e-7 (favourable)	Expressed in all	Mixed			heart muscle: 3.2	Mixed		
MMAB	cblB, CFAP23	ENSG00000139428	Methylmalonic aciduria (cobalamin deficiency) cblB type	12	109553737-109573874	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039017	Approved		Approved	Mitochondria	Renal cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 32.5	Expressed in all		
MOCOS	FLJ20733, HMCS, MOS	ENSG00000075643	Molybdenum cofactor sulfurase	18	36187519-36272157	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039412, HPA047958	Uncertain		Supported	Mitochondria<br>Cytosol	Renal cancer:3.03e-12 (unfavourable), Pancreatic cancer:1.29e-4 (unfavourable), Lung cancer:3.55e-4 (unfavourable)	Mixed	Mixed			adrenal gland: 11.4	Cell line enhanced		hTERT-HME1: 38.4;SiHa: 58.4;SK-MEL-30: 30.1
MOCS1	MOCOD	ENSG00000124615	Molybdenum cofactor synthesis 1	6	39899578-39934551	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045783, HPA058177, HPA075505	Uncertain		Approved	Plasma membrane<br>Cytosol	Cervical cancer:1.07e-5 (unfavourable), Pancreatic cancer:6.07e-5 (favourable)	Expressed in all	Mixed			placenta: 60.3	Cell line enhanced		CACO-2: 38.2
MOCS2	MOCO1	ENSG00000164172	Molybdenum cofactor synthesis 2	5	53095679-53110063	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037679, HPA037680	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:3.68e-6 (favourable)	Expressed in all	Expressed in all			kidney: 106.4	Expressed in all		
MOGS	CWH41, DER7, GCS1	ENSG00000115275	Mannosyl-oligosaccharide glucosidase	2	74461057-74465410	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011322, HPA011969	Approved		Enhanced	Endoplasmic reticulum	Renal cancer:2.79e-8 (unfavourable), Liver cancer:2.34e-6 (unfavourable), Colorectal cancer:5.33e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 63.1	Expressed in all		
MPC1	BRP44L, CGI-129, dJ68L15.3	ENSG00000060762	Mitochondrial pyruvate carrier 1	6	166364919-166383013	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA045119, HPA055790	Enhanced		Enhanced	Mitochondria	Renal cancer:4.79e-11 (favourable), Lung cancer:1.29e-4 (favourable), Cervical cancer:1.45e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 432.9	Expressed in all		
MPI		ENSG00000178802	Mannose phosphate isomerase	15	74890005-74902219	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007200	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:2.39e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 52.3	Expressed in all		
MPO		ENSG00000005381	Myeloperoxidase	17	58269856-58280935	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000059, HPA021147, HPA061464	Enhanced		Supported	Nucleus<br>Vesicles		Tissue enhanced	Tissue enriched	82	bone marrow: 2499.6	salivary gland: 30.6	Group enriched	98	HL-60: 2786.8;NB-4: 2892.7
MPST	MST, TST2, TUM1	ENSG00000128309	Mercaptopyruvate sulfurtransferase	22	37019635-37029822	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001240	Enhanced		Approved	Mitochondria<br>Cytosol	Urothelial cancer:5.89e-4 (favourable)	Expressed in all	Mixed			duodenum: 108.8	Expressed in all		
MPV17	SYM1	ENSG00000115204	MPV17, mitochondrial inner membrane protein	2	27309492-27325680	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Liver cancer:6.99e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 84.3	Expressed in all		
MSMO1	DESP4, ERG25, SC4MOL	ENSG00000052802	Methylsterol monooxygenase 1	4	165327623-165343160	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA056127	Approved				Cervical cancer:2.97e-4 (unfavourable), Renal cancer:9.21e-4 (favourable)	Expressed in all	Expressed in all			liver: 297.1	Expressed in all		
MST1R	CD136, CDw136, PTK8, RON	ENSG00000164078	Macrophage stimulating 1 receptor	3	49887002-49903873	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007657, HPA008180, CAB008972	Enhanced		Approved	Cytosol	Urothelial cancer:2.33e-5 (favourable)	Mixed	Tissue enhanced		skin: 69.4	stomach: 37.2	Cell line enhanced		CAPAN-2: 84.1;HaCaT: 46.9;HBEC3-KT: 41.5;hTCEpi: 57.4;RT4: 49.8
MT-CO1	COI, COX1, MTCO1	ENSG00000198804	Mitochondrially encoded cytochrome c oxidase I	MT	5904-7445	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016241, HPA069328	Enhanced		Supported	Mitochondria	Liver cancer:2.29e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 79421.5	Expressed in all		
MT-CO2	CO2, COX2, MTCO2	ENSG00000198712	Mitochondrially encoded cytochrome c oxidase II	MT	7586-8269	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016243, HPA051505, HPA054758	Enhanced				Liver cancer:2.89e-4 (favourable), Pancreatic cancer:7.10e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 40900.1	Expressed in all		
MT-CO3	CO3, COIII, COX3, MTCO3	ENSG00000198938	Mitochondrially encoded cytochrome c oxidase III	MT	9207-9990	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042788	Approved		Approved	Nucleoplasm	Pancreatic cancer:1.04e-4 (favourable), Liver cancer:2.01e-4 (favourable)	Expressed in all	Expressed in all			kidney: 54081.3	Expressed in all		
MT-ND1	MTND1, NAD1, ND1	ENSG00000198888	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	MT	3307-4262	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB033779	Approved				Pancreatic cancer:3.26e-4 (favourable), Breast cancer:3.63e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 23817.4	Expressed in all		
MT-ND2	MTND2, NAD2, ND2	ENSG00000198763	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	MT	4470-5511	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			heart muscle: 24880.0	Expressed in all		
MT-ND3	MTND3, NAD3, ND3	ENSG00000198840	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	MT	10059-10404	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA063296	Enhanced		Approved	Cytosol	Liver cancer:4.63e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 30083.4	Expressed in all		
MT-ND4	LHON, MTND4, NAD4, ND4	ENSG00000198886	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	MT	10760-12137	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA053928	Approved				Ovarian cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 36982.3	Expressed in all		
MT-ND4L	MTND4L, NAD4L, ND4L	ENSG00000212907	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	MT	10470-10766	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA075648			Supported	Mitochondria	Liver cancer:4.47e-4 (favourable)	Expressed in all	Expressed in all			kidney: 23320.0	Expressed in all		
MT-ND5	MTND5, NAD5, ND5	ENSG00000198786	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	MT	12337-14148	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.31e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 13037.2	Expressed in all		
MT-ND6	MTND6, NAD6, ND6	ENSG00000198695	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	MT	14149-14673	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Renal cancer:8.91e-6 (favourable)	Expressed in all	Expressed in all			heart muscle: 22714.1	Expressed in all		
MTAP	c86fus, MSAP	ENSG00000099810	Methylthioadenosine phosphorylase	9	21802543-21937651	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046915			Supported	Cytosol	Liver cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 15.7	Mixed		
MTFMT	FMT1	ENSG00000103707	Mitochondrial methionyl-tRNA formyltransferase	15	65001512-65029639	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040710	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.31e-8 (favourable)	Expressed in all	Mixed			smooth muscle: 2.7	Mixed		
MTHFD1	MTHFC, MTHFD	ENSG00000100714	Methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1	14	64388031-64463457	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000704, HPA001290, HPA015006, HPA050052	Approved		Enhanced	Cytosol	Renal cancer:5.93e-5 (favourable), Pancreatic cancer:6.96e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 198.5	Expressed in all		
MTHFR		ENSG00000177000	Methylenetetrahydrofolate reductase	1	11785723-11806920	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA063389			Approved	Cell Junctions	Head and neck cancer:3.97e-5 (favourable), Pancreatic cancer:4.81e-5 (favourable), Liver cancer:1.19e-4 (unfavourable), Renal cancer:2.12e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 64.9	Expressed in all		
MTM1		ENSG00000171100	Myotubularin 1	X	150568619-150673322	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA010008, HPA010665	Approved		Supported	Plasma membrane	Renal cancer:7.40e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 27.3	Expressed in all		
MTMR2	CMT4B, KIAA1073	ENSG00000087053	Myotubularin related protein 2	11	95832882-95925315	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049831	Approved		Supported	Vesicles	Liver cancer:1.61e-8 (unfavourable), Pancreatic cancer:3.60e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 57.8	Expressed in all		
MTPAP	FLJ10486, mtPAP, PAPD1, SPAX4	ENSG00000107951	Mitochondrial poly(A) polymerase	10	30309801-30374448	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038620, HPA058232	Approved		Supported	Mitochondria	Liver cancer:4.20e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 22.7	Expressed in all		
MTRR	cblE	ENSG00000124275	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	5	7851186-7906025	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038113	Supported		Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Liver cancer:6.60e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 20.5	Expressed in all		
MUSK		ENSG00000030304	Muscle associated receptor tyrosine kinase	9	110668771-110801620	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Mixed			testis: 3.0	Group enriched	19	LHCN-M2: 20.0;RH-30: 23.3
MVD	MPD	ENSG00000167508	Mevalonate diphosphate decarboxylase	16	88651935-88663161	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041404, HPA048250	Uncertain		Approved	Cell Junctions<br>Cytosol	Endometrial cancer:2.17e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 33.9	Expressed in all		
MVK	LRBP, MK	ENSG00000110921	Mevalonate kinase	12	109573255-109598117	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016961	Approved					Expressed in all	Expressed in all			testis: 31.6	Expressed in all		
MYLK	MLCK, MLCK1, MYLK1, smMLCK	ENSG00000065534	Myosin light chain kinase	3	123610049-123884331	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB020789, HPA031677, HPA048055	Enhanced		Enhanced	Plasma membrane<br>Actin filaments	Renal cancer:2.04e-6 (unfavourable), Urothelial cancer:4.46e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 3002.5	Cell line enhanced		BJ: 144.8;BJ hTERT+: 209.1;fHDF/TERT166: 165.3;RPTEC TERT1: 207.7
MYLK2	KMLC, MLCK2, skMLCK	ENSG00000101306	Myosin light chain kinase 2	20	31819308-31834689	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059704, HPA059890	Enhanced		Supported	Endoplasmic reticulum	Glioma:5.74e-4 (favourable)	Tissue enhanced	Tissue enriched	49	skeletal muscle: 253.1	esophagus: 5.1	Cell line enhanced		RH-30: 10.2;RPMI-8226: 6.2
MYO3A	DFNB30	ENSG00000095777	Myosin IIIA	10	25934267-26212527	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048951, HPA051893	Approved		Supported	Plasma membrane<br>Actin filaments<br>Cytoplasmic bodies		Mixed	Tissue enriched	9	testis: 6.8	skin: 0.8	Cell line enhanced		CAPAN-2: 2.0;HEK93: 2.2;SCLC-21H: 2.3;U-2 OS: 3.7;U-698: 8.6
NAA10	ARD1, ARD1A, DXS707, TE2	ENSG00000102030	N(alpha)-acetyltransferase 10, NatA catalytic subunit	X	153929242-153935223	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB006269, HPA030711	Supported		Enhanced	Nucleoli<br>Cytosol	Renal cancer:3.29e-8 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 25.7	Expressed in all		
NADK2	C5orf33, FLJ30596, MNADK, NADKD1	ENSG00000152620	NAD kinase 2, mitochondrial	5	36192592-36242279	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038366, HPA038367, HPA061492	Enhanced					Expressed in all	Expressed in all			liver: 173.0	Expressed in all		
NAGA	D22S674	ENSG00000198951	Alpha-N-acetylgalactosaminidase	22	42058354-42070842	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA000649	Enhanced					Expressed in all	Expressed in all			parathyroid gland: 63.7	Expressed in all		
NAGLU	NAG	ENSG00000108784	N-acetyl-alpha-glucosaminidase	17	42536172-42544449	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038815	Supported	Approved			Renal cancer:2.58e-6 (favourable), Glioma:3.43e-4 (unfavourable), Endometrial cancer:4.17e-4 (favourable), Pancreatic cancer:6.90e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.5	Expressed in all		
NAGPA	APAA, UCE	ENSG00000103174	N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase	16	5024844-5034141	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA064055	Approved				Renal cancer:2.67e-5 (unfavourable), Liver cancer:4.67e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 9.6	Mixed		
NAGS	AGAS, ARGA, NAT7	ENSG00000161653	N-acetylglutamate synthase	17	44004546-44009063	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027300			Supported	Mitochondria		Expressed in all	Tissue enhanced		duodenum: 14.8;small intestine: 13.6	liver: 5.0	Cell line enhanced		HHSteC: 4.0;TIME: 5.0;U-87 MG: 8.7
NALCN	bA430M15.1, CanIon, VGCNL1	ENSG00000102452	Sodium leak channel, non-selective	13	101053776-101416492	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031889, HPA031890, HPA031958	Approved					Mixed	Tissue enhanced		cerebral cortex: 28.1	adrenal gland: 6.0	Cell line enhanced		HaCaT: 12.6;HHSteC: 12.3;TIME: 15.4;U-87 MG: 11.1
NANS	SAS	ENSG00000095380	N-acetylneuraminate synthase	9	98056739-98083075	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019223	Approved		Approved	Nucleoplasm	Endometrial cancer:1.71e-4 (favourable), Liver cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 148.2	Expressed in all		
NARS2	DFNB94, FLJ23441, SLM5	ENSG00000137513	Asparaginyl-tRNA synthetase 2, mitochondrial (putative)	11	78435961-78574874	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026793	Supported		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:1.22e-6 (favourable), Ovarian cancer:1.39e-5 (favourable)	Expressed in all	Expressed in all			kidney: 19.8	Expressed in all		
NAT8L	FLJ37478, Hcml3	ENSG00000185818	N-acetyltransferase 8 like	4	2059512-2069089	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040677			Supported	Mitochondria	Endometrial cancer:1.01e-5 (unfavourable)	Group enriched	Group enriched	7	adipose tissue: 48.6;cerebral cortex: 64.9;testis: 19.0	kidney: 6.7	Cell line enhanced		SCLC-21H: 32.4
NAXE	AIBP, APOA1BP, MGC119143, MGC119144, MGC119145, YJEFN1	ENSG00000163382	NAD(P)HX epimerase	1	156591762-156594299	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043766, HPA048164	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:4.94e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 112.2	Expressed in all		
NCOA1	bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1	ENSG00000084676	Nuclear receptor coactivator 1	2	24491914-24770702	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019402, HPA070213, HPA070520	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 59.0	Expressed in all		
NDST1	HSST, NST1	ENSG00000070614	N-deacetylase and N-sulfotransferase 1	5	150485818-150558211	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060532	Approved				Ovarian cancer:5.13e-4 (unfavourable), Endometrial cancer:6.99e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 59.7	Expressed in all		
NDUFS1	CI-75k	ENSG00000023228	NADH:ubiquinone oxidoreductase core subunit S1	2	206114817-206159603	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA064605, CAB070844	Approved		Supported	Mitochondria	Renal cancer:1.47e-12 (favourable), Breast cancer:3.85e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 71.1	Expressed in all		
NDUFS2	CI-49	ENSG00000158864	NADH:ubiquinone oxidoreductase core subunit S2	1	161197104-161214395	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA055140, HPA061953	Enhanced		Enhanced	Nucleoplasm<br>Mitochondria	Renal cancer:2.32e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 124.0	Expressed in all		
NDUFS7	CI-20, FLJ45860, FLJ46880, PSST	ENSG00000115286	NADH:ubiquinone oxidoreductase core subunit S7	19	1383527-1395589	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.90e-7 (favourable), Cervical cancer:2.03e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 96.7	duodenum: 40.7	Mixed		
NDUFS8	CI-23k, TYKY	ENSG00000110717	NADH:ubiquinone oxidoreductase core subunit S8	11	68030617-68036644	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018524	Approved		Supported	Mitochondria	Renal cancer:3.27e-8 (favourable)	Expressed in all	Expressed in all			adrenal gland: 152.6	Expressed in all		
NDUFV1	CI-51K	ENSG00000167792	NADH:ubiquinone oxidoreductase core subunit V1	11	67606852-67612535	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045211, HPA075051	Approved		Supported	Mitochondria<br>Cytosol	Renal cancer:7.49e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 222.1	Expressed in all		
NEDD4L	KIAA0439, NEDD4-2, RSP5	ENSG00000049759	Neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase	18	58044367-58401540	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024618, HPA064730	Approved		Approved	Focal adhesion sites	Renal cancer:6.55e-15 (favourable)	Expressed in all	Expressed in all			prostate: 71.5	Mixed		
NEK1	KIAA1901, NY-REN-55	ENSG00000137601	NIMA related kinase 1	4	169392857-169612629	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020873, HPA040413	Approved		Approved	Nuclear membrane<br>Nucleoli	Renal cancer:1.42e-4 (favourable)	Expressed in all	Mixed			testis: 21.8	Expressed in all		
NEK2	NEK2A, NLK1, PPP1R111, RP67	ENSG00000117650	NIMA related kinase 2	1	211658657-211675630	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017530, HPA064967	Enhanced		Supported	Nucleus<br>Centrosome	Liver cancer:9.47e-6 (unfavourable), Lung cancer:9.11e-4 (unfavourable)	Mixed	Tissue enriched	11	testis: 121.2	bone marrow: 11.2	Mixed		
NEK8	NPHP9	ENSG00000160602	NIMA related kinase 8	17	28725897-28743455	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040661, HPA040679	Approved				Lung cancer:4.52e-4 (favourable), Colorectal cancer:6.98e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 9.7	Mixed		
NEK9	DKFZp434D0935, MGC16714, Nek8, NERCC	ENSG00000119638	NIMA related kinase 9	14	75079353-75127344	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001405	Approved		Approved	Mitochondria	Pancreatic cancer:5.63e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 29.9	Mixed		
NEU1	NEU	ENSG00000204386	Neuraminidase 1	6	31857659-31862906	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015634, HPA021506	Approved		Supported	Vesicles<br>Cell Junctions		Expressed in all	Mixed			thyroid gland: 14.3	Expressed in all		
NGLY1	FLJ11005, PNG1	ENSG00000151092	N-glycanase 1	3	25718944-25790039	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036825	Approved				Liver cancer:1.96e-6 (unfavourable), Colorectal cancer:1.17e-5 (favourable)	Expressed in all	Expressed in all			testis: 116.0	Expressed in all		
NHLRC1	bA204B7.2, EPM2B, malin	ENSG00000187566	NHL repeat containing E3 ubiquitin protein ligase 1	6	18120440-18122687	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA066030			Uncertain	Vesicles	Urothelial cancer:5.30e-4 (favourable), Endometrial cancer:9.01e-4 (unfavourable)	Expressed in all	Mixed			skin: 4.5	Cell line enhanced		EFO-21: 6.4;SCLC-21H: 7.2
NIPA1	MGC35570, SPG6	ENSG00000170113	Non imprinted in Prader-Willi/Angelman syndrome 1	15	22773063-22829791	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA023269	Uncertain					Expressed in all	Tissue enhanced		cerebral cortex: 38.2	parathyroid gland: 16.8	Mixed		
NIPAL4	ICHYN	ENSG00000172548	NIPA like domain containing 4	5	157460019-157474717	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038259	Approved				Urothelial cancer:6.82e-4 (favourable)	Tissue enhanced	Tissue enhanced		skin: 41.9	esophagus: 10.2	Group enriched	10	hTCEpi: 21.3;RT4: 80.1
NKAIN2	FAM77B, TCBA1	ENSG00000188580	Sodium/potassium transporting ATPase interacting 2	6	123804141-124825657	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA045860			Approved	Cytosol		Mixed	Tissue enriched	44	cerebral cortex: 46.1	adipose tissue,skeletal muscle: 1.0	Cell line enhanced		HEK93: 4.5;HEL: 5.8;Karpas-707: 7.5
NMNAT1	LCA9, NMNAT, PNAT1	ENSG00000173614	Nicotinamide nucleotide adenylyltransferase 1	1	9943428-9985501	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059447	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:3.85e-14 (favourable)	Expressed in all	Mixed			thyroid gland: 12.5	Mixed		
NNT		ENSG00000112992	Nicotinamide nucleotide transhydrogenase	5	43602692-43707405	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004829, CAB004975	Enhanced		Enhanced	Mitochondria	Renal cancer:1.22e-15 (favourable)	Expressed in all	Expressed in all			heart muscle: 130.6	Expressed in all		
NOX1	GP91-2, MOX1, NOH-1, NOH1	ENSG00000007952	NADPH oxidase 1	X	100843324-100874345	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Colorectal cancer:9.71e-4 (favourable)	Tissue enriched	Group enriched	17	colon: 58.7;rectum: 79.9	appendix: 3.9	Cell line enriched	19	CACO-2: 25.5
NPC1		ENSG00000141458	NPC intracellular cholesterol transporter 1	18	23506184-23586898	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026618, CAB070132, HPA077445	Approved		Supported	Nucleus<br>Vesicles	Liver cancer:2.26e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 110.1	Expressed in all		
NPC2	EDDM1, HE1, NP-C2	ENSG00000119655	NPC intracellular cholesterol transporter 2	14	74476192-74494177	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA000835	Enhanced				Colorectal cancer:4.83e-5 (unfavourable), Stomach cancer:2.66e-4 (unfavourable), Liver cancer:3.13e-4 (unfavourable), Thyroid cancer:6.55e-4 (favourable)	Expressed in all	Tissue enriched	19	epididymis: 16336.0	lung: 849.0	Expressed in all		
NPHS2	PDCN, SRN1	ENSG00000116218	NPHS2, podocin	1	179550539-179575952	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB037267, HPA049486	Enhanced					Not detected	Tissue enriched	87	kidney: 93.6	testis: 1.0	Cell line enriched	12	NTERA-2: 1.1
NPSR1	GPR154, GPRA, PGR14	ENSG00000187258	Neuropeptide S receptor 1	7	34658239-34878332	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA007489	Supported					Tissue enhanced	Not detected			stomach: 0.5	Cell line enhanced		HAP1: 1.1
NSD1	ARA267, FLJ22263, KMT3B, STO	ENSG00000165671	Nuclear receptor binding SET domain protein 1	5	177133025-177300215	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048431, HPA070333, HPA073705	Supported		Supported	Nucleus<br>Plasma membrane		Expressed in all	Expressed in all			testis: 43.2	Mixed		
NSD2	KMT3G, MMSET, WHSC1	ENSG00000109685	Nuclear receptor binding SET domain protein 2	4	1871424-1982207	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015801, CAB068246, CAB068247	Enhanced		Supported	Nucleus	Liver cancer:2.61e-4 (unfavourable), Renal cancer:7.19e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 66.6	Expressed in all		
NSD3	FLJ20353, KMT3F, WHISTLE, WHSC1L1	ENSG00000147548	Nuclear receptor binding SET domain protein 3	8	38269697-38382272	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005659, CAB013721, HPA018893	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Pancreatic cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 47.8	Expressed in all		
NSDHL	H105e3, SDR31E1, XAP104	ENSG00000147383	NAD(P) dependent steroid dehydrogenase-like	X	152830967-152869729	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000248, HPA000571	Enhanced		Enhanced	Endoplasmic reticulum<br>Lipid droplets	Renal cancer:6.09e-5 (favourable), Liver cancer:5.04e-4 (unfavourable), Cervical cancer:5.65e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 54.1	Expressed in all		
NSUN2	FLJ20303, Misu, MRT5, TRM4	ENSG00000037474	NOP2/Sun RNA methyltransferase family member 2	5	6599239-6633291	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037896	Enhanced		Supported	Nucleus	Renal cancer:5.69e-5 (unfavourable)	Expressed in all	Expressed in all			breast: 44.2	Expressed in all		
NT5C2	cN-II, GMP, NT5B, PNT5, SPG65	ENSG00000076685	5'-nucleotidase, cytosolic II	10	103088017-103193306	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003751	Approved					Expressed in all	Expressed in all			thyroid gland: 119.6	Expressed in all		
NT5C3A	cN-III, hUMP1, NT5C3, p36, P5'N-1, PN-I, POMP, PSN1, UMPH, UMPH1	ENSG00000122643	5'-nucleotidase, cytosolic IIIA	7	33014114-33062797	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA010630, HPA029058	Uncertain				Renal cancer:1.70e-4 (unfavourable), Liver cancer:2.42e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 46.5	Expressed in all		
NT5E	CALJA, CD73, eN, eNT, NT5	ENSG00000135318	5'-nucleotidase ecto	6	85449584-85495791	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017357	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 172.7	smooth muscle: 106.3	Cell line enhanced		LHCN-M2: 772.3;U-87 MG: 800.0
NTHL1	NTH1, OCTS3	ENSG00000065057	Nth like DNA glycosylase 1	16	2039815-2047866	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB025152	Supported					Expressed in all	Expressed in all			fallopian tube: 21.3	Expressed in all		
NTRK2	TRKB	ENSG00000148053	Neurotrophic receptor tyrosine kinase 2	9	84668551-85027070	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA007637, CAB010346	Enhanced		Approved	Cytosol		Group enriched	Tissue enhanced		cerebral cortex: 439.6;thyroid gland: 215.7	breast: 82.1	Group enriched	5	AF22: 9.4;HaCaT: 3.1;RPTEC TERT1: 8.1;SH-SY5Y: 12.9;WM-115: 2.8
NTRK3	TRKC	ENSG00000140538	Neurotrophic receptor tyrosine kinase 3	15	87859751-88256768	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009233, HPA027484, HPA048065	Enhanced		Supported	Nuclear membrane<br>Nucleoli		Tissue enhanced	Tissue enhanced		cerebral cortex: 39.6	testis: 15.2	Cell line enriched	8	U-138 MG: 99.2
NUP107	NUP84	ENSG00000111581	Nucleoporin 107	12	68686734-68745809	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031679			Uncertain	Nucleoplasm<br>Nuclear membrane<br>Centrosome	Liver cancer:3.12e-9 (unfavourable), Renal cancer:1.28e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 38.1	Expressed in all		
NUP155	KIAA0791, N155	ENSG00000113569	Nucleoporin 155	5	37288137-37371181	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA037775	Enhanced		Enhanced	Nuclear membrane	Liver cancer:1.35e-6 (unfavourable)	Expressed in all	Tissue enriched	9	testis: 126.8	parathyroid gland: 14.4	Expressed in all		
NUP188	KIAA0169	ENSG00000095319	Nucleoporin 188	9	128947699-129007096	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA061750, HPA063942	Approved		Supported	Nucleus	Endometrial cancer:5.20e-5 (favourable)	Expressed in all	Expressed in all			testis: 104.6	Expressed in all		
NUP205	C7orf14, KIAA0225	ENSG00000155561	Nucleoporin 205	7	135557919-135648757	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Liver cancer:1.90e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.3	Expressed in all		
NUP214	CAIN, CAN, D9S46E, N214	ENSG00000126883	Nucleoporin 214	9	131125561-131234670	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA048789			Supported	Nucleus<br>Vesicles<br>Focal adhesion sites	Renal cancer:2.39e-5 (favourable)	Expressed in all	Expressed in all			testis: 123.0	Expressed in all		
NUP62	DKFZp547L134, FLJ20822, FLJ43869, IBSN, MGC841, p62, SNDI	ENSG00000213024	Nucleoporin 62	19	49906825-49929763	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA005435, CAB020724	Enhanced		Supported	Nucleus<br>Nuclear membrane	Renal cancer:5.71e-12 (unfavourable), Liver cancer:2.50e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 76.9	Expressed in all		
NUP93	KIAA0095	ENSG00000102900	Nucleoporin 93	16	56730105-56850286	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017937	Uncertain				Liver cancer:1.72e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 74.6	Expressed in all		
NUS1	C6orf68, MGC7199, NgBR, TANGO14	ENSG00000153989	NUS1 dehydrodolichyl diphosphate synthase subunit	6	117675502-117710640	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA027504	Supported		Approved	Vesicles<br>Plasma membrane	Cervical cancer:6.99e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 92.2	Expressed in all		
OAT	HOGA	ENSG00000065154	Ornithine aminotransferase	10	124397303-124418976	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033576, HPA040098, HPA064742	Enhanced		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			small intestine: 859.8	Mixed		
OBSCN	ARHGEF30, KIAA1556, KIAA1639, UNC89	ENSG00000154358	Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF	1	228208130-228378874	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021186	Enhanced		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:1.64e-4 (unfavourable)	Mixed	Tissue enriched	7	skeletal muscle: 301.1	heart muscle: 45.7	Mixed		
OCA2	BEY, BEY1, BEY2, D15S12, EYCL, EYCL2, EYCL3, P	ENSG00000104044	OCA2 melanosomal transmembrane protein	15	27754875-28099358	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enhanced		skin: 7.4;thyroid gland: 5.8	testis: 2.5	Group enriched	6	SH-SY5Y: 6.3;SK-MEL-30: 18.3
OCLN	PPP1R115	ENSG00000197822	Occludin	5	69492292-69558104	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005933, CAB013075, CAB068212, CAB068213, CAB068214	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:6.59e-11 (favourable)	Mixed	Tissue enhanced		thyroid gland: 78.7	lung: 39.8	Cell line enhanced		CAPAN-2: 60.2;HaCaT: 48.8
OCRL	OCRL1	ENSG00000122126	OCRL, inositol polyphosphate-5-phosphatase	X	129539849-129592561	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA012495	Approved		Approved	Microtubules<br>Cytosol	Breast cancer:2.93e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.3	Mixed		
OGG1	HMMH, HOGG1, MUTM, OGH1	ENSG00000114026	8-oxoguanine DNA glycosylase	3	9749944-9788219	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027514, CAB047301	Approved		Enhanced	Nucleoplasm	Liver cancer:5.77e-5 (unfavourable), Renal cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 30.5	Expressed in all		
OGT	FLJ23071, HRNT1, MGC22921, O-GLCNAC	ENSG00000147162	O-linked N-acetylglucosamine (GlcNAc) transferase	X	71533083-71575897	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030751, HPA030752, HPA030753, HPA030754, CAB034099	Approved		Supported	Nucleoplasm<br>Plasma membrane	Urothelial cancer:6.85e-7 (favourable), Renal cancer:2.36e-6 (unfavourable), Head and neck cancer:1.97e-4 (favourable), Endometrial cancer:8.33e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 83.2	Expressed in all		
OPA1	FLJ12460, KIAA0567, MGM1, NPG, NTG	ENSG00000198836	OPA1, mitochondrial dynamin like GTPase	3	193593144-193697823	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA036926, HPA036927	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Pancreatic cancer:8.44e-5 (unfavourable), Renal cancer:1.84e-4 (favourable), Endometrial cancer:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 56.2	Expressed in all		
OPLAH	5-Opase, OPLA	ENSG00000178814	5-oxoprolinase (ATP-hydrolysing)	8	144051266-144063965	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026562, HPA028260, HPA052429	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:1.53e-6 (favourable)	Expressed in all	Tissue enhanced		testis: 58.2	duodenum: 13.8	Cell line enhanced		AN3-CA: 31.2;BEWO: 20.2;PC-3: 24.2
OPN1LW	CBBM, CBP, COD5, RCP	ENSG00000102076	Opsin 1, long wave sensitive	X	154144224-154159032	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
OPN1MW	CBBM, CBD, COD5, GCP, OPN1MW1	ENSG00000268221	Opsin 1, medium wave sensitive	X	154182596-154196135	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			appendix: 0.1	Not detected		
OPN1SW	BCP, BOP, CBT	ENSG00000128617	Opsin 1, short wave sensitive	7	128772491-128775790	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA013562, HPA014083	Enhanced				Renal cancer:2.26e-8 (unfavourable), Stomach cancer:5.98e-8 (unfavourable), Liver cancer:8.50e-5 (unfavourable), Urothelial cancer:9.33e-4 (unfavourable)	Expressed in all	Mixed			heart muscle: 6.7	Cell line enhanced		U-87 MG: 64.7
OTC		ENSG00000036473	Ornithine carbamoyltransferase	X	38352545-38421450	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000243, HPA000570	Enhanced		Supported	Mitochondria		Tissue enriched	Group enriched	26	duodenum: 114.4;liver: 195.4;small intestine: 96.9	colon: 5.3	Not detected		
OTULIN	FAM105B, FLJ34884	ENSG00000154124	OTU deubiquitinase with linear linkage specificity	5	14664664-14699711	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051074	Uncertain		Approved	Plasma membrane<br>Mitochondria	Renal cancer:2.59e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 17.1	Expressed in all		
OXCT1	OXCT, SCOT	ENSG00000083720	3-oxoacid CoA-transferase 1	5	41730065-41870519	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012047, HPA061425	Enhanced		Enhanced	Mitochondria	Renal cancer:1.86e-8 (favourable), Liver cancer:1.03e-4 (unfavourable)	Expressed in all	Tissue enhanced		heart muscle: 162.3	cerebral cortex: 98.7	Cell line enhanced		SiHa: 338.4
P3H1	GROS1, LEPRE1, LEPRECAN, MGC117314	ENSG00000117385	Prolyl 3-hydroxylase 1	1	42746335-42767084	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA012113, HPA016980	Approved		Approved	Nucleoli<br>Vesicles	Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.95e-7 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 53.5	smooth muscle: 28.8	Expressed in all		
P3H2	FLJ10718, LEPREL1, MLAT4	ENSG00000090530	Prolyl 3-hydroxylase 2	3	189956728-190122437	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007890, HPA013355	Approved					Expressed in all	Mixed			prostate: 60.8	Cell line enhanced		HaCaT: 97.1;RPTEC TERT1: 83.3
P4HA2	C-P4Halpha(II)	ENSG00000072682	Prolyl 4-hydroxylase subunit alpha 2	5	132191838-132295315	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA016997, HPA027824, CAB062557	Enhanced		Enhanced	Endoplasmic reticulum<br>Vesicles	Renal cancer:2.77e-7 (unfavourable), Cervical cancer:1.24e-5 (unfavourable), Urothelial cancer:3.12e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 95.3	Mixed		
P4HB	DSI, ERBA2L, GIT, P4Hbeta, PDI, PDIA1, PO4DB, PO4HB, PROHB	ENSG00000185624	Prolyl 4-hydroxylase subunit beta	17	81843159-81860694	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB012463, HPA018884	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:2.30e-11 (unfavourable)	Expressed in all	Expressed in all			small intestine: 504.4	Expressed in all		
PADI3	PDI3	ENSG00000142619	Peptidyl arginine deiminase 3	1	17249098-17284233	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043739	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.55e-11 (unfavourable), Endometrial cancer:3.22e-4 (unfavourable)	Tissue enhanced	Group enriched	10	esophagus: 3.7;seminal vesicle: 4.9;urinary bladder: 10.2	epididymis: 0.6	Cell line enhanced		EFO-21: 13.2;RT4: 13.9;T-47d: 12.0
PADI4	PAD, PADI5, PDI4, PDI5	ENSG00000159339	Peptidyl arginine deiminase 4	1	17308195-17364004	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017007, HPA042825	Enhanced					Not detected	Tissue enriched	12	bone marrow: 71.8	spleen: 5.9	Cell line enhanced		HEL: 1.1;RPMI-8226: 1.0
PADI6		ENSG00000276747	Peptidyl arginine deiminase 6	1	17372196-17401699	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PAK3	bPAK, hPAK3, MRX30, MRX47	ENSG00000077264	P21 (RAC1) activated kinase 3	X	110944285-111227361	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA044791, HPA060219	Approved		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 34.3	thyroid gland: 10.4	Cell line enhanced		EFO-21: 10.2;HAP1: 10.2;HDLM-2: 11.9;NTERA-2: 9.6;SCLC-21H: 14.7;U-251 MG: 11.1
PANK2	C20orf48, FLJ11729, HARP, HSS, NBIA1, PKAN	ENSG00000125779	Pantothenate kinase 2	20	3888839-3929882	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008440	Approved		Supported	Cytosol	Liver cancer:1.20e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 51.9	Expressed in all		
PAPSS2	ATPSK2	ENSG00000198682	3'-phosphoadenosine 5'-phosphosulfate synthase 2	10	87659613-87747705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA071224			Approved	Mitochondria	Melanoma:1.33e-6 (unfavourable), Thyroid cancer:3.21e-5 (unfavourable), Pancreatic cancer:6.58e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 157.6	Cell line enhanced		fHDF/TERT166: 365.8
PARK7	DJ-1, DJ1	ENSG00000116288	Parkinsonism associated deglycase	1	7954291-7985505	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004190, CAB005870	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 515.7	Expressed in all		
PARN	DAN	ENSG00000140694	Poly(A)-specific ribonuclease	16	14435701-14632728	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006314, CAB011673, HPA012010	Enhanced		Approved	Nucleoli<br>Nuclear speckles	Head and neck cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.0	Expressed in all		
PARP9	BAL, BAL1	ENSG00000138496	Poly(ADP-ribose) polymerase family member 9	3	122527924-122564577	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA066708			Supported	Nucleoplasm<br>Mitochondria<br>Cytosol	Ovarian cancer:6.65e-4 (favourable)	Expressed in all	Expressed in all			spleen: 60.9	Cell line enhanced		BJ hTERT+ SV40 Large T+: 89.2;BJ hTERT+ SV40 Large T+ RasG12V: 110.6
PC	PCB	ENSG00000173599	Pyruvate carboxylase	11	66848233-66958376	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033742, HPA043922, HPA058765	Uncertain		Enhanced	Mitochondria	Ovarian cancer:7.86e-5 (unfavourable), Renal cancer:8.22e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 63.8	Mixed		
PCBD1	DCOH, PCBD, PCD	ENSG00000166228	Pterin-4 alpha-carbinolamine dehydratase 1	10	70882280-70888784	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037575, HPA061723	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			liver: 157.7	Mixed		
PCCA		ENSG00000175198	Propionyl-CoA carboxylase alpha subunit	13	100089015-100530437	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041716, HPA047792	Enhanced				Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			epididymis: 266.0	Cell line enhanced		RPTEC TERT1: 124.8;SCLC-21H: 107.6;U-937: 103.1
PCCB		ENSG00000114054	Propionyl-CoA carboxylase beta subunit	3	136250306-136337896	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036939, HPA036940	Enhanced				Renal cancer:6.47e-7 (favourable)	Expressed in all	Expressed in all			liver: 103.1	Expressed in all		
PCK1	PEPCK-C	ENSG00000124253	Phosphoenolpyruvate carboxykinase 1	20	57561080-57568112	Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006277, HPA006507, CAB017027	Approved				Renal cancer:1.47e-5 (favourable)	Tissue enriched	Tissue enhanced		kidney: 425.9;liver: 319.7	small intestine: 157.6	Cell line enriched	9	ASC diff: 14.0
PCK2	PEPCK, PEPCK2	ENSG00000100889	Phosphoenolpyruvate carboxykinase 2, mitochondrial	14	24094053-24110598	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB018734, HPA051162, HPA053502	Enhanced		Enhanced	Mitochondria	Liver cancer:2.81e-4 (favourable)	Expressed in all	Group enriched	6	duodenum: 367.6;kidney: 192.2;liver: 258.6;small intestine: 276.5	colon: 47.0	Expressed in all		
PCSK1	NEC1, PC1, PC3, SPC3	ENSG00000175426	Proprotein convertase subtilisin/kexin type 1	5	96390415-96434143	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048564	Approved				Glioma:1.31e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 33.6	adrenal gland: 8.3	Group enriched	6	SCLC-21H: 26.6;U-138 MG: 18.8;U-87 MG: 15.5
PCYT1A	CT, CTPCT, PCYT1	ENSG00000161217	Phosphate cytidylyltransferase 1, choline, alpha	3	196214222-196287957	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035428	Approved		Approved	Nucleus	Liver cancer:8.65e-5 (unfavourable)	Expressed in all	Expressed in all			duodenum: 66.9	Expressed in all		
PDE11A		ENSG00000128655	Phosphodiesterase 11A	2	177623252-178108339	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA034560	Approved					Tissue enhanced	Tissue enhanced		parathyroid gland: 10.5;prostate: 8.8	testis: 6.4	Cell line enhanced		fHDF/TERT166: 2.2;Hep G2: 2.0
PDE6A	PDEA, RP43	ENSG00000132915	Phosphodiesterase 6A	5	149857955-149944793	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016970, HPA074677	Enhanced					Not detected	Tissue enriched	8	epididymis: 20.2	testis: 2.4	Cell line enhanced		CACO-2: 2.1
PDE6B	CSNB3, CSNBAD2, PDEB, rd1, RP40	ENSG00000133256	Phosphodiesterase 6B	4	625584-670782	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA054148, HPA059929	Supported		Approved	Cytosol	Lung cancer:5.34e-4 (favourable)	Mixed	Mixed			cerebral cortex: 22.3	Cell line enhanced		MOLT-4: 25.1;REH: 15.3;SCLC-21H: 23.8;SH-SY5Y: 12.6;U-266/84: 16.5
PDE6C	ACHM5, COD4, PDEA2	ENSG00000095464	Phosphodiesterase 6C	10	93612588-93666010	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			skin: 0.6	Not detected		
PDE6G	PDEG, RP57	ENSG00000185527	Phosphodiesterase 6G	17	81650459-81663112	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045118	Supported					Tissue enhanced	Tissue enhanced		lymph node: 26.1;spleen: 33.3	placenta: 18.9	Cell line enhanced		NTERA-2: 10.5;REH: 11.5
PDE6H		ENSG00000139053	Phosphodiesterase 6H	12	14973022-14981865	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045118	Supported					Not detected	Tissue enhanced		bone marrow: 2.4;placenta: 1.3	adrenal gland: 0.5	Not detected		
PDE8B		ENSG00000113231	Phosphodiesterase 8B	5	77210449-77429807	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036911, HPA036912	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	6	thyroid gland: 293.7	cerebral cortex: 53.0	Cell line enhanced		BJ hTERT+: 14.6;HeLa: 32.2;SK-BR-3: 10.4
PDHA1	PDHA	ENSG00000131828	Pyruvate dehydrogenase (lipoamide) alpha 1	X	19343893-19361705	Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047487, HPA047864, HPA063053	Approved		Supported	Mitochondria	Renal cancer:1.13e-7 (favourable)	Expressed in all	Expressed in all			heart muscle: 222.0	Expressed in all		
PDHB		ENSG00000168291	Pyruvate dehydrogenase (lipoamide) beta	3	58427630-58433857	Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033794, HPA036744, HPA036745	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:2.79e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 112.0	Expressed in all		
PDK3		ENSG00000067992	Pyruvate dehydrogenase kinase 3	X	24465221-24539837	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046583, HPA072492	Approved		Supported	Nucleoli<br>Mitochondria	Liver cancer:2.76e-4 (unfavourable)	Expressed in all	Mixed			testis: 24.9	Mixed		
PDP1	PDH, PDP, PPM2A, PPM2C	ENSG00000164951	Pyruvate dehyrogenase phosphatase catalytic subunit 1	8	93857807-93926066	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018483, HPA019081, HPA021152	Uncertain		Supported	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:8.42e-9 (favourable), Breast cancer:8.61e-5 (unfavourable), Ovarian cancer:5.60e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 82.3	Expressed in all		
PDSS1	COQ1, TPRT, TPT	ENSG00000148459	Decaprenyl diphosphate synthase subunit 1	10	26697659-26746798	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038032, HPA042741	Uncertain		Approved	Cytosol	Liver cancer:1.25e-5 (unfavourable), Endometrial cancer:1.66e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 18.4	Expressed in all		
PDSS2	bA59I9.3, C6orf210	ENSG00000164494	Decaprenyl diphosphate synthase subunit 2	6	107152557-107459564	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029685, HPA029686	Approved		Enhanced	Cytosol	Renal cancer:3.75e-7 (favourable), Breast cancer:1.34e-5 (unfavourable), Colorectal cancer:5.74e-5 (favourable)	Expressed in all	Expressed in all			prostate: 23.4	Expressed in all		
PDYN	ADCA, PENKB, SCA23	ENSG00000101327	Prodynorphin	20	1978757-1994285	Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049841, HPA053342	Approved	Supported				Group enriched	Tissue enriched	11	cerebral cortex: 63.3	testis: 5.5	Not detected		
PEPD		ENSG00000124299	Peptidase D	19	33386950-33521794	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015599, HPA072045	Approved		Supported	Nucleoplasm	Renal cancer:6.50e-9 (favourable)	Expressed in all	Expressed in all			kidney: 342.6	Expressed in all		
PEX1	ZWS, ZWS1	ENSG00000127980	Peroxisomal biogenesis factor 1	7	92487020-92528531	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA020235	Approved		Supported	Peroxisomes		Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
PEX10	RNF69	ENSG00000157911	Peroxisomal biogenesis factor 10	1	2403964-2413797	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049458, HPA049755	Approved		Approved	Nucleoplasm	Renal cancer:4.16e-6 (favourable), Breast cancer:4.50e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.2	Expressed in all		
PEX12		ENSG00000108733	Peroxisomal biogenesis factor 12	17	35574795-35578863	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA069386	Enhanced				Renal cancer:3.58e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 17.3	Mixed		
PEX13		ENSG00000162928	Peroxisomal biogenesis factor 13	2	61017225-61051990	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032141, HPA032142, CAB032689	Enhanced		Supported	Vesicles	Pancreatic cancer:8.07e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 27.5	Expressed in all		
PEX14		ENSG00000142655	Peroxisomal biogenesis factor 14	1	10472288-10630758	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046104, HPA049231	Supported		Supported	Nucleoli fibrillar center<br>Peroxisomes		Expressed in all	Expressed in all			seminal vesicle: 32.7	Expressed in all		
PEX16		ENSG00000121680	Peroxisomal biogenesis factor 16	11	45909669-45918812	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043286	Approved				Urothelial cancer:9.06e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 27.5	Expressed in all		
PEX19	D1S2223E, HK33, PMP1, PMPI, PXF, PXMP1	ENSG00000162735	Peroxisomal biogenesis factor 19	1	160276812-160286348	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA044837, HPA051966	Supported		Enhanced	Peroxisomes	Renal cancer:2.92e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 86.2	Expressed in all		
PEX2	PAF-1, PMP35, PXMP3, RNF72, ZWS3	ENSG00000164751	Peroxisomal biogenesis factor 2	8	76980258-77001044	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010983, HPA011410, HPA027729	Approved		Supported	Vesicles		Expressed in all	Expressed in all			seminal vesicle: 111.5	Expressed in all		
PEX26	FLJ20695	ENSG00000215193	Peroxisomal biogenesis factor 26	22	18077920-18131138	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB070429	Approved				Renal cancer:1.38e-4 (favourable), Liver cancer:3.10e-4 (unfavourable), Colorectal cancer:9.92e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 34.1	Expressed in all		
PEX3		ENSG00000034693	Peroxisomal biogenesis factor 3	6	143450807-143490010	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042830, HPA058006	Enhanced		Supported	Nucleoplasm<br>Peroxisomes	Renal cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 54.3	Expressed in all		
PEX6	PAF-2, PXAAA1	ENSG00000124587	Peroxisomal biogenesis factor 6	6	42963870-42979220	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA025924, HPA074179	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Expressed in all	Expressed in all			fallopian tube: 36.5	Expressed in all		
PEX7	PTS2R, RD	ENSG00000112357	Peroxisomal biogenesis factor 7	6	136822564-136913937	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA049202	Uncertain		Supported	Nucleoplasm<br>Vesicles	Renal cancer:1.85e-10 (favourable), Colorectal cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 25.3	Mixed		
PFKM	PFK-1, PFKX, PPP1R122	ENSG00000152556	Phosphofructokinase, muscle	12	48105139-48146404	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002117	Approved		Approved	Endoplasmic reticulum	Renal cancer:2.28e-7 (favourable), Endometrial cancer:5.85e-6 (unfavourable), Head and neck cancer:7.91e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 549.3	Expressed in all		
PGAM2	PGAM-M	ENSG00000164708	Phosphoglycerate mutase 2	7	44062727-44065587	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050314, HPA060173	Enhanced		Approved	Nucleoplasm<br>Cytosol		Not detected	Group enriched	8	heart muscle: 521.3;skeletal muscle: 1459.5	testis: 126.6	Cell line enriched	10	SCLC-21H: 77.0
PGAP2	CWH43-N, FRAG1, MRT21	ENSG00000148985	Post-GPI attachment to proteins 2	11	3797724-3826371	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA063099	Approved		Approved	Microtubules	Liver cancer:7.49e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 263.3	Expressed in all		
PGK1		ENSG00000102144	Phosphoglycerate kinase 1	X	78065188-78129296	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010065, HPA045385, HPA073644, HPA073656	Approved				Breast cancer:7.05e-8 (unfavourable), Head and neck cancer:2.65e-6 (unfavourable), Cervical cancer:2.69e-5 (unfavourable), Liver cancer:2.74e-4 (unfavourable), Pancreatic cancer:8.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 118.2	Expressed in all		
PGM1		ENSG00000079739	Phosphoglucomutase 1	1	63593276-63660245	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004666, HPA024190, HPA024637, HPA046329	Approved		Enhanced	Actin filaments	Pancreatic cancer:8.74e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 512.9	Mixed		
PGM3	AGM1, DKFZP434B187, PAGM	ENSG00000013375	Phosphoglucomutase 3	6	83161150-83193936	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004998, HPA029759, HPA029760	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.39e-7 (unfavourable), Cervical cancer:5.67e-4 (unfavourable), Breast cancer:8.78e-4 (unfavourable), Ovarian cancer:9.96e-4 (favourable)	Expressed in all	Expressed in all			prostate: 82.2	Expressed in all		
PHEX	HPDR, HPDR1, HYP, HYP1, PEX, XLH	ENSG00000102174	Phosphate regulating endopeptidase homolog, X-linked	X	22032441-22251310	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Thyroid cancer:2.51e-4 (favourable)	Tissue enhanced	Tissue enhanced		endometrium: 3.5	lung: 2.9	Cell line enhanced		PC-3: 2.8;U-87 MG: 6.5;WM-115: 2.8
PHF8	JHDM1F, KDM7B, KIAA1111, ZNF422	ENSG00000172943	PHD finger protein 8	X	53936676-54048958	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038779, HPA062015	Approved		Supported	Nucleus	Urothelial cancer:3.74e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 85.8	Expressed in all		
PHGDH	PDG, PGDH, SERA	ENSG00000092621	Phosphoglycerate dehydrogenase	1	119659798-119744215	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003681, HPA021241, HPA024031, CAB068216	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:1.48e-4 (unfavourable), Glioma:2.26e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 216.7	skin: 115.9	Mixed		
PHKG2		ENSG00000156873	Phosphorylase kinase catalytic subunit gamma 2	16	30748270-30761176	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065618, HPA068751			Supported	Cytosol	Lung cancer:1.90e-4 (favourable), Cervical cancer:7.90e-4 (favourable), Pancreatic cancer:8.02e-4 (favourable), Colorectal cancer:9.92e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 149.4	Expressed in all		
PHYH	PAHX, PHYH1, RD	ENSG00000107537	Phytanoyl-CoA 2-hydroxylase	10	13277796-13302412	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007598, HPA011796	Enhanced				Renal cancer:7.28e-12 (favourable)	Expressed in all	Expressed in all			liver: 334.1	Mixed		
PHYKPL	AGXT2L2, MGC15875	ENSG00000175309	5-phosphohydroxy-L-lysine phospho-lyase	5	178208497-178232791	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036461, HPA063608	Approved		Approved	Mitochondria	Renal cancer:3.82e-5 (unfavourable)	Expressed in all	Expressed in all			rectum: 34.5	Expressed in all		
PI4KA	PI4K-ALPHA, pi4K230, PIK4CA	ENSG00000241973	Phosphatidylinositol 4-kinase alpha	22	20707691-20859417	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009092, HPA075515	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:7.22e-5 (favourable), Lung cancer:5.24e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 113.6	Expressed in all		
PIEZO1	FAM38A, KIAA0233	ENSG00000103335	Piezo type mechanosensitive ion channel component 1	16	88715343-88785211	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047185	Uncertain				Renal cancer:8.89e-7 (unfavourable), Lung cancer:2.36e-5 (unfavourable), Cervical cancer:2.37e-4 (unfavourable), Ovarian cancer:3.78e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 42.0	Expressed in all		
PIEZO2	C18orf30, C18orf58, FAM38B, FAM38B2, FLJ23144, FLJ23403, FLJ34907, HsT748, HsT771	ENSG00000154864	Piezo type mechanosensitive ion channel component 2	18	10666483-11148762	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015986, HPA031974, HPA031975, HPA040616	Enhanced		Approved	Vesicles	Renal cancer:9.57e-7 (unfavourable)	Mixed	Mixed			lung: 12.8	Cell line enhanced		AF22: 17.1;BJ hTERT+ SV40 Large T+ RasG12V: 24.8;HeLa: 26.7;U-266/70: 19.5
PIGA	GPI3	ENSG00000165195	Phosphatidylinositol glycan anchor biosynthesis class A	X	15319451-15335580	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001174	Approved				Pancreatic cancer:7.64e-4 (unfavourable)	Expressed in all	Mixed			lung: 9.8	Expressed in all		
PIGL		ENSG00000108474	Phosphatidylinositol glycan anchor biosynthesis class L	17	16217191-16351797	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA012739	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.47e-4 (unfavourable), Prostate cancer:2.57e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis,thyroid gland: 14.7	Mixed		
PIK3CA	PI3K	ENSG00000121879	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	179148114-179240093	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA009985, CAB017804	Approved		Approved	Cytosol		Expressed in all	Mixed			parathyroid gland: 23.8	Expressed in all		
PIK3CD	p110D	ENSG00000171608	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	9651732-9729114	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB015420, HPA044953	Enhanced		Approved	Vesicles<br>Cytokinetic bridge		Expressed in all	Tissue enhanced		lymph node: 56.4	spleen: 51.2	Cell line enhanced		HDLM-2: 146.7;REH: 64.7;U-937: 63.7
PIKFYVE	FAB1, KIAA0981, MGC40423, p235, PIKfyve, PIP5K, PIP5K3, ZFYVE29	ENSG00000115020	Phosphoinositide kinase, FYVE-type zinc finger containing	2	208266267-208358751	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042604	Uncertain		Uncertain	Nuclear speckles	Head and neck cancer:6.81e-4 (favourable)	Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
PINK1	PARK6	ENSG00000158828	PTEN induced putative kinase 1	1	20633455-20651511	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001931, CAB026191	Uncertain				Renal cancer:1.11e-16 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 145.5	Expressed in all		
PIP5K1C	KIAA0589, LCCS3, PIP5Kgamma	ENSG00000186111	Phosphatidylinositol-4-phosphate 5-kinase type 1 gamma	19	3630183-3700479	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017168	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:7.28e-5 (favourable), Cervical cancer:1.79e-4 (favourable), Pancreatic cancer:2.32e-4 (favourable), Renal cancer:3.00e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 52.9	Expressed in all		
PKD1	PBP, Pc-1, TRPP1	ENSG00000008710	Polycystin 1, transient receptor potential channel interacting	16	2088710-2135898	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB046448	Approved				Pancreatic cancer:3.38e-5 (favourable), Head and neck cancer:3.35e-4 (favourable), Colorectal cancer:7.43e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 21.6	Expressed in all		
PKD1L1	PRO19563	ENSG00000158683	Polycystin 1 like 1, transient receptor potential channel interacting	7	47774652-47948491	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020422, HPA022424	Uncertain					Tissue enhanced	Tissue enhanced		testis: 2.4	adipose tissue: 1.8	Group enriched	8	T-47d: 5.0;U-266/70: 10.5;U-266/84: 3.7
PKD2	Pc-2, PC2, PKD4, TRPP2	ENSG00000118762	Polycystin 2, transient receptor potential cation channel	4	88007668-88077777	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB004544, HPA015794	Approved		Enhanced	Endoplasmic reticulum		Expressed in all	Expressed in all			endometrium: 101.0	Cell line enhanced		BJ hTERT+: 167.9
PKLR		ENSG00000143627	Pyruvate kinase, liver and RBC	1	155289839-155301434	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006653, CAB034376, CAB034378	Enhanced		Approved	Endoplasmic reticulum<br>Golgi apparatus		Tissue enriched	Tissue enhanced		kidney: 14.0;liver: 26.4	bone marrow: 7.8	Cell line enriched	16	K-562: 72.0
PLA2G5		ENSG00000127472	Phospholipase A2 group V	1	20028179-20091190	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA053361	Approved					Group enriched	Tissue enhanced		heart muscle: 48.6	seminal vesicle: 19.8	Cell line enhanced		U-138 MG: 1.0;U-2197: 2.1
PLA2G7	LDL-PLA2, PAFAH	ENSG00000146070	Phospholipase A2 group VII	6	46704201-46735693	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA035916			Uncertain	Vesicles		Expressed in all	Mixed			spleen: 37.5	Cell line enhanced		NTERA-2: 1.7;PC-3: 3.2;RT4: 1.3;U-2 OS: 1.7
PLCB1	KIAA0581, PLC-I, PLC154	ENSG00000182621	Phospholipase C beta 1	20	8077251-8968360	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004275, CAB005334, HPA034743, HPA057910	Enhanced		Approved	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 68.3;parathyroid gland: 121.3	placenta: 28.2	Cell line enhanced		Hep G2: 46.8
PLCB4		ENSG00000101333	Phospholipase C beta 4	20	9068763-9481242	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007951	Supported		Approved	Nucleoplasm<br>Microtubules	Endometrial cancer:2.11e-4 (favourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 58.5	epididymis: 30.5	Cell line enhanced		fHDF/TERT166: 87.3;LHCN-M2: 74.5;RPTEC TERT1: 85.5
PLCD1		ENSG00000187091	Phospholipase C delta 1	3	38007496-38029762	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009913, HPA020107, HPA021677	Approved		Approved	Microtubules	Renal cancer:9.25e-11 (favourable)	Expressed in all	Mixed			testis: 38.3	Mixed		
PLCE1	KIAA1516, NPHS3, PLCE	ENSG00000138193	Phospholipase C epsilon 1	10	94030812-94332823	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA015597, HPA015598	Enhanced		Supported	Cytosol		Expressed in all	Mixed			endometrium: 21.6	Cell line enhanced		RT4: 17.8;U-2 OS: 13.5
PLCG2		ENSG00000197943	Phospholipase C gamma 2	16	81739097-81962693	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004280, HPA020099, HPA020100	Enhanced		Approved	Vesicles	Renal cancer:4.88e-4 (favourable), Head and neck cancer:6.71e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 78.9	tonsil: 65.8	Cell line enhanced		Daudi: 130.7;HMC-1: 74.1;U-698: 278.1
PLCZ1	NYD-SP27, PLCzeta	ENSG00000139151	Phospholipase C zeta 1	12	18683169-18738057	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	23	testis: 48.5	skin: 2.1	Not detected		
PLD3	HU-K4	ENSG00000105223	Phospholipase D family member 3	19	40348456-40380439	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012800, CAB020812	Approved				Renal cancer:2.21e-4 (favourable), Pancreatic cancer:6.44e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 494.9	Expressed in all		
PLK1	PLK	ENSG00000166851	Polo like kinase 1	16	23677656-23690367	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051638, HPA053229	Approved				Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.70e-7 (unfavourable), Lung cancer:2.28e-5 (unfavourable), Pancreatic cancer:4.12e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 44.2	lymph node: 32.8	Expressed in all		
PLK4	Sak, STK18	ENSG00000142731	Polo like kinase 4	4	127880861-127899195	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017327, HPA035026, HPA043198	Approved		Supported	Centrosome<br>Cytosol	Colorectal cancer:7.46e-5 (favourable), Lung cancer:5.13e-4 (unfavourable), Pancreatic cancer:5.14e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 40.9	bone marrow: 13.9	Mixed		
PLN	CMD1P, PLB	ENSG00000198523	Phospholamban	6	118548298-118560730	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB005597, HPA026900	Enhanced				Renal cancer:4.11e-4 (unfavourable), Urothelial cancer:5.59e-4 (unfavourable)	Mixed	Tissue enriched	5	heart muscle: 1461.9	smooth muscle: 270.2	Not detected		
PLOD1	LH1, LLH, PLOD	ENSG00000083444	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1	1	11934205-11975538	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA049137, HPA055799	Uncertain		Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:1.91e-12 (unfavourable), Urothelial cancer:2.43e-4 (unfavourable), Liver cancer:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 122.3	Expressed in all		
PLOD2	LH2	ENSG00000152952	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2	3	146069440-146163653	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025898, HPA069126	Approved		Uncertain	Nucleoli<br>Cytosol	Renal cancer:4.99e-11 (unfavourable), Liver cancer:7.64e-10 (unfavourable), Lung cancer:1.42e-4 (unfavourable), Cervical cancer:1.97e-4 (unfavourable), Stomach cancer:2.83e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 150.8	Cell line enhanced		HBF TERT88: 615.2;U-87 MG: 554.9
PLOD3	LH3	ENSG00000106397	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3	7	101205977-101218420	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001236	Uncertain				Cervical cancer:1.91e-5 (unfavourable), Colorectal cancer:3.26e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 48.1	Expressed in all		
PMM2	CDG1, CDG1a, CDGS, PMI, PMI1	ENSG00000140650	Phosphomannomutase 2	16	8788823-8849331	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040852, HPA063649	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:8.97e-6 (unfavourable), Colorectal cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			rectum: 28.3	Expressed in all		
PMP22	GAS3, HNPP, Sp110	ENSG00000109099	Peripheral myelin protein 22	17	15229777-15265326	Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 316.4	Cell line enhanced		ASC diff: 277.3;HMC-1: 278.9;WM-115: 491.1
PMPCA	Alpha-MPP, INPP5E, KIAA0123	ENSG00000165688	Peptidase, mitochondrial processing alpha subunit	9	136410570-136423761	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021648, HPA063735	Enhanced		Enhanced	Mitochondria	Renal cancer:2.14e-6 (favourable), Pancreatic cancer:8.00e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 38.6	Expressed in all		
PMVK	HUMPMKI, PMK, PMKA	ENSG00000163344	Phosphomevalonate kinase	1	154924734-154936991	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029900	Approved				Renal cancer:4.96e-4 (favourable), Ovarian cancer:9.70e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.5	Expressed in all		
PNKP	PNK	ENSG00000039650	Polynucleotide kinase 3'-phosphatase	19	49859882-49878351	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006782	Supported		Supported	Nucleus<br>Nucleoli	Breast cancer:9.18e-4 (favourable)	Expressed in all	Expressed in all			spleen: 38.1	Expressed in all		
PNPLA2	ATGL, desnutrin, FP17548, iPLA2zeta, TTS-2.2	ENSG00000177666	Patatin like phospholipase domain containing 2	11	818902-825573	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA055173, HPA062602			Enhanced	Nucleoplasm<br>Lipid droplets		Expressed in all	Tissue enriched	13	adipose tissue: 420.0	skeletal muscle: 33.4	Expressed in all		
PNPLA3	adiponutrin, ADPN, C22orf20, dJ796I17.1, FLJ22012, iPLA2epsilon	ENSG00000100344	Patatin like phospholipase domain containing 3	22	43923739-43964488	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA058058	Approved		Approved	Nucleoli<br>Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		liver: 16.2	kidney: 4.7	Mixed		
PNPLA4	DXS1283E, GS2, iPLA2eta	ENSG00000006757	Patatin like phospholipase domain containing 4	X	7898247-7927739	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003656	Approved				Renal cancer:2.23e-12 (favourable), Glioma:4.67e-4 (unfavourable), Head and neck cancer:5.37e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 50.2	Mixed		
PNPLA6	iPLA2delta, NTE, SPG39, sws	ENSG00000032444	Patatin like phospholipase domain containing 6	19	7534004-7561764	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007522	Uncertain				Pancreatic cancer:3.51e-5 (favourable), Head and neck cancer:5.25e-4 (favourable), Renal cancer:7.53e-4 (favourable)	Expressed in all	Expressed in all			testis: 49.1	Expressed in all		
PNPLA8	IPLA2-2, IPLA2G, iPLA2gamma	ENSG00000135241	Patatin like phospholipase domain containing 8	7	108470422-108569666	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020083	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.86e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 63.1	Expressed in all		
PNPO	PDXPO	ENSG00000108439	Pyridoxamine 5'-phosphate oxidase	17	47941506-47948288	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023204, HPA027776	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			liver: 51.3	Mixed		
PNPT1	DFNB70, old-35, OLD35, PNPase	ENSG00000138035	Polyribonucleotide nucleotidyltransferase 1	2	55634265-55693910	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033424, HPA034602, HPA034603	Supported		Enhanced	Mitochondria	Liver cancer:1.95e-7 (unfavourable), Pancreatic cancer:5.44e-5 (unfavourable), Endometrial cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 9.9	Expressed in all		
POFUT1	FUT12, KIAA0180, O-Fuc-T, O-FUT	ENSG00000101346	Protein O-fucosyltransferase 1	20	32207880-32238667	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA054519, HPA059935	Approved		Approved	Centrosome		Expressed in all	Expressed in all			parathyroid gland: 35.7	Expressed in all		
POGLUT1	9630046K23Rik, C3orf9, hCLP46, KDELCL1, KTELC1, MDS010, MDSRP, MGC32995, Rumi	ENSG00000163389	Protein O-glucosyltransferase 1	3	119468938-119494708	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037855, HPA037856	Approved				Renal cancer:7.02e-7 (unfavourable), Urothelial cancer:2.23e-4 (favourable)	Expressed in all	Mixed			seminal vesicle: 16.5	Expressed in all		
POLD1	CDC2, POLD	ENSG00000062822	DNA polymerase delta 1, catalytic subunit	19	50384204-50418018	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004375, HPA046524	Enhanced		Supported	Nucleoplasm	Liver cancer:2.87e-6 (unfavourable)	Expressed in all	Mixed			bone marrow: 21.4	Expressed in all		
POLG	POLG1, POLGA	ENSG00000140521	DNA polymerase gamma, catalytic subunit	15	89305198-89334861	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA056821	Approved				Prostate cancer:5.73e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 19.7	Expressed in all		
POLG2	HP55, MTPOLB	ENSG00000256525	DNA polymerase gamma 2, accessory subunit	17	64477785-64497036	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017030, HPA023202	Approved		Approved	Nuclear bodies<br>Mitochondria	Liver cancer:1.39e-6 (unfavourable), Renal cancer:1.17e-5 (unfavourable), Prostate cancer:6.59e-4 (unfavourable)	Expressed in all	Mixed			testis: 20.2	Expressed in all		
POLH	RAD30A, XP-V	ENSG00000170734	DNA polymerase eta	6	43576150-43615660	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006721, HPA026762	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 20.8	Expressed in all		
POLQ	POLH	ENSG00000051341	DNA polymerase theta	3	121431427-121546641	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048931, HPA053359			Uncertain	Nucleus<br>Golgi apparatus<br>Cytosol	Endometrial cancer:5.46e-5 (unfavourable), Stomach cancer:1.04e-4 (favourable)	Mixed	Mixed			testis: 4.0	Mixed		
POLR1A	DKFZP586M0122, FLJ21915, RPA1, RPO1-4	ENSG00000068654	RNA polymerase I subunit A	2	86020216-86106155	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010145, HPA031513, HPA049700	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:3.70e-9 (unfavourable), Ovarian cancer:3.37e-4 (unfavourable), Thyroid cancer:8.41e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 12.3	Expressed in all		
POLR3A	hRPC155, RPC1, RPC155	ENSG00000148606	RNA polymerase III subunit A	10	77969251-78029545	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA037926	Uncertain		Supported	Nucleoplasm	Liver cancer:3.64e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 17.9	Expressed in all		
POLR3B	FLJ10388, RPC2	ENSG00000013503	RNA polymerase III subunit B	12	106357658-106510198	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA036466	Supported		Approved	Nuclear speckles	Renal cancer:1.21e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 24.1	Expressed in all		
POMK	FLJ23356, SgK196	ENSG00000185900	Protein-O-mannose kinase	8	43093506-43123434	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA013321	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Mixed			cerebral cortex: 6.2	Expressed in all		
POMT1	LGMD2K	ENSG00000130714	Protein O-mannosyltransferase 1	9	131502902-131523806	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA065252			Approved	Golgi apparatus	Pancreatic cancer:3.90e-5 (favourable), Renal cancer:4.68e-5 (favourable)	Expressed in all	Expressed in all			testis: 62.7	Expressed in all		
POMT2	LGMD2N	ENSG00000009830	Protein O-mannosyltransferase 2	14	77274956-77320884	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA003663	Uncertain				Liver cancer:2.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.9	Expressed in all		
PON1	ESA, PON	ENSG00000005421	Paraoxonase 1	7	95297676-95324707	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	HPA001610	Uncertain				Liver cancer:7.24e-7 (favourable)	Tissue enriched	Tissue enriched	69	liver: 233.6	adrenal gland: 3.3	Not detected		
POP1		ENSG00000104356	POP1 homolog, ribonuclease P/MRP subunit	8	98117297-98159834	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA066194			Supported	Nucleoli	Liver cancer:1.26e-6 (unfavourable), Breast cancer:2.54e-4 (unfavourable), Renal cancer:5.97e-4 (unfavourable), Lung cancer:9.88e-4 (unfavourable)	Expressed in all	Mixed			testis: 6.0	Expressed in all		
POR	CYPOR, FLJ26468	ENSG00000127948	Cytochrome p450 oxidoreductase	7	75899200-75986855	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004372, HPA010136	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Glioma:5.23e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 220.8	Expressed in all		
PPA2	FLJ20459	ENSG00000138777	Pyrophosphatase (inorganic) 2	4	105369077-105474081	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030888, HPA031671, HPA031672	Supported		Approved	Nucleus<br>Mitochondria	Renal cancer:1.27e-11 (favourable), Breast cancer:2.98e-4 (unfavourable), Colorectal cancer:6.60e-4 (favourable)	Expressed in all	Expressed in all			prostate: 21.3	Expressed in all		
PPIB	CYPB, OI9	ENSG00000166794	Peptidylprolyl isomerase B	15	64155812-64163205	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	CAB011487, HPA012720	Enhanced		Supported	Nucleus<br>Endoplasmic reticulum	Renal cancer:2.02e-11 (unfavourable), Endometrial cancer:1.56e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 855.2	Expressed in all		
PPM1K	BDP, DKFZp761G058, hPTMP, PP2Ckappa, PP2Cm	ENSG00000163644	Protein phosphatase, Mg2+/Mn2+ dependent 1K	4	88257620-88284769	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020066, HPA020862, HPA023891	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			heart muscle: 61.4	Mixed		
PPOX	PPO, VP	ENSG00000143224	Protoporphyrinogen oxidase	1	161166410-161178013	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030123	Uncertain		Approved	Mitochondria<br>Cytosol	Renal cancer:9.89e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 38.9	Expressed in all		
PPP1CB	PP-1B, PP1B, PP1beta	ENSG00000213639	Protein phosphatase 1 catalytic subunit beta	2	28751640-28802940	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB022558, HPA065425, CAB069426	Supported		Enhanced	Nucleus<br>Plasma membrane	Liver cancer:6.52e-6 (unfavourable)	Expressed in all	Expressed in all			esophagus: 273.8	Expressed in all		
PPT1	CLN1, INCL, PPT	ENSG00000131238	Palmitoyl-protein thioesterase 1	1	40072705-40097703	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021546	Supported				Liver cancer:6.98e-8 (unfavourable)	Expressed in all	Expressed in all			spleen: 193.0	Expressed in all		
PRDM6	KMT8C, PRISM	ENSG00000061455	PR/SET domain 6	5	123089121-123194266	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030322, HPA030324	Uncertain		Uncertain	Nucleoplasm		Mixed	Tissue enhanced		gallbladder: 5.2;placenta: 5.9	lung: 4.0	Cell line enhanced		BEWO: 3.5;HEK93: 4.7
PREPL	KIAA0436	ENSG00000138078	Prolyl endopeptidase-like	2	44316281-44361862	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA063238	Approved					Expressed in all	Expressed in all			cerebral cortex: 257.4	Expressed in all		
PRF1	HPLH2, P1, PFP	ENSG00000180644	Perforin 1	10	70597348-70602775	Cancer-related genes, Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	CAB002436, HPA037940	Approved		Approved	Cytosol	Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:2.09e-4 (favourable), Head and neck cancer:3.54e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 52.8	lymph node: 20.8	Cell line enriched	16	HDLM-2: 221.2
PRKACA	PKACa	ENSG00000072062	Protein kinase cAMP-activated catalytic subunit alpha	19	14091688-14118084	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010361, HPA071185	Approved		Approved	Cytosol	Cervical cancer:6.28e-6 (favourable), Endometrial cancer:6.26e-5 (unfavourable), Pancreatic cancer:6.47e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 200.4	Expressed in all		
PRKACG	PKACg	ENSG00000165059	Protein kinase cAMP-activated catalytic subunit gamma	9	69012529-69014113	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004530, HPA071185	Supported		Approved	Cytosol		Not detected	Tissue enriched	302	testis: 30.1	all non-specific tissues: 0.0	Not detected		
PRKCD		ENSG00000163932	Protein kinase C delta	3	53156009-53192717	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001863, HPA001890, CAB010469, CAB013225	Enhanced		Enhanced	Endoplasmic reticulum<br>Golgi apparatus<br>Cytosol	Liver cancer:2.24e-4 (unfavourable), Lung cancer:9.01e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 70.4	Expressed in all		
PRKCG	MGC57564, PKCC, PKCG, SCA14	ENSG00000126583	Protein kinase C gamma	19	53879190-53907652	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB013051, HPA047870, HPA054560	Supported					Mixed	Tissue enriched	9	cerebral cortex: 40.9	testis: 4.7	Cell line enhanced		A549: 2.0;SH-SY5Y: 1.5
PRKCH	PKC-L, PKCL, PRKCL	ENSG00000027075	Protein kinase C eta	14	61187559-61550976	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026294, HPA053709	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:8.55e-6 (favourable)	Expressed in all	Expressed in all			lymph node: 61.7	Cell line enhanced		BEWO: 78.7;HUVEC TERT2: 90.5;MOLT-4: 60.3;TIME: 58.5
PRKDC	DNA-PKcs, DNAPK, DNPK1, HYRC, HYRC1, p350, XRCC7	ENSG00000253729	Protein kinase, DNA-activated, catalytic polypeptide	8	47773108-47960183	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005167, HPA035174	Supported		Enhanced	Nucleoplasm	Endometrial cancer:1.03e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.6	Expressed in all		
PRKG1	PGK, PKG, PRKG1B, PRKGR1B	ENSG00000185532	Protein kinase, cGMP-dependent, type I	10	50991358-52298350	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007699, CAB009629	Enhanced		Approved	Vesicles<br>Cytosol		Mixed	Mixed			smooth muscle: 25.1	Cell line enhanced		AN3-CA: 19.3;BJ hTERT+: 17.6;fHDF/TERT166: 13.4
PRKX	PKX1	ENSG00000183943	Protein kinase, X-linked	X	3604370-3713608	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015324	Supported		Supported	Nucleus		Expressed in all	Tissue enhanced		thyroid gland: 58.0	fallopian tube: 31.8	Cell line enhanced		HMC-1: 67.0
PRMT7	FLJ10640, KIAA1933	ENSG00000132600	Protein arginine methyltransferase 7	16	68310974-68358563	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044241	Supported		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Endometrial cancer:2.31e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 25.0	Expressed in all		
PRNP	AltPrP, CD230, CJD, GSS, PRIP, PRP	ENSG00000171867	Prion protein	20	4686236-4701590	CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA042754, HPA043398	Enhanced		Approved	Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:7.41e-5 (unfavourable), Glioma:1.99e-4 (unfavourable), Colorectal cancer:2.96e-4 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 619.4	Cell line enhanced		WM-115: 985.1
PRODH	HSPOX2, PIG6, PRODH1, PRODH2, TP53I6	ENSG00000100033	Proline dehydrogenase 1	22	18912777-18936553	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020361	Uncertain				Cervical cancer:1.54e-4 (favourable)	Tissue enhanced	Tissue enhanced		small intestine: 25.2	duodenum: 5.7	Cell line enriched	6	RPTEC TERT1: 28.5
PROKR2	dJ680N4.3, GPR73b, GPR73L1, GPRg2, KAL3, PKR2	ENSG00000101292	Prokineticin receptor 2	20	5302040-5314369	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA047281	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 3.0	bone marrow: 0.8	Cell line enhanced		NTERA-2: 1.1;SH-SY5Y: 2.2
PRPH2	CACD2, rd2, RDS, RP7, TSPAN22	ENSG00000112619	Peripherin 2	6	42696600-42722574	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029458	Supported					Mixed	Mixed			parathyroid gland: 8.6	Cell line enhanced		ASC TERT1: 2.4;fHDF/TERT166: 4.1;HHSteC: 6.6;HSkMC: 4.4;LHCN-M2: 3.0
PRPS1	CMTX5, DFN2, DFNX1	ENSG00000147224	Phosphoribosyl pyrophosphate synthetase 1	X	107628424-107651026	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043760	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			thyroid gland: 73.9	Expressed in all		
PRRT2	DKFZp547J199, DSPB3, DYT10, EKD1, FICCA, FLJ25513, ICCA, IFITMD1, PKC	ENSG00000167371	Proline rich transmembrane protein 2	16	29811382-29815892	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014447, HPA019203	Enhanced		Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 98.1	ovary: 54.6	Cell line enhanced		AF22: 26.4;REH: 19.4;U-138 MG: 18.0
PRSS1	TRY1	ENSG00000204983	Protease, serine 1	7	142749468-142753076	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025487, CAB025538, HPA062452, HPA063471	Enhanced				Endometrial cancer:6.41e-6 (unfavourable), Thyroid cancer:4.91e-4 (favourable), Ovarian cancer:7.05e-4 (favourable)	Tissue enriched	Tissue enriched	318	pancreas: 81683.0	ovary: 257.2	Cell line enhanced		EFO-21: 1.3;RPMI-8226: 2.0;U-2 OS: 1.7
PRSS12	BSSP-3, MRT1	ENSG00000164099	Protease, serine 12	4	118280038-118353003	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA035054, HPA035055	Uncertain		Approved	Nucleus<br>Actin filaments	Head and neck cancer:1.03e-4 (favourable), Glioma:1.53e-4 (favourable)	Mixed	Mixed			cervix, uterine: 22.4	Cell line enhanced		SH-SY5Y: 228.5;THP-1: 67.4
PRSS56		ENSG00000237412	Protease, serine 56	2	232520463-232525716	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		skeletal muscle: 3.4	testis: 0.8	Not detected		
PSAP	GLBA, SAP1	ENSG00000197746	Prosaposin	10	71816298-71851375	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA004426, CAB004647	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			cerebral cortex: 1912.4	Expressed in all		
PSAT1	PSA	ENSG00000135069	Phosphoserine aminotransferase 1	9	78297143-78330093	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB014882, CAB040567, HPA042924	Enhanced		Enhanced	Cytosol	Renal cancer:6.00e-7 (unfavourable), Endometrial cancer:5.62e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 186.0	liver: 138.7	Cell line enhanced		hTCEpi: 853.3
PSEN1	AD3, FAD, PS1, S182	ENSG00000080815	Presenilin 1	14	73136418-73223691	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB006844, HPA030760, HPA067496	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cell Junctions	Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 66.0	Expressed in all		
PSEN2	AD3L, AD4, PS2, STM2	ENSG00000143801	Presenilin 2	1	226870184-226896105	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB013634, HPA038005			Supported	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 28.8	Mixed		
PSPH	PSP	ENSG00000146733	Phosphoserine phosphatase	7	56011051-56051604	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020376, HPA029515	Approved		Approved	Cytosol	Liver cancer:2.75e-5 (unfavourable), Breast cancer:2.30e-4 (unfavourable), Pancreatic cancer:3.77e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 25.3	Expressed in all		
PTDSS1	KIAA0024, PSS1, PSSA	ENSG00000156471	Phosphatidylserine synthase 1	8	96261715-96336995	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA016852	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum	Liver cancer:1.08e-5 (unfavourable), Lung cancer:9.83e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 14.1	Expressed in all		
PTEN	BZS, MHAM, MMAC1, PTEN1, TEP1	ENSG00000171862	Phosphatase and tensin homolog	10	87863113-87971930	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004076, HPA031335	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:7.35e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 83.6	Expressed in all		
PTGDR	DP, DP1, PTGDR1	ENSG00000168229	Prostaglandin D2 receptor	14	52267713-52276724	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		rectum: 8.6;spleen: 8.7	colon: 5.6	Not detected		
PTH1R	PTHR, PTHR1	ENSG00000160801	Parathyroid hormone 1 receptor	3	46877746-46903799	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007978	Approved				Renal cancer:6.79e-6 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 158.9	adrenal gland: 36.7	Cell line enriched	8	RPTEC TERT1: 88.0
PTK2	FADK, FAK, FAK1, PPP1R71	ENSG00000169398	Protein tyrosine kinase 2	8	140657900-141002216	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001842, CAB004036, HPA029671	Approved		Supported	Vesicles<br>Focal adhesion sites<br>Cytosol	Breast cancer:3.21e-4 (unfavourable), Endometrial cancer:9.11e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 107.1	Mixed		
PTK2B	CADTK, CAKB, FAK2, PTK, PYK2, RAFTK	ENSG00000120899	Protein tyrosine kinase 2 beta	8	27311482-27459391	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003850, HPA026091, HPA026276	Approved		Enhanced	Plasma membrane<br>Cytosol	Cervical cancer:3.32e-4 (favourable), Thyroid cancer:5.11e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 91.1	Cell line enhanced		REH: 128.1
PTPN11	BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2	ENSG00000179295	Protein tyrosine phosphatase, non-receptor type 11	12	112418351-112509913	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB005377	Approved		Supported	Nucleus<br>Nucleoli<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 126.0	Expressed in all		
PTPN14	PEZ	ENSG00000152104	Protein tyrosine phosphatase, non-receptor type 14	1	214348696-214552449	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011469, HPA053864, CAB069441	Uncertain		Enhanced	Nucleoplasm	Pancreatic cancer:2.29e-4 (unfavourable), Stomach cancer:5.16e-4 (unfavourable)	Expressed in all	Mixed			skin: 19.9	Mixed		
PTPN22	Lyp, Lyp1, Lyp2, PTPN8	ENSG00000134242	Protein tyrosine phosphatase, non-receptor type 22	1	113813811-113871759	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004912, CAB012209, HPA013350	Approved		Uncertain	Nucleoplasm<br>Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		bone marrow: 24.8	lymph node: 23.3	Cell line enhanced		Daudi: 49.5;U-698: 25.4
PTPRF	LAR	ENSG00000142949	Protein tyrosine phosphatase, receptor type F	1	43525187-43623666	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012710	Uncertain		Approved	Golgi apparatus	Liver cancer:3.47e-4 (unfavourable), Stomach cancer:7.03e-4 (favourable)	Expressed in all	Mixed			skin: 128.2	Mixed		
PTPRN2	IA-2beta, ICAAR, KIAA0387, phogrin	ENSG00000155093	Protein tyrosine phosphatase, receptor type N2	7	157539056-158587788	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006900, HPA026656	Approved		Supported	Vesicles	Glioma:7.72e-5 (unfavourable), Renal cancer:8.68e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 82.3	stomach: 38.9	Cell line enhanced		AF22: 28.0;HDLM-2: 38.8;NB-4: 27.1;SCLC-21H: 26.6;SH-SY5Y: 24.3;U-87 MG: 27.1
PTPRO	GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2	ENSG00000151490	Protein tyrosine phosphatase, receptor type O	12	15322397-15597399	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA034525	Enhanced					Tissue enhanced	Tissue enhanced		rectum: 33.0	cerebral cortex: 21.7	Cell line enhanced		NTERA-2: 6.6;SCLC-21H: 4.7;SH-SY5Y: 8.4
PTRH2	BIT1, CFAP37, CGI-147, PTH2	ENSG00000141378	Peptidyl-tRNA hydrolase 2	17	59674636-59707626	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA012897	Supported		Supported	Mitochondria	Renal cancer:1.01e-8 (unfavourable), Liver cancer:1.50e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 43.9	Expressed in all		
PTS	PTPS	ENSG00000150787	6-pyruvoyltetrahydropterin synthase	11	112226365-112269955	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001481	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			adrenal gland: 66.9	Expressed in all		
PUS1		ENSG00000177192	Pseudouridylate synthase 1	12	131929200-131945896	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051636, HPA057593	Approved		Supported	Nucleus<br>Mitochondria	Renal cancer:3.49e-8 (unfavourable)	Expressed in all	Expressed in all			lymph node: 21.4	Expressed in all		
PUS3	FKSG32	ENSG00000110060	Pseudouridylate synthase 3	11	125893485-125903221	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038040, HPA063802	Uncertain		Approved	Nucleus<br>Cytosol	Head and neck cancer:8.10e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 16.9	Expressed in all		
PXDN	D2S448, D2S448E, KIAA0230, MG50, PRG2, PXN	ENSG00000130508	Peroxidasin	2	1631887-1744852	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012375	Approved				Endometrial cancer:2.75e-4 (unfavourable), Cervical cancer:6.28e-4 (unfavourable), Stomach cancer:6.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 87.2	adipose tissue: 66.9	Mixed		
PYCR1	P5C	ENSG00000183010	Pyrroline-5-carboxylate reductase 1	17	81932384-81942412	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047660	Approved				Renal cancer:7.33e-12 (unfavourable), Liver cancer:2.33e-4 (unfavourable)	Expressed in all	Mixed			salivary gland: 52.3	Mixed		
PYCR2	P5CR2	ENSG00000143811	Pyrroline-5-carboxylate reductase family member 2	1	225919877-225924340	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA056873	Approved		Approved	Mitochondria	Renal cancer:1.42e-6 (unfavourable), Colorectal cancer:5.02e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 71.9	Expressed in all		
PYGL		ENSG00000100504	Glycogen phosphorylase L	14	50857891-50944736	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000962, HPA004119	Enhanced		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:2.63e-4 (unfavourable), Head and neck cancer:5.97e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 116.5	Mixed		
PYGM		ENSG00000068976	Glycogen phosphorylase, muscle associated	11	64746389-64760297	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA056003	Enhanced					Mixed	Tissue enriched	32	skeletal muscle: 2831.9	esophagus: 89.0	Cell line enhanced		HSkMC: 2.6
QARS		ENSG00000172053	Glutaminyl-tRNA synthetase	3	49095932-49105135	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036986, HPA036987	Enhanced		Enhanced	Cytosol	Renal cancer:5.60e-6 (favourable), Breast cancer:1.43e-4 (favourable)	Expressed in all	Expressed in all			rectum: 117.0	Expressed in all		
QDPR	DHPR, PKU2, SDR33C1	ENSG00000151552	Quinoid dihydropteridine reductase	4	17460261-17512234	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA058951, HPA065649	Enhanced		Approved	Mitochondria	Renal cancer:7.84e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 226.3	Expressed in all		
QRSL1	DKFZP564C1278, FLJ10989, FLJ12189, FLJ13447, GatA	ENSG00000130348	Glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1	6	106629578-106668417	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029585, HPA029587	Approved		Approved	Vesicles<br>Centrosome	Liver cancer:7.97e-5 (unfavourable), Renal cancer:3.83e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 18.6	Expressed in all		
RAG1	MGC43321, RNF74	ENSG00000166349	Recombination activating 1	11	36510709-36593156	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043939			Supported	Nucleus		Mixed	Tissue enhanced		thyroid gland: 4.2	spleen: 3.6	Group enriched	102	MOLT-4: 227.0;REH: 243.3
RANBP2	ADANE, ANE1, NUP358	ENSG00000153201	RAN binding protein 2	2	108719481-108785811	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564	Supported					Expressed in all	Expressed in all			parathyroid gland: 74.9	Expressed in all		
RARS	DALRD1	ENSG00000113643	Arginyl-tRNA synthetase	5	168486445-168519299	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003979, HPA004130	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.10e-8 (unfavourable), Head and neck cancer:7.59e-5 (unfavourable)	Expressed in all	Expressed in all			duodenum: 54.4	Expressed in all		
RARS2	DALRD2, dJ382I10.6, MGC14993, MGC23778, PRO1992, RARSL	ENSG00000146282	Arginyl-tRNA synthetase 2, mitochondrial	6	87514378-87590003	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039987, HPA042645	Uncertain		Approved	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 56.9	Expressed in all		
RBCK1	C20orf18, HOIL1, RBCK2, RNF54, UBCE7IP3, XAP4, ZRANB4	ENSG00000125826	RANBP2-type and C3HC4-type zinc finger containing 1	20	407498-430966	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.41e-9 (unfavourable)	Expressed in all	Expressed in all			spleen: 51.2	Expressed in all		
RBP3	D10S64, D10S65, D10S66, RP66	ENSG00000265203	Retinol binding protein 3	10	47348371-47357875	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA041301, HPA044239	Supported					Not detected	Not detected			duodenum: 0.4	Not detected		
RDH11	ARSDR1, MDT1, SDR7C1	ENSG00000072042	Retinol dehydrogenase 11 (all-trans/9-cis/11-cis)	14	67676801-67695814	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB046011	Enhanced				Renal cancer:1.30e-7 (favourable), Head and neck cancer:2.89e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable)	Tissue enriched	Tissue enriched	7	prostate: 941.3	parathyroid gland: 125.7	Expressed in all		
RDH5	HSD17B9, RDH1, SDR9C5	ENSG00000135437	Retinol dehydrogenase 5	12	55720367-55724705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA063345			Approved	Vesicles		Mixed	Tissue enhanced		adipose tissue: 97.7	liver: 30.0	Cell line enhanced		ASC diff: 19.5;ASC TERT1: 17.1;hTEC/SVTERT24-B: 15.2;LHCN-M2: 12.8;U-87 MG: 26.2
RFT1	CDG1N	ENSG00000163933	RFT1 homolog	3	53088483-53130462	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA060327, HPA069022	Approved		Approved	Vesicles	Liver cancer:1.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
RGR	RP44	ENSG00000148604	Retinal G protein coupled receptor	10	84245053-84259960	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	13	cerebral cortex: 16.1	testis: 1.2	Not detected		
RHAG	CD241, RH50A, SLC42A1	ENSG00000112077	Rh-associated glycoprotein	6	49605158-49636839	CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046051, HPA055331	Approved		Uncertain	Endoplasmic reticulum		Not detected	Tissue enriched	24	bone marrow: 73.7	placenta: 3.1	Group enriched	223	HEL: 448.1;K-562: 429.7
RHBDF2	FLJ22341, iRhom2, RHBDL5, RHBDL6, TOC, TOCG	ENSG00000129667	Rhomboid 5 homolog 2	17	76470891-76501790	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018080	Uncertain				Renal cancer:3.96e-11 (unfavourable)	Expressed in all	Expressed in all			appendix: 49.4	Mixed		
RHO	CSNBAD1, OPN2, RP4	ENSG00000163914	Rhodopsin	3	129528640-129535169	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013440, CAB022486, CAB034887, CAB034888	Supported					Not detected	Not detected			cerebral cortex: 0.3	Not detected		
RIPK4	ANKK2, ANKRD3, DIK, PKK, RIP4	ENSG00000183421	Receptor interacting serine/threonine kinase 4	21	41739369-41767106	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030942	Enhanced				Ovarian cancer:6.22e-5 (unfavourable), Pancreatic cancer:3.48e-4 (unfavourable), Renal cancer:6.52e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 31.5	small intestine: 15.0	Cell line enhanced		CAPAN-2: 27.8;HaCaT: 41.4
RLIM	MGC15161, NY-REN-43, RNF12	ENSG00000131263	Ring finger protein, LIM domain interacting	X	74585217-74614617	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018895	Approved		Supported	Nucleoplasm<br>Cytosol	Thyroid cancer:6.04e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 29.0	Expressed in all		
RNASEH1		ENSG00000171865	Ribonuclease H1	2	3544793-3558616	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043037	Uncertain				Liver cancer:7.83e-6 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 10.9	Expressed in all		
RNASEH2A	AGS4, RNASEHI, RNHIA, RNHL	ENSG00000104889	Ribonuclease H2 subunit A	19	12802063-12813638	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042692			Enhanced	Nucleus<br>Cytosol	Renal cancer:6.29e-6 (unfavourable), Liver cancer:8.72e-5 (unfavourable), Cervical cancer:1.18e-4 (favourable), Ovarian cancer:1.22e-4 (favourable), Colorectal cancer:6.18e-4 (favourable)	Expressed in all	Expressed in all			testis: 26.5	Expressed in all		
RNF125	FLJ20456	ENSG00000101695	Ring finger protein 125	18	32018372-32073213	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041514	Uncertain		Uncertain	Nucleoli<br>Golgi apparatus<br>Cytosol	Renal cancer:4.06e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 11.5	Cell line enhanced		HMC-1: 42.3
RNF135	MGC13061	ENSG00000181481	Ring finger protein 135	17	30968785-30999911	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021576, HPA052404	Approved		Approved	Vesicles	Renal cancer:7.51e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Mixed		
RNF139	HRCA1, RCA1, TRC8	ENSG00000170881	Ring finger protein 139	8	124474738-124487914	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001202	Approved				Pancreatic cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 114.8	Expressed in all		
RNF146	dactylidin, dJ351K20.1, DKFZp434O1427	ENSG00000118518	Ring finger protein 146	6	127266610-127288567	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027158, HPA027209	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:5.26e-5 (favourable), Renal cancer:7.32e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 94.6	Expressed in all		
RNF168	FLJ35794	ENSG00000163961	Ring finger protein 168	3	196468783-196503768	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046109			Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:2.29e-4 (unfavourable), Cervical cancer:8.21e-4 (favourable), Pancreatic cancer:8.31e-4 (unfavourable)	Expressed in all	Mixed			testis: 20.0	Expressed in all		
RNF170	ADSA, DKFZP564A022, SNAX1	ENSG00000120925	Ring finger protein 170	8	42849637-42897290	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA050931, HPA054621	Uncertain					Expressed in all	Expressed in all			thyroid gland: 47.9	Expressed in all		
RNF213	C17orf27, KIAA1554, KIAA1618, MYMY2, NET57	ENSG00000173821	Ring finger protein 213	17	80260866-80398786	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003347, HPA026790	Approved		Supported	Cytosol	Endometrial cancer:4.65e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.3	Expressed in all		
RNF216	TRIAD3, UBCE7IP1, ZIN	ENSG00000011275	Ring finger protein 216	7	5620047-5781739	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018955, HPA021123	Supported		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:6.24e-5 (favourable), Liver cancer:2.26e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.0	Expressed in all		
RNF43	DKFZp781H0392, FLJ20315, URCC	ENSG00000108375	Ring finger protein 43	17	58352500-58417595	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA008079	Uncertain				Renal cancer:6.04e-9 (favourable)	Tissue enhanced	Mixed			duodenum: 23.4	Cell line enhanced		CACO-2: 20.6;Hep G2: 33.5
RNF6	DKFZp686P0776	ENSG00000127870	Ring finger protein 6	13	26132115-26222493	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039343, HPA040048	Approved		Supported	Nuclear membrane	Cervical cancer:3.07e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 61.0	Mixed		
ROR2	BDB, BDB1, NTRKR2	ENSG00000169071	Receptor tyrosine kinase like orphan receptor 2	9	91563091-91950162	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA021868	Uncertain				Thyroid cancer:4.28e-8 (unfavourable), Renal cancer:9.86e-7 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 35.1	endometrium: 21.4	Cell line enhanced		AF22: 25.3;HHSteC: 55.3;HSkMC: 39.9;U-266/70: 29.6
ROS1	c-ros-1, MCF3, ROS	ENSG00000047936	ROS proto-oncogene 1, receptor tyrosine kinase	6	117288300-117425855	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049098, HPA072424	Uncertain		Approved	Vesicles		Tissue enriched	Group enriched	18	epididymis: 70.9;lung: 47.2	seminal vesicle: 3.2	Cell line enhanced		HSkMC: 7.5;hTCEpi: 15.7;LHCN-M2: 12.7
RPE65	BCO3, LCA2, rd12, RP20	ENSG00000116745	RPE65, retinoid isomerohydrolase	1	68428822-68449959	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 2.7;prostate: 3.0;seminal vesicle: 6.2	endometrium: 1.0	Group enriched	27	A-431: 3.0;PC-3: 5.3;U-2 OS: 1.4
RPIA		ENSG00000153574	Ribose 5-phosphate isomerase A	2	88691644-88750935	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042620	Approved				Renal cancer:8.53e-6 (unfavourable), Liver cancer:1.46e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 54.2	Expressed in all		
RPS6KA3	CLS, HU-3, MRX19, RSK, RSK2	ENSG00000177189	Ribosomal protein S6 kinase A3	X	20149911-20267100	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003221, CAB003853, CAB013520	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 92.7	Mixed		
RTEL1	bK3184A7.3, C20orf41, DKFZP434C013, KIAA1088, NHL, RTEL	ENSG00000258366	Regulator of telomere elongation helicase 1	20	63657810-63696253	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020622, HPA067329, HPA078328			Approved	Nuclear speckles<br>Nuclear bodies		Not detected	Expressed in all			testis: 13.2	Expressed in all		
RXFP2	GPR106, GREAT, INSL3R, LGR8, RXFPR2	ENSG00000133105	Relaxin/insulin like family peptide receptor 2	13	31739542-31803388	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			endometrium: 0.8	Not detected		
S1PR2	AGR16, DFNB68, EDG5, Gpcr13, H218	ENSG00000267534	Sphingosine-1-phosphate receptor 2	19	10221435-10231272	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA014255, HPA014307	Approved		Uncertain	Nuclear speckles<br>Golgi apparatus	Renal cancer:4.36e-10 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 27.0	lymph node: 13.3	Cell line enhanced		Daudi: 38.8;U-698: 40.3;WM-115: 38.8
SARDH	DMGDHL1, SDH	ENSG00000123453	Sarcosine dehydrogenase	9	133663560-133739955	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057267, HPA058086	Approved		Approved	Mitochondria	Glioma:3.50e-4 (unfavourable)	Tissue enriched	Tissue enhanced		epididymis: 59.3;liver: 43.0	kidney: 12.5	Group enriched	5	AN3-CA: 16.3;Hep G2: 20.7;LHCN-M2: 9.2;MOLT-4: 18.0;RH-30: 17.5;RPMI-8226: 26.5;SH-SY5Y: 15.4
SARS2	FLJ20450, mtSerRS, SARS, SARSM, SerRSmt, SERS, SYS	ENSG00000104835	Seryl-tRNA synthetase 2, mitochondrial	19	38915266-38930896	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA052730, HPA056957	Approved					Expressed in all	Expressed in all			thyroid gland: 8.9	Expressed in all		
SAT1	SAT, SSAT	ENSG00000130066	Spermidine/spermine N1-acetyltransferase 1	X	23783173-23786226	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB047343, HPA055312, CAB069914	Supported				Endometrial cancer:2.87e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 1269.5	Expressed in all		
SC5D	SC5DL	ENSG00000109929	Sterol-C5-desaturase	11	121292453-121308694	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA066283, HPA070248	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:1.07e-7 (favourable), Head and neck cancer:3.30e-4 (unfavourable), Melanoma:3.98e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 193.5	Expressed in all		
SCN8A	CerIII, MED, NaCh6, Nav1.6, PN4	ENSG00000196876	Sodium voltage-gated channel alpha subunit 8	12	51590266-51812864	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enriched	7	cerebral cortex: 22.1	testis: 3.1	Mixed		
SCP2		ENSG00000116171	Sterol carrier protein 2	1	52927229-53051703	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027101, HPA027135, HPA027317	Supported		Enhanced	Peroxisomes	Renal cancer:7.85e-8 (favourable), Colorectal cancer:7.05e-5 (favourable)	Expressed in all	Expressed in all			liver: 601.5	Expressed in all		
SCYL1	GKLP, HT019, MGC78454, NKTL, NTKL, P105, TAPK, TEIF, TRAP	ENSG00000142186	SCY1 like pseudokinase 1	11	65525077-65538704	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015015	Uncertain		Supported	Cytosol		Expressed in all	Expressed in all			thyroid gland: 55.2	Expressed in all		
SDHA	FP, SDH2, SDHF	ENSG00000073578	Succinate dehydrogenase complex flavoprotein subunit A	5	218241-256700	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB034929, HPA041981, HPA064582	Enhanced		Enhanced	Mitochondria	Renal cancer:9.53e-8 (favourable), Breast cancer:6.00e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 248.9	Expressed in all		
SDHB	SDH, SDH1	ENSG00000117118	Succinate dehydrogenase complex iron sulfur subunit B	1	17018722-17054170	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002868, CAB009822, CAB068233, CAB068234, CAB068235	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Mitochondria	Renal cancer:2.93e-7 (favourable)	Expressed in all	Expressed in all			kidney: 215.2	Expressed in all		
SEC31A	ABP125, ABP130, KIAA0905, SEC31L1	ENSG00000138674	SEC31 homolog A, COPII coat complex component	4	82818661-82901166	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005457	Approved		Supported	Vesicles<br>Cytosol	Urothelial cancer:2.69e-4 (unfavourable), Liver cancer:3.32e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 281.0	Expressed in all		
SEC61A1		ENSG00000058262	Sec61 translocon alpha 1 subunit	3	128051641-128071683	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022076			Supported	Endoplasmic reticulum	Renal cancer:6.84e-9 (unfavourable), Liver cancer:1.07e-6 (unfavourable), Endometrial cancer:7.82e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 218.2	Expressed in all		
SEC63	DNAJC23, ERdj2, PRO2507, SEC63L	ENSG00000025796	SEC63 homolog, protein translocation regulator	6	107867756-107958189	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA053295, HPA060535	Enhanced		Supported	Endoplasmic reticulum	Breast cancer:3.32e-4 (unfavourable), Cervical cancer:4.01e-4 (unfavourable), Renal cancer:6.16e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 87.4	Expressed in all		
SEPSECS	SLA, SLA/LP	ENSG00000109618	Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase	4	25120014-25160442	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA070409			Approved	Vesicles		Expressed in all	Expressed in all			liver: 16.7	Expressed in all		
SETD2	FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A	ENSG00000181555	SET domain containing 2	3	47016429-47163967	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042451	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:7.99e-6 (favourable), Melanoma:8.19e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.8	Expressed in all		
SFXN4		ENSG00000183605	Sideroflexin 4	10	119140767-119165667	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018028, HPA020872	Approved		Supported	Vesicles		Expressed in all	Expressed in all			thyroid gland: 47.3	Expressed in all		
SGSH	HSS, MPS3A, SFMD	ENSG00000181523	N-sulfoglucosamine sulfohydrolase	17	80206716-80220923	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023436, HPA023451	Enhanced				Renal cancer:2.66e-4 (unfavourable), Lung cancer:2.72e-4 (favourable), Pancreatic cancer:3.10e-4 (favourable), Testis cancer:5.37e-4 (unfavourable), Liver cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 36.3	Mixed		
SHPK	CARKL, SHK	ENSG00000197417	Sedoheptulokinase	17	3608262-3636322	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024361, HPA064939	Enhanced		Approved	Nucleoplasm<br>Nuclear speckles		Expressed in all	Mixed			duodenum: 13.4	Expressed in all		
SIAE	CSE-C, LSE, MGC87009, YSG2	ENSG00000110013	Sialic acid acetylesterase	11	124633113-124695707	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038052, HPA038053	Approved				Renal cancer:4.42e-11 (favourable), Endometrial cancer:4.66e-5 (favourable)	Expressed in all	Expressed in all			rectum: 114.5	Mixed		
SIK1	msk, SNF1LK	ENSG00000142178	Salt inducible kinase 1	21	43414515-43427128	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB023801, HPA038211	Approved		Supported	Cytosol		Mixed	Mixed			seminal vesicle: 13.9	Cell line enhanced		HaCaT: 18.5;HBEC3-KT: 22.7;HeLa: 32.3;hTCEpi: 25.9;SiHa: 16.7;U-266/84: 20.5
SLC10A2	ASBT, ISBT	ENSG00000125255	Solute carrier family 10 member 2	13	103043998-103066846	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004795	Approved				Renal cancer:5.78e-5 (favourable)	Tissue enriched	Group enriched	31	duodenum: 21.0;kidney: 15.4;small intestine: 51.4	gallbladder: 0.9	Not detected		
SLC11A2	DCT1, DMT1, NRAMP2	ENSG00000110911	Solute carrier family 11 member 2	12	50979401-51028566	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032139, HPA032140	Uncertain		Supported	Mitochondria	Lung cancer:3.07e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 75.1	Expressed in all		
SLC12A6	ACCPN, KCC3	ENSG00000140199	Solute carrier family 12 member 6	15	34229996-34338060	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA034563	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:3.33e-6 (favourable)	Expressed in all	Mixed			testis: 46.4	Cell line enhanced		HaCaT: 38.6
SLC12A8	CCC9	ENSG00000221955	Solute carrier family 12 member 8	3	125082636-125212864	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031123	Uncertain		Supported	Nucleoplasm	Renal cancer:5.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 39.6	gallbladder: 16.2	Cell line enhanced		HHSteC: 28.8;U-2197: 63.6
SLC16A1	MCT, MCT1	ENSG00000155380	Solute carrier family 16 member 1	1	112911847-112957013	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003324, CAB017489, HPA071055, CAB079035	Enhanced	Supported	Enhanced	Plasma membrane<br>Cell Junctions	Renal cancer:6.78e-8 (unfavourable), Endometrial cancer:8.37e-6 (unfavourable), Pancreatic cancer:2.10e-4 (unfavourable), Lung cancer:4.05e-4 (unfavourable)	Expressed in all	Mixed			testis: 31.4	Mixed		
SLC16A11	FLJ90193, MCT11	ENSG00000174326	Solute carrier family 16 member 11	17	7041630-7043923	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level						Renal cancer:3.19e-7 (favourable), Pancreatic cancer:1.45e-5 (favourable), Liver cancer:2.56e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 8.9;parathyroid gland: 11.0	seminal vesicle: 3.8	Not detected		
SLC16A13	MCT13	ENSG00000174327	Solute carrier family 16 member 13	17	7036075-7040121	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA065245			Supported	Golgi apparatus	Pancreatic cancer:1.50e-4 (favourable)	Expressed in all	Mixed			liver: 15.4	Cell line enhanced		A549: 21.3
SLC16A2	AHDS, DXS128, MCT7, MCT8, MRX22, XPCT	ENSG00000147100	Solute carrier family 16 member 2	X	74421461-74533917	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA072719			Approved	Plasma membrane	Breast cancer:8.88e-5 (unfavourable), Renal cancer:1.83e-4 (unfavourable), Urothelial cancer:3.16e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 24.0	Cell line enhanced		BJ: 73.2
SLC17A8	DFNA25, VGLUT3	ENSG00000179520	Solute carrier family 17 member 8	12	100357079-100422059	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB079058		Supported				Tissue enhanced	Tissue enhanced		small intestine: 5.8	cerebral cortex: 1.2	Not detected		
SLC17A9	C20orf59, FLJ23412, VNUT	ENSG00000101194	Solute carrier family 17 member 9	20	62952647-62969585	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047470, HPA056499	Uncertain		Approved	Nucleoplasm	Renal cancer:2.78e-15 (unfavourable)	Mixed	Mixed			stomach: 8.6	Cell line enhanced		Hep G2: 46.7;U-937: 33.7
SLC18A3	VACHT	ENSG00000187714	Solute carrier family 18 member A3	10	49610301-49612720	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB037102, CAB079011	Uncertain	Supported				Mixed	Not detected			placenta: 0.6	Group enriched	6	SCLC-21H: 2.0;SH-SY5Y: 7.6
SLC19A2	THTR1, TRMA	ENSG00000117479	Solute carrier family 19 member 2	1	169463909-169486003	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006119, HPA016599	Uncertain		Approved	Cytosol	Renal cancer:2.70e-5 (favourable), Glioma:2.11e-4 (favourable), Breast cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 49.2	Mixed		
SLC19A3	THTR2	ENSG00000135917	Solute carrier family 19 member 3	2	227685210-227718012	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038898	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		adipose tissue: 50.2;placenta: 35.3	duodenum: 12.3	Cell line enhanced		ASC diff: 6.9;BEWO: 6.1;CACO-2: 12.7
SLC1A1	EAAC1, EAAT3	ENSG00000106688	Solute carrier family 1 member 1	9	4490444-4587469	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB015466, HPA020086	Approved				Renal cancer:2.86e-8 (favourable)	Expressed in all	Tissue enhanced		small intestine: 71.2	epididymis: 54.5	Cell line enhanced		HDLM-2: 65.4;RPTEC TERT1: 50.1
SLC1A2	EAAT2, GLT-1	ENSG00000110436	Solute carrier family 1 member 2	11	35251206-35420063	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002574, HPA009172	Enhanced					Tissue enriched	Tissue enriched	30	cerebral cortex: 365.8	liver: 12.2	Cell line enhanced		fHDF/TERT166: 1.5;NTERA-2: 2.4;SCLC-21H: 1.5
SLC1A3	EA6, EAAT1, GLAST	ENSG00000079215	Solute carrier family 1 member 3	5	36606355-36688334	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002573, HPA037467, HPA037468	Enhanced		Approved	Nucleoli<br>Mitochondria		Tissue enriched	Tissue enriched	16	cerebral cortex: 518.2	adipose tissue: 31.9	Cell line enhanced		AF22: 49.5;CACO-2: 68.8;HaCaT: 55.0
SLC1A4	ASCT1, SATT	ENSG00000115902	Solute carrier family 1 member 4	2	64988477-65023865	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA034963, HPA034964	Approved		Supported	Centrosome	Liver cancer:4.23e-5 (unfavourable), Cervical cancer:3.59e-4 (favourable), Renal cancer:4.87e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 79.1	Expressed in all		
SLC20A2	Glvr-2, GLVR2, MLVAR, PiT-2, Ram-1	ENSG00000168575	Solute carrier family 20 member 2	8	42416475-42541926	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026540	Approved				Renal cancer:1.01e-4 (favourable), Breast cancer:7.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 138.4	Expressed in all		
SLC22A18	BWR1A, BWSCR1A, IMPT1, ITM, ORCTL2, SLC22A1L, TSSC5	ENSG00000110628	Solute carrier family 22 member 18	11	2899721-2925246	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA067812, HPA071461	Enhanced					Expressed in all	Tissue enhanced		duodenum: 43.2;small intestine: 31.7	colon: 10.3	Cell line enhanced		CAPAN-2: 28.3;Karpas-707: 21.3
SLC22A5	CDSP, OCTN2, SCD	ENSG00000197375	Solute carrier family 22 member 5	5	132369752-132395614	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA063062			Approved	Mitochondria	Endometrial cancer:2.87e-5 (favourable), Pancreatic cancer:7.36e-4 (favourable), Renal cancer:8.36e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 32.1	Cell line enhanced		SiHa: 40.6
SLC24A1	CSNB1D, HsT17412, KIAA0702, NCKX, NCKX1, RODX	ENSG00000074621	Solute carrier family 24 member 1	15	65611366-65660995	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039370	Supported		Approved	Microtubules	Renal cancer:2.33e-6 (favourable)	Expressed in all	Mixed			fallopian tube: 8.5	Mixed		
SLC24A4	NCKX4	ENSG00000140090	Solute carrier family 24 member 4	14	92322581-92501483	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 7.1	spleen: 2.7	Cell line enhanced		SCLC-21H: 1.5
SLC24A5	JSX, OCA6	ENSG00000188467	Solute carrier family 24 member 5	15	48120972-48142672	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Group enriched	21	skin: 9.6;testis: 2.9	breast: 0.3	Cell line enriched	760	SK-MEL-30: 193.4
SLC25A1	CTP, SLC20A3	ENSG00000100075	Solute carrier family 25 member 1	22	19175575-19178830	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level							Expressed in all	Expressed in all			duodenum: 112.7	Expressed in all		
SLC25A12	Aralar	ENSG00000115840	Solute carrier family 25 member 12	2	171784370-171999859	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035333, HPA035334	Enhanced		Uncertain	Nuclear speckles<br>Cytosol	Renal cancer:2.91e-8 (favourable), Endometrial cancer:7.86e-4 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 55.3	Mixed		
SLC25A13	ARALAR2, CITRIN, CTLN2	ENSG00000004864	Solute carrier family 25 member 13	7	96120220-96322147	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018997	Approved		Supported	Mitochondria	Renal cancer:9.14e-4 (favourable)	Expressed in all	Expressed in all			liver: 77.3	Mixed		
SLC25A15	D13S327, HHH, ORC1, ORNT1	ENSG00000102743	Solute carrier family 25 member 15	13	40789412-40810111	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042146	Approved				Renal cancer:1.74e-4 (favourable), Liver cancer:2.16e-4 (favourable), Urothelial cancer:5.46e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 49.6	Expressed in all		
SLC25A19	DNC, MCPHA, MUP1, TPC	ENSG00000125454	Solute carrier family 25 member 19	17	75272981-75289510	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Liver cancer:1.21e-7 (unfavourable), Endometrial cancer:8.72e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 49.2	Expressed in all		
SLC25A20	CAC, CACT	ENSG00000178537	Solute carrier family 25 member 20	3	48856931-48898993	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016862, HPA029863	Approved		Supported	Mitochondria<br>Cytosol		Expressed in all	Expressed in all			liver: 70.9	Cell line enhanced		RPMI-8226: 88.8
SLC25A22	EIEE3, FLJ13044, GC1, NET44	ENSG00000177542	Solute carrier family 25 member 22	11	790475-798333	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014662	Approved		Enhanced	Nucleoplasm<br>Mitochondria		Expressed in all	Tissue enriched	6	cerebral cortex: 89.6	testis: 15.2	Expressed in all		
SLC25A26		ENSG00000144741	Solute carrier family 25 member 26	3	66133610-66388116	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026887	Enhanced		Supported	Mitochondria	Renal cancer:1.73e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.5	Expressed in all		
SLC25A3	PHC	ENSG00000075415	Solute carrier family 25 member 3	12	98593591-98606379	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA045709			Supported	Mitochondria	Renal cancer:8.11e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 595.7	Expressed in all		
SLC25A32	MFTC	ENSG00000164933	Solute carrier family 25 member 32	8	103398635-103415189	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA024763, HPA047402	Uncertain		Supported	Mitochondria	Renal cancer:1.53e-6 (unfavourable), Lung cancer:2.09e-4 (unfavourable), Endometrial cancer:7.23e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder,lymph node: 21.0	Expressed in all		
SLC25A38	FLJ20551	ENSG00000144659	Solute carrier family 25 member 38	3	39383348-39397351	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041027	Approved				Renal cancer:1.58e-5 (favourable), Urothelial cancer:7.29e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 65.9	Expressed in all		
SLC25A46		ENSG00000164209	Solute carrier family 25 member 46	5	110738136-110765161	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039601, HPA071582	Approved		Supported	Mitochondria	Thyroid cancer:2.52e-4 (unfavourable), Colorectal cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.6	Expressed in all		
SLC26A1	EDM4, SAT-1	ENSG00000145217	Solute carrier family 26 member 1	4	979073-993440	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041654	Uncertain		Approved	Microtubules	Renal cancer:1.19e-4 (favourable)	Mixed	Mixed			adrenal gland,kidney: 6.0	Mixed		
SLC26A2	DTD, DTDST	ENSG00000155850	Solute carrier family 26 member 2	5	149960737-149993455	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041957, HPA058090	Enhanced		Approved	Vesicles	Renal cancer:3.27e-4 (unfavourable), Liver cancer:4.66e-4 (unfavourable), Endometrial cancer:7.29e-4 (favourable)	Expressed in all	Tissue enhanced		colon: 213.0;rectum: 207.1	parathyroid gland: 82.7	Expressed in all		
SLC26A3	CLD, DRA	ENSG00000091138	Solute carrier family 26 member 3	7	107765467-107803225	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036055	Approved					Tissue enriched	Tissue enhanced		colon: 1075.0;duodenum: 577.9;rectum: 961.7	seminal vesicle: 185.8	Cell line enhanced		RPMI-8226: 1.9
SLC26A4	DFNB4, PDS	ENSG00000091137	Solute carrier family 26 member 4	7	107660635-107717809	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042860	Approved					Tissue enriched	Tissue enriched	28	thyroid gland: 419.0	cerebral cortex: 15.1	Cell line enhanced		LHCN-M2: 3.7;SCLC-21H: 1.9
SLC26A5	DFNB61, PRES	ENSG00000170615	Solute carrier family 26 member 5	7	103352730-103446177	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level							Mixed	Not detected			breast,parathyroid gland: 0.9	Not detected		
SLC26A8		ENSG00000112053	Solute carrier family 26 member 8	6	35943514-36024868	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038081	Enhanced					Not detected	Tissue enriched	27	testis: 76.1	bone marrow: 2.8	Not detected		
SLC27A4	ACSVL4, FATP4	ENSG00000167114	Solute carrier family 27 member 4	9	128340646-128361470	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007293, CAB009771	Approved		Supported	Vesicles	Renal cancer:2.61e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 72.1	Expressed in all		
SLC29A3	ENT3, FLJ11160	ENSG00000198246	Solute carrier family 29 member 3	10	71319258-71363385	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046085, HPA054976, HPA057905	Approved		Supported	Golgi apparatus<br>Vesicles	Liver cancer:6.07e-6 (unfavourable), Renal cancer:5.53e-5 (unfavourable), Thyroid cancer:1.16e-4 (favourable)	Expressed in all	Mixed			placenta: 18.8	Cell line enhanced		BEWO: 35.2
SLC2A1	CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR	ENSG00000117394	Solute carrier family 2 member 1	1	42925375-42959173	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002759, HPA031345, HPA058494	Enhanced	Supported	Enhanced	Plasma membrane	Renal cancer:4.55e-9 (unfavourable), Liver cancer:3.65e-8 (unfavourable), Pancreatic cancer:4.39e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Urothelial cancer:4.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 293.0	skin: 59.3	Expressed in all		
SLC2A10	GLUT10	ENSG00000197496	Solute carrier family 2 member 10	20	46709487-46736347	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041015	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			prostate: 49.3	Cell line enhanced		SK-MEL-30: 45.7
SLC2A2	GLUT2	ENSG00000163581	Solute carrier family 2 member 2	3	170996348-171026750	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB010444, HPA028997, HPA028998	Enhanced		Approved	Nucleoplasm	Liver cancer:2.63e-5 (favourable)	Tissue enriched	Tissue enriched	7	liver: 433.0	duodenum: 65.7	Group enriched	61	CACO-2: 6.7;Hep G2: 18.6
SLC2A4	GLUT4	ENSG00000181856	Solute carrier family 2 member 4	17	7281667-7288257	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016544	Enhanced					Mixed	Tissue enhanced		heart muscle: 32.6;skeletal muscle: 45.0	adipose tissue: 21.8	Cell line enhanced		Hep G2: 3.7
SLC2A9	Glut9, GLUTX, URATv1	ENSG00000109667	Solute carrier family 2 member 9	4	9771153-10054936	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA066229	Enhanced				Renal cancer:1.32e-11 (favourable)	Mixed	Tissue enhanced		kidney: 30.8;seminal vesicle: 27.2	placenta: 11.1	Cell line enhanced		HBEC3-KT: 34.8;Hep G2: 16.1;hTCEpi: 14.4;THP-1: 13.9;U-937: 10.7
SLC30A10	DKFZp547M236, ZnT-10, ZNT8, ZRC1	ENSG00000196660	Solute carrier family 30 member 10	1	219685427-219958647	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064547	Enhanced					Tissue enriched	Tissue enhanced		duodenum: 2.1;liver: 2.3	testis: 1.2	Cell line enhanced		HEK93: 1.2
SLC30A2	ZNT2	ENSG00000158014	Solute carrier family 30 member 2	1	26037252-26046133	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017979			Approved	Vesicles	Renal cancer:2.86e-6 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 22.0;thyroid gland: 42.4	pancreas: 16.5	Group enriched	5	BEWO: 2.4;RPTEC TERT1: 4.3;WM-115: 3.5
SLC33A1	ACATN, AT-1, AT1, SPG42	ENSG00000169359	Solute carrier family 33 member 1	3	155821024-155854429	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042430, HPA060345	Uncertain		Approved	Nucleus		Expressed in all	Expressed in all			thyroid gland: 67.3	Expressed in all		
SLC34A1	NAPI-3, NPT2, NPTIIa, SLC11, SLC17A2	ENSG00000131183	Solute carrier family 34 member 1	5	177379235-177398848	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051255	Approved		Supported	Nuclear speckles<br>Plasma membrane<br>Mitotic spindle		Tissue enriched	Tissue enriched	164	kidney: 161.7	liver: 0.9	Group enriched	12	HEL: 2.1;U-937: 1.2
SLC34A2	NAPI-3B	ENSG00000157765	Solute carrier family 34 member 2	4	25655301-25678748	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037989	Enhanced					Tissue enhanced	Tissue enriched	10	lung: 1121.1	fallopian tube: 111.8	Group enriched	76	BEWO: 31.0;EFO-21: 114.1;RPTEC TERT1: 66.5
SLC34A3	FLJ38680, NPTIIc	ENSG00000198569	Solute carrier family 34 member 3	9	137230757-137236554	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA023776	Enhanced					Mixed	Group enriched	15	kidney: 11.8;small intestine: 9.1	testis: 0.7	Cell line enhanced		CAPAN-2: 2.9;MCF7: 4.2
SLC35A1	CMPST, hCST	ENSG00000164414	Solute carrier family 35 member A1	6	87470623-87512336	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:2.70e-6 (unfavourable)	Expressed in all	Expressed in all			prostate: 59.5	Expressed in all		
SLC35A2	UGALT, UGAT, UGT, UGT1, UGT2, UGTL	ENSG00000102100	Solute carrier family 35 member A2	X	48903180-48911958	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036087	Approved		Supported	Golgi apparatus	Liver cancer:9.64e-5 (unfavourable), Breast cancer:3.16e-4 (unfavourable), Stomach cancer:8.23e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 45.0	Expressed in all		
SLC35A3		ENSG00000117620	Solute carrier family 35 member A3	1	99969351-100035637	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015253	Uncertain					Expressed in all	Expressed in all			rectum: 58.7	Expressed in all		
SLC35C1	FLJ11320, FUCT1	ENSG00000181830	Solute carrier family 35 member C1	11	45804072-45813015	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064001	Enhanced		Supported	Golgi apparatus	Thyroid cancer:3.64e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 29.4	Expressed in all		
SLC35D1	KIAA0260, UGTREL7	ENSG00000116704	Solute carrier family 35 member D1	1	66999332-67054099	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Lung cancer:6.55e-4 (unfavourable), Endometrial cancer:7.47e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 38.5	Expressed in all		
SLC36A2	PAT2, TRAMD1, tramdorin	ENSG00000186335	Solute carrier family 36 member 2	5	151314978-151347590	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044002, HPA062229	Enhanced					Tissue enriched	Group enriched	27	kidney: 67.7;skeletal muscle: 28.0	testis: 1.7	Not detected		
SLC38A8		ENSG00000166558	Solute carrier family 38 member 8	16	84009667-84042636	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Not detected			testis: 0.9	Cell line enriched	5	SCLC-21H: 4.0
SLC39A13	FLJ25785	ENSG00000165915	Solute carrier family 39 member 13	11	47407132-47416501	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043971	Approved		Uncertain	Cytosol	Ovarian cancer:2.73e-5 (unfavourable), Renal cancer:1.96e-4 (favourable), Colorectal cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 58.3	Expressed in all		
SLC39A5		ENSG00000139540	Solute carrier family 39 member 5	12	56230049-56237846	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018423			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:5.05e-4 (favourable)	Tissue enhanced	Group enriched	12	colon: 73.2;duodenum: 240.2;kidney: 115.0;liver: 86.0;pancreas: 53.1;rectum: 48.9;small intestine: 240.4	gallbladder: 10.0	Group enriched	62	CACO-2: 33.1;Hep G2: 39.7
SLC39A8	BIGM103	ENSG00000138821	Solute carrier family 39 member 8	4	102251041-102431258	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038832, HPA038833	Approved				Renal cancer:6.34e-6 (favourable), Colorectal cancer:1.34e-4 (favourable), Breast cancer:6.69e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 257.0	cervix, uterine: 129.4	Cell line enhanced		BJ hTERT+: 128.9;Karpas-707: 123.0
SLC3A1	ATR1, CSNU1, D2H, NBAT, RBAT	ENSG00000138079	Solute carrier family 3 member 1	2	44275458-44321494	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA038360, HPA071102	Enhanced		Approved	Nuclear bodies<br>Mitochondria	Renal cancer:3.67e-7 (favourable)	Tissue enriched	Tissue enhanced		kidney: 688.2	small intestine: 148.9	Cell line enriched	14	RPTEC TERT1: 80.7
SLC40A1	FPN1, HFE4, IREG1, MTP1, SLC11A3	ENSG00000138449	Solute carrier family 40 member 1	2	189560579-189583758	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA065634	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.55e-5 (favourable)	Expressed in all	Expressed in all			spleen: 489.1	Group enriched	6	ASC diff: 336.9;CACO-2: 97.8;HEL: 380.0;HMC-1: 94.0;T-47d: 188.1
SLC44A4	C6orf29, CTL4, FLJ14491, NG22, TPPT	ENSG00000204385	Solute carrier family 44 member 4	6	31863192-31879046	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046977, HPA054176	Enhanced				Renal cancer:1.06e-6 (favourable), Head and neck cancer:3.54e-4 (favourable), Urothelial cancer:6.06e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 35.1	colon: 28.7	Cell line enhanced		Hep G2: 1.0
SLC45A2	AIM-1, MATP, OCA4	ENSG00000164175	Solute carrier family 45 member 2	5	33944616-33984730	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enhanced		skin: 1.2;testis: 1.2	prostate,rectum: 0.3	Cell line enriched	43	SK-MEL-30: 48.5
SLC46A1	HCP1, MGC9564, PCFT	ENSG00000076351	Solute carrier family 46 member 1	17	28394756-28407197	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB011614	Approved		Supported	Plasma membrane<br>Cytosol	Glioma:3.90e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 95.1	Cell line enhanced		CACO-2: 169.5
SLC4A1	AE1, CD233, DI, EPB3, FR, RTA1A, SW, WD, WR	ENSG00000004939	Solute carrier family 4 member 1 (Diego blood group)	17	44248385-44268141	Blood group antigen proteins, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015584, CAB034438, HPA063911	Enhanced					Tissue enriched	Tissue enriched	8	bone marrow: 238.0	kidney: 30.0	Mixed		
SLC4A11	BTR1, CDPD1, CHED2, dJ794I6.2, FECD4, NaBC1	ENSG00000088836	Solute carrier family 4 member 11	20	3227417-3239190	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018120, HPA058377	Uncertain		Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:6.21e-6 (favourable), Cervical cancer:9.03e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 27.7	salivary gland: 19.2	Cell line enhanced		HaCaT: 55.7
SLC4A4	hhNMC, HNBC1, NBC1, NBC2, pNBC, SLC4A5	ENSG00000080493	Solute carrier family 4 member 4	4	71186757-71572087	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022493, HPA035628, HPA035629	Enhanced				Renal cancer:1.18e-4 (favourable), Colorectal cancer:7.69e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 125.8	cerebral cortex: 59.3	Cell line enhanced		BJ: 12.5;RPTEC TERT1: 11.7;U-138 MG: 8.0
SLC52A3	bA371L19.1, C20orf54, hRFT2, RFVT3	ENSG00000101276	Solute carrier family 52 member 3	20	760080-776015	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049391, HPA059078	Approved				Stomach cancer:5.51e-6 (favourable)	Expressed in all	Tissue enhanced		testis: 62.3	small intestine: 18.1	Cell line enhanced		CAPAN-2: 33.7;SK-BR-3: 10.4;T-47d: 16.0
SLC5A1	D22S675, NAGT, SGLT1	ENSG00000100170	Solute carrier family 5 member 1	22	32043032-32113029	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB015467, HPA051805, HPA055106	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:6.97e-7 (favourable), Endometrial cancer:2.59e-4 (favourable)	Mixed	Group enriched	10	duodenum: 505.0;small intestine: 313.4	gallbladder: 40.2	Cell line enhanced		CACO-2: 2.1;RPMI-8226: 1.3;SH-SY5Y: 1.0
SLC5A5	NIS	ENSG00000105641	Solute carrier family 5 member 5	19	17871973-17895174	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022364, HPA049055	Enhanced					Mixed	Tissue enhanced		salivary gland: 28.3;stomach: 56.1;thyroid gland: 20.7	cervix, uterine: 8.3	Cell line enriched	5	BEWO: 10.8
SLC5A7	CHT1, hCHT	ENSG00000115665	Solute carrier family 5 member 7	2	107986523-108013994	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046105			Approved	Nuclear bodies<br>Cell Junctions<br>Intermediate filaments		Tissue enhanced	Mixed			thyroid gland: 2.0	Group enriched	21	RT4: 2.9;SCLC-21H: 1.2
SLC6A14		ENSG00000268104	Solute carrier family 6 member 14	X	116436622-116461458	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA003193	Uncertain		Approved	Vesicles	Pancreatic cancer:9.74e-4 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 11.0;lung: 23.9	breast: 9.1	Cell line enhanced		HeLa: 1.0;Hep G2: 2.3
SLC6A17		ENSG00000197106	Solute carrier family 6 member 17	1	110150486-110202202	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007663, HPA008044	Enhanced		Approved	Nucleus<br>Golgi apparatus		Tissue enriched	Tissue enriched	10	cerebral cortex: 75.4	adrenal gland: 7.9	Cell line enhanced		SiHa: 6.6;SK-MEL-30: 28.5;U-87 MG: 7.0
SLC6A18	FLJ31236, Xtrp2	ENSG00000164363	Solute carrier family 6 member 18	5	1225355-1246189	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA011885	Enhanced					Tissue enriched	Tissue enriched	83	kidney: 8.2	all non-specific tissues: 0.0	Not detected		
SLC6A19		ENSG00000174358	Solute carrier family 6 member 19	5	1201595-1225117	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037415, HPA043207	Enhanced		Approved	Nucleoli	Renal cancer:4.14e-6 (favourable)	Tissue enhanced	Group enriched	21	duodenum: 139.5;kidney: 91.8;small intestine: 156.9	rectum: 6.2	Group enriched	6	BEWO: 13.7;HEL: 16.3
SLC6A20	XT3, Xtrp3	ENSG00000163817	Solute carrier family 6 member 20	3	45755450-45796535	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029873	Uncertain				Renal cancer:1.55e-5 (favourable)	Mixed	Tissue enhanced		duodenum: 24.4;small intestine: 19.3	gallbladder: 10.9	Cell line enhanced		HaCaT: 1.5
SLC6A5	GLYT2, NET1	ENSG00000165970	Solute carrier family 6 member 5	11	20599400-20659285	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		lung: 1.4	testis: 0.6	Not detected		
SLC6A9	GLYT1	ENSG00000196517	Solute carrier family 6 member 9	1	43991500-44031467	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA013977	Uncertain		Approved	Nucleus<br>Golgi apparatus	Renal cancer:5.93e-4 (unfavourable), Endometrial cancer:9.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 49.7	adrenal gland: 30.8	Cell line enhanced		hTCEpi: 77.6
SLC7A14	KIAA1613, PPP1R142	ENSG00000013293	Solute carrier family 7 member 14	3	170459584-170586074	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA045929	Approved					Group enriched	Tissue enriched	8	cerebral cortex: 26.7	adrenal gland: 3.1	Cell line enhanced		LHCN-M2: 2.7;SCLC-21H: 3.7
SLC7A7	LPI, y+LAT-1	ENSG00000155465	Solute carrier family 7 member 7	14	22773222-22829820	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036227	Enhanced				Renal cancer:6.28e-6 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 281.9	parathyroid gland: 162.5	Group enriched	5	BEWO: 191.5;CACO-2: 274.5;EFO-21: 65.6
SLC7A9	CSNU3	ENSG00000021488	Solute carrier family 7 member 9	19	32830509-32869766	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042591	Enhanced					Group enriched	Group enriched	10	duodenum: 79.0;kidney: 70.1;small intestine: 123.5	liver: 8.9	Group enriched	20	BEWO: 3.3;CACO-2: 6.7;Hep G2: 5.4
SLC9A1	APNH, NHE1, PPP1R143	ENSG00000090020	Solute carrier family 9 member A1	1	27098815-27166981	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022371, HPA048532, HPA052891	Enhanced		Supported	Plasma membrane	Glioma:6.32e-4 (unfavourable), Ovarian cancer:7.10e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 65.5	Expressed in all		
SLC9A3	NHE3	ENSG00000066230	Solute carrier family 9 member A3	5	473310-524332	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036493, HPA036669	Enhanced		Supported	Plasma membrane	Melanoma:8.49e-4 (unfavourable)	Mixed	Tissue enhanced		colon: 80.9;gallbladder: 66.1;small intestine: 72.6	kidney: 57.3	Cell line enhanced		HDLM-2: 30.4
SLC9A3R1	EBP50, NHERF	ENSG00000109062	SLC9A3 regulator 1	17	74748652-74769353	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB001962, HPA009672, HPA027247	Enhanced		Approved	Vesicles<br>Plasma membrane<br>Microtubule organizing center	Liver cancer:9.83e-5 (unfavourable)	Expressed in all	Expressed in all			small intestine: 302.4	Expressed in all		
SLC9A6	KIAA0267, NHE6	ENSG00000198689	Solute carrier family 9 member A6	X	135973841-136047269	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA059445, HPA059590	Enhanced		Supported	Vesicles		Expressed in all	Tissue enhanced		cerebral cortex: 67.9	parathyroid gland: 16.6	Mixed		
SLC9A9	FLJ35613, NHE9	ENSG00000181804	Solute carrier family 9 member A9	3	143265222-143848531	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA058234	Approved				Renal cancer:5.57e-7 (unfavourable), Lung cancer:8.18e-4 (favourable)	Expressed in all	Mixed			placenta: 22.3	Cell line enhanced		ASC TERT1: 17.2;Karpas-707: 44.4;RPMI-8226: 20.5;U-266/70: 21.8
SLCO1B1	LST-1, OATP-C, OATP1B1, SLC21A6	ENSG00000134538	Solute carrier organic anion transporter family member 1B1	12	21131202-21239246	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050892	Supported					Tissue enriched	Tissue enriched	248	liver: 308.0	breast: 1.2	Not detected		
SLCO1B3	OATP1B3, OATP8, SLC21A8	ENSG00000111700	Solute carrier organic anion transporter family member 1B3	12	20810702-20916911	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004943, HPA050892	Enhanced		Supported	Plasma membrane		Tissue enhanced	Tissue enriched	7	liver: 138.9	cervix, uterine: 19.5	Cell line enhanced		A-431: 56.7;A549: 15.8;CAPAN-2: 11.0;PC-3: 16.0;U-2 OS: 15.2
SLCO2A1	MATR1, OATP2A1, PGT, SLC21A2	ENSG00000174640	Solute carrier organic anion transporter family member 2A1	3	133932696-134052184	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013742	Enhanced				Liver cancer:9.24e-5 (favourable), Stomach cancer:3.25e-4 (unfavourable), Endometrial cancer:9.69e-4 (favourable)	Expressed in all	Tissue enhanced		seminal vesicle: 114.6	thyroid gland: 71.3	Group enriched	5	EFO-21: 83.6;TIME: 17.5
SMARCAD1	DKFZP762K2015, ETL1, KIAA1122	ENSG00000163104	SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1	4	94207611-94291292	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016737	Approved		Enhanced	Nucleoplasm	Liver cancer:3.22e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 25.6	Expressed in all		
SMPD1	ASM	ENSG00000166311	Sphingomyelin phosphodiesterase 1	11	6390431-6394998	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.57e-6 (favourable), Glioma:1.09e-4 (unfavourable), Pancreatic cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.5	Mixed		
SNCA	alpha-synuclein, NACP, PARK1, PARK4, PD1	ENSG00000145335	Synuclein alpha	4	89724099-89838315	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA005459, CAB010877	Enhanced					Tissue enriched	Group enriched	5	bone marrow: 160.8;cerebral cortex: 459.2	endometrium: 57.1	Cell line enhanced		HEL: 198.4;HUVEC TERT2: 218.9;SK-MEL-30: 203.3;TIME: 246.6
SNRNP200	ASCC3L1, BRR2, HELIC2, KIAA0788, RP33, U5-200KD	ENSG00000144028	Small nuclear ribonucleoprotein U5 subunit 200	2	96274336-96305515	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029321	Approved		Supported	Nucleoplasm	Endometrial cancer:3.89e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 116.4	Expressed in all		
SOD1	ALS, ALS1, IPOA	ENSG00000142168	Superoxide dismutase 1	21	31659622-31668931	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001401, CAB008670	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			liver: 768.9	Expressed in all		
SOD2		ENSG00000112096	Superoxide dismutase 2	6	159669057-159762529	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001814, CAB002013	Supported				Renal cancer:1.72e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 734.4	Expressed in all		
SON	BASS1, C21orf50, DBP-5, FLJ21099, FLJ33914, KIAA1019, NREBP	ENSG00000159140	SON DNA binding protein	21	33542618-33577481	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023535, HPA031755, HPA031756	Supported		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 223.1	Expressed in all		
SPAST	ADPSP, FSP2, KIAA1083, SPG4	ENSG00000021574	Spastin	2	32063611-32157637	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017311	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.62e-4 (unfavourable), Renal cancer:4.15e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 20.0	Expressed in all		
SPEG	APEG1, BPEG, KIAA1297, MGC12676, SPEGalpha, SPEGbeta	ENSG00000072195	SPEG complex locus	2	219434846-219498287	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018904	Enhanced		Approved	Vesicles		Mixed	Mixed			skeletal muscle: 43.2	Cell line enhanced		U-2 OS: 22.8;U-87 MG: 23.6
SPG7	CAR, CMAR, SPG5C	ENSG00000197912	SPG7, paraplegin matrix AAA peptidase subunit	16	89490917-89557768	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:2.22e-4 (favourable), Urothelial cancer:4.25e-4 (favourable), Pancreatic cancer:4.91e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.2	Expressed in all		
SPR	SDR38C1	ENSG00000116096	Sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase)	2	72887360-72892158	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039505	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 49.9	Mixed		
SPTLC1	hLCB1, HSAN1, HSN1, LCB1, SPTI	ENSG00000090054	Serine palmitoyltransferase long chain base subunit 1	9	92031999-92115384	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA010860, CAB018747, HPA063907	Supported		Supported	Endoplasmic reticulum	Renal cancer:1.36e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 108.3	Expressed in all		
SPTLC2	hLCB2a, KIAA0526, LCB2, LCB2A	ENSG00000100596	Serine palmitoyltransferase long chain base subunit 2	14	77505997-77616773	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA027552			Approved	Mitochondria	Renal cancer:6.69e-8 (favourable), Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 29.0	Expressed in all		
SRD5A3	FLJ13352, SRD5A2L, SRD5A2L1	ENSG00000128039	Steroid 5 alpha-reductase 3	4	55346109-55373096	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA027006	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.85e-10 (unfavourable), Liver cancer:1.80e-6 (unfavourable), Endometrial cancer:9.39e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 28.2	Expressed in all		
SRP72		ENSG00000174780	Signal recognition particle 72	4	56466915-56503680	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034621	Approved				Liver cancer:3.25e-6 (unfavourable), Colorectal cancer:3.83e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 89.0	Expressed in all		
ST14	HAI, MT-SP1, PRSS14, SNC19, TMPRSS14	ENSG00000149418	Suppression of tumorigenicity 14	11	130159562-130210376	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA047014			Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.03e-11 (favourable)	Expressed in all	Mixed			small intestine: 149.0	Cell line enhanced		CAPAN-2: 361.3;HaCaT: 255.1;RPMI-8226: 192.2;T-47d: 268.8
ST3GAL3	MRT12, SIAT6	ENSG00000126091	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	1	43705824-43931165	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051102	Uncertain					Expressed in all	Expressed in all			skeletal muscle: 30.5	Mixed		
ST3GAL5	SIAT9, SIATGM3S, ST3GalV	ENSG00000115525	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	2	85837120-85905199	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034708, HPA040425, HPA068928	Uncertain		Approved	Vesicles	Renal cancer:2.25e-7 (unfavourable), Urothelial cancer:4.48e-4 (favourable), Thyroid cancer:4.99e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 44.7	cerebral cortex: 40.7	Cell line enhanced		AN3-CA: 50.3;RT4: 37.4
STAMBP	AMSH	ENSG00000124356	STAM binding protein	2	73828916-73873659	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035800, HPA035801	Uncertain		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:4.70e-5 (unfavourable), Pancreatic cancer:5.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.1	Cell line enriched	11	LHCN-M2: 926.0
STIM1	D11S4896E, GOK	ENSG00000167323	Stromal interaction molecule 1	11	3854527-4093210	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA011088, HPA012123, CAB037128, CAB037288	Enhanced		Enhanced	Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 86.8	Expressed in all		
STK10	LOK, PRO2729	ENSG00000072786	Serine/threonine kinase 10	5	172042073-172188386	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015083, CAB020840	Enhanced				Renal cancer:1.63e-4 (unfavourable), Colorectal cancer:2.76e-4 (favourable)	Expressed in all	Expressed in all			spleen: 61.0	Expressed in all		
STK11	LKB1, PJS	ENSG00000118046	Serine/threonine kinase 11	19	1177558-1228435	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB016231, HPA017254, CAB022105, HPA067481	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:3.69e-5 (favourable), Head and neck cancer:1.96e-4 (favourable)	Expressed in all	Expressed in all			testis: 77.1	Mixed		
STK4	KRS2, MST1, YSK3	ENSG00000101109	Serine/threonine kinase 4	20	44966474-45079959	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004038, HPA015270	Approved		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.84e-5 (unfavourable), Liver cancer:8.04e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 50.6	Expressed in all		
STRA6	FLJ12541	ENSG00000137868	Stimulated by retinoic acid 6	15	74179466-74212267	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA040839	Approved		Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		cervix, uterine: 37.0;placenta: 20.4	endometrium: 13.2	Cell line enhanced		CAPAN-2: 162.1;SH-SY5Y: 119.5;WM-115: 273.5
STRADA	LYK5, NY-BR-96, Stlk, STRAD	ENSG00000266173	STE20-related kinase adaptor alpha	17	63682336-63741986	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031637	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.08e-7 (unfavourable), Pancreatic cancer:5.34e-5 (favourable), Urothelial cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			testis: 67.7	Expressed in all		
STS	ARSC, ARSC1	ENSG00000101846	Steroid sulfatase	X	7219456-7354810	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA002904	Enhanced				Pancreatic cancer:3.47e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 36.5	adipose tissue: 18.9	Cell line enhanced		U-266/70: 79.0
STT3A	ITM1, MGC9042, STT3-A, TMC	ENSG00000134910	STT3A, catalytic subunit of the oligosaccharyltransferase complex	11	125591712-125625215	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA030735	Approved		Uncertain	Nucleoplasm<br>Vesicles<br>Cytosol	Endometrial cancer:1.32e-4 (favourable), Liver cancer:3.57e-4 (unfavourable), Renal cancer:4.96e-4 (unfavourable)	Expressed in all	Tissue enriched	7	parathyroid gland: 1131.8	epididymis: 173.0	Expressed in all		
STT3B	FLJ90106, SIMP, STT3-B	ENSG00000163527	STT3B, catalytic subunit of the oligosaccharyltransferase complex	3	31532638-31637622	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA036448, HPA036646	Approved		Supported	Endoplasmic reticulum	Colorectal cancer:7.91e-5 (favourable)	Expressed in all	Expressed in all			testis: 165.5	Expressed in all		
STUB1	CHIP, HSPABP2, NY-CO-7, SDCCAG7, UBOX1	ENSG00000103266	STIP1 homology and U-box containing protein 1	16	680224-682870	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037202, CAB037209, HPA041222, HPA043531	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.49e-9 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 137.7	Expressed in all		
SUCLA2		ENSG00000136143	Succinate-CoA ligase ADP-forming beta subunit	13	47936491-48001354	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039435, HPA039536, HPA061528	Enhanced	Supported	Enhanced	Mitochondria	Renal cancer:7.59e-14 (favourable), Urothelial cancer:1.22e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 78.7	Expressed in all		
SUCLG1		ENSG00000163541	Succinate-CoA ligase alpha subunit	2	84423523-84460045	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA036683, HPA036684	Enhanced		Supported	Plasma membrane<br>Mitochondria	Renal cancer:2.21e-8 (favourable), Endometrial cancer:5.23e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 471.2	Expressed in all		
SUGCT	C7orf10, DERP13, FLJ11808, ORF19	ENSG00000175600	Succinyl-CoA:glutarate-CoA transferase	7	40134977-40860763	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026698, HPA026704, HPA026705	Enhanced				Renal cancer:3.93e-7 (favourable), Urothelial cancer:2.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 45.0	liver: 14.6	Cell line enhanced		HBEC3-KT: 30.6;LHCN-M2: 21.2
SUOX		ENSG00000139531	Sulfite oxidase	12	55997180-56006641	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038208, HPA038209	Approved				Renal cancer:4.77e-7 (favourable), Urothelial cancer:8.32e-5 (favourable), Pancreatic cancer:6.28e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 108.9	Mixed		
SYNJ1	INPP5G, PARK20	ENSG00000159082	Synaptojanin 1	21	32628759-32728048	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA011916	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Prostate cancer:2.58e-4 (unfavourable), Head and neck cancer:4.43e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 65.9	testis: 18.4	Expressed in all		
SYP	MRX96	ENSG00000102003	Synaptophysin	X	49187804-49200259	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000076, HPA002858, CAB055505, CAB078999	Enhanced	Supported				Group enriched	Tissue enriched	11	cerebral cortex: 571.4	adrenal gland: 51.1	Cell line enhanced		SCLC-21H: 116.7;SH-SY5Y: 38.0
SYT1	P65, SVP65, SYT	ENSG00000067715	Synaptotagmin 1	12	78863993-79452008	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008394, HPA064788	Enhanced	Supported				Mixed	Tissue enriched	13	cerebral cortex: 476.5	smooth muscle: 36.7	Cell line enhanced		hTERT-HME1: 29.8;LHCN-M2: 26.5;SH-SY5Y: 32.1;WM-115: 28.3
TACR3	NK3R	ENSG00000169836	Tachykinin receptor 3	4	103586031-103719816	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA009418	Uncertain					Not detected	Not detected			cerebral cortex: 0.5	Cell line enriched	13	BEWO: 6.9
TAF1	BA2R, CCG1, CCGS, DYT3, DYT3/TAF1, KAT4, NSCL2, TAF2A, TAFII250	ENSG00000147133	TATA-box binding protein associated factor 1	X	71366239-71532374	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001075, CAB016283	Supported		Enhanced	Nucleoplasm	Renal cancer:6.03e-4 (unfavourable), Lung cancer:6.54e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 26.2	Expressed in all		
TALDO1		ENSG00000177156	Transaldolase 1	11	747329-765024	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040373, HPA048089			Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.29e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 262.9	Expressed in all		
TAP1	ABCB2, D6S114E, PSF1, RING4	ENSG00000168394	Transporter 1, ATP binding cassette subfamily B member	6	32845209-32853978	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009516, HPA072354	Approved		Supported	Endoplasmic reticulum<br>Microtubule organizing center	Renal cancer:6.58e-5 (unfavourable), Ovarian cancer:4.07e-4 (favourable), Colorectal cancer:9.01e-4 (favourable)	Expressed in all	Mixed			appendix: 19.9	Mixed		
TAP2	ABCB3, D6S217E, PSF2, RING11	ENSG00000204267	Transporter 2, ATP binding cassette subfamily B member	6	32821833-32838780	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA001312	Approved		Approved	Nuclear speckles<br>Endoplasmic reticulum	Renal cancer:5.22e-8 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable)	Expressed in all	Mixed			urinary bladder: 15.1	Cell line enhanced		U-251 MG: 53.5
TARS2	FLJ12528, TARSL1	ENSG00000143374	Threonyl-tRNA synthetase 2, mitochondrial (putative)	1	150487364-150507609	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028626	Approved		Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 29.2	Expressed in all		
TAT		ENSG00000198650	Tyrosine aminotransferase	16	71565660-71577130	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.51e-4 (favourable)	Tissue enriched	Tissue enriched	8	liver: 619.8	breast: 75.9	Cell line enhanced		Hep G2: 1.7
TBC1D4	AS160, DKFZp779C0666, KIAA0603	ENSG00000136111	TBC1 domain family member 4	13	75284665-75482114	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA040145, HPA059885	Approved		Supported	Cytosol	Renal cancer:1.07e-11 (favourable)	Expressed in all	Expressed in all			adrenal gland: 82.8	Cell line enhanced		CACO-2: 70.0
TBCK	HSPC302, MGC16169	ENSG00000145348	TBC1 domain containing kinase	4	106041599-106321495	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039951, HPA051611	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center	Renal cancer:3.20e-4 (favourable)	Expressed in all	Mixed			testis: 16.0	Expressed in all		
TBK1	NAK	ENSG00000183735	TANK binding kinase 1	12	64451880-64502108	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA045797, HPA060211	Uncertain		Supported	Nucleoplasm	Renal cancer:4.20e-6 (unfavourable), Liver cancer:3.30e-4 (unfavourable), Melanoma:3.48e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.3	Expressed in all		
TECR	GPSN2, MRT14, SC2, TER	ENSG00000099797	Trans-2,3-enoyl-CoA reductase	19	14517085-14565980	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029780, HPA056488	Supported		Supported	Endoplasmic reticulum	Urothelial cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 404.6	Expressed in all		
TERT	EST2, hEST2, TCS1, TP2, TRT	ENSG00000164362	Telomerase reverse transcriptase	5	1253147-1295069	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA054641, HPA065897	Supported		Enhanced	Nucleoplasm<br>Nuclear speckles<br>Cytosol		Mixed	Not detected			lymph node,testis: 0.5	Cell line enhanced		ASC TERT1: 349.5;fHDF/TERT166: 388.9;HBEC3-KT: 725.5;hTEC/SVTERT24-B: 626.8;TIME: 672.9
TET1	bA119F7.1, CXXC6, KIAA1676, LCX	ENSG00000138336	Tet methylcytosine dioxygenase 1	10	68560656-68694482	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019032, HPA057273			Supported	Nucleus<br>Nuclear membrane		Tissue enriched	Mixed			parathyroid gland: 2.4	Cell line enhanced		BEWO: 17.6;HAP1: 21.7;K-562: 11.0;NTERA-2: 12.2
TET2	FLJ20032, KIAA1546	ENSG00000168769	Tet methylcytosine dioxygenase 2	4	105145875-105279816	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043135	Supported		Approved	Nucleoplasm		Mixed	Mixed			bone marrow: 15.7	Mixed		
TFR2	HFE3, TFRC2	ENSG00000106327	Transferrin receptor 2	7	100620416-100642779	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA011937, CAB016255	Enhanced				Liver cancer:2.48e-4 (favourable)	Tissue enriched	Tissue enriched	11	liver: 155.5	bone marrow: 13.9	Group enriched	14	HEL: 62.3;HMC-1: 81.2;K-562: 58.4
TFRC	CD71, p90, TFR1	ENSG00000072274	Transferrin receptor	3	196027183-196082189	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000153, HPA028598	Enhanced		Supported	Endosomes<br>Lysosomes	Liver cancer:1.15e-4 (unfavourable), Thyroid cancer:2.96e-4 (unfavourable), Cervical cancer:3.67e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 157.4	Expressed in all		
TGDS	SDR2E1, TDPGD	ENSG00000088451	TDP-glucose 4,6-dehydratase	13	94574051-94596257	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039927, HPA040857	Approved		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments<br>Cleavage furrow	Prostate cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 21.7	Expressed in all		
TGFBR1	ACVRLK4, ALK-5, ALK5, ESS1, MSSE	ENSG00000106799	Transforming growth factor beta receptor 1	9	99104038-99154192	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002441, CAB031481, HPA056473	Uncertain		Supported	Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			placenta: 69.8	Expressed in all		
TGFBR2	MFS2	ENSG00000163513	Transforming growth factor beta receptor 2	3	30606502-30694142	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB073537			Supported	Plasma membrane		Expressed in all	Expressed in all			adipose tissue: 292.3	Cell line enhanced		ASC TERT1: 366.2;LHCN-M2: 371.8;TIME: 336.9
TGM1	ICR2, LI, LI1, TGASE, TGK	ENSG00000092295	Transglutaminase 1	14	24249114-24264432	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015159, HPA040171	Enhanced					Tissue enhanced	Tissue enriched	12	esophagus: 831.8	tonsil: 72.2	Cell line enhanced		BEWO: 33.0;HaCaT: 42.3;MCF7: 27.0;SK-BR-3: 31.6
TGM3	TGE	ENSG00000125780	Transglutaminase 3	20	2296001-2341078	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004728	Enhanced					Tissue enriched	Tissue enriched	12	esophagus: 1513.9	tonsil: 126.4	Cell line enriched	7	EFO-21: 5.7
TGM5	TGX	ENSG00000104055	Transglutaminase 5	15	43232595-43266857	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	7	esophagus: 8.4;skin: 22.3	breast: 2.3	Cell line enriched	8	HEL: 16.7
TGM6	dJ734P14.3, SCA35, TGM3L, TGY	ENSG00000166948	Transglutaminase 6	20	2380908-2432753	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059196	Uncertain					Not detected	Not detected			tonsil: 0.4	Not detected		
TK2	SCA31	ENSG00000166548	Thymidine kinase 2, mitochondrial	16	66508003-66552544	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041162	Uncertain				Renal cancer:2.18e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 89.9	Mixed		
TKT		ENSG00000163931	Transketolase	3	53224707-53256052	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029480, HPA029481	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.21e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 431.3	Expressed in all		
TLL1		ENSG00000038295	Tolloid like 1	4	165873258-166103895	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060767			Approved	Vesicles		Mixed	Tissue enhanced		placenta: 10.5	gallbladder: 4.4	Cell line enhanced		HeLa: 4.3;Karpas-707: 7.1;PC-3: 3.3
TM4SF20	FLJ22800, TCCE518	ENSG00000168955	Transmembrane 4 L six family member 20	2	227362156-227381995	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051838, HPA063184, HPA065531	Uncertain		Supported	Plasma membrane<br>Focal adhesion sites		Group enriched	Group enriched	35	duodenum: 277.2;small intestine: 163.8	testis: 6.3	Cell line enhanced		A549: 2.5;RPMI-8226: 1.2
TMC6	EVER1, EVIN1, LAK-4P	ENSG00000141524	Transmembrane channel like 6	17	78110458-78132407	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051430	Uncertain				Stomach cancer:1.82e-4 (favourable), Urothelial cancer:3.20e-4 (favourable)	Expressed in all	Expressed in all			spleen: 82.8	Cell line enhanced		K-562: 99.9;SK-BR-3: 90.6
TMC8	EVER2, EVIN2	ENSG00000167895	Transmembrane channel like 8	17	78130770-78142968	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047387, HPA054429	Uncertain		Uncertain	Golgi apparatus	Renal cancer:1.96e-7 (unfavourable), Cervical cancer:8.45e-6 (favourable), Head and neck cancer:4.19e-5 (favourable)	Expressed in all	Tissue enhanced		lymph node: 118.8;spleen: 104.5	appendix: 72.5	Cell line enhanced		HL-60: 50.1;HMC-1: 106.6;Karpas-707: 74.8;RPMI-8226: 46.3;U-266/70: 38.2;U-937: 41.2
TMCO1	HP10122, TMCC4	ENSG00000143183	Transmembrane and coiled-coil domains 1	1	165724293-165827755	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA054768			Supported	Endoplasmic reticulum	Head and neck cancer:5.17e-7 (unfavourable), Renal cancer:1.25e-4 (unfavourable), Liver cancer:3.21e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 157.4	Expressed in all		
TMEM165	GDT1, TMPT27, TPARL	ENSG00000134851	Transmembrane protein 165	4	55395957-55453397	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038299, HPA062424	Supported		Enhanced	Golgi apparatus<br>Vesicles	Renal cancer:1.18e-8 (unfavourable), Liver cancer:2.08e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 87.1	Expressed in all		
TMEM17	FLJ34583	ENSG00000186889	Transmembrane protein 17	2	62500221-62511894	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018100	Uncertain		Approved	Actin filaments		Expressed in all	Mixed			testis: 8.2	Mixed		
TMEM199	C17orf32, MGC45714, VMA12, VPH2	ENSG00000244045	Transmembrane protein 199	17	28357581-28363683	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA027051	Uncertain				Liver cancer:1.54e-4 (unfavourable), Endometrial cancer:5.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 19.3	Expressed in all		
TMEM38B	bA219P18.1, C9orf87, D4Ertd89e, FLJ10493, TRIC-B	ENSG00000095209	Transmembrane protein 38B	9	105694544-105776612	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018465	Uncertain				Renal cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			testis: 51.9	Expressed in all		
TMEM67	JBTS6, MGC26979, MKS3, NPHP11	ENSG00000164953	Transmembrane protein 67	8	93754844-93819234	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:7.62e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 21.5	testis: 12.5	Mixed		
TMIE	DFNB6	ENSG00000181585	Transmembrane inner ear	3	46701333-46710886	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038298	Uncertain		Uncertain	Vesicles<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 7.4;cerebral cortex: 5.2	testis: 1.6	Cell line enhanced		CAPAN-2: 2.2;EFO-21: 2.1;SH-SY5Y: 2.3
TMLHE	BBOX2, FLJ10727, TMLH, XAP130	ENSG00000185973	Trimethyllysine hydroxylase, epsilon	X	155490115-155669944	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034589, HPA040331	Approved		Supported	Mitochondria	Renal cancer:3.68e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.7	Mixed		
TMPRSS15	ENTK, MGC133046, PRSS7	ENSG00000154646	Transmembrane protease, serine 15	21	18269116-18485879	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015611, HPA072934	Enhanced					Group enriched	Tissue enriched	44	duodenum: 1010.9	small intestine: 22.7	Group enriched	22	U-138 MG: 50.9;U-87 MG: 140.8
TMPRSS3	DFNB10, DFNB8	ENSG00000160183	Transmembrane protease, serine 3	21	42371890-42396846	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Colorectal cancer:3.64e-4 (unfavourable), Renal cancer:8.24e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 35.2	stomach: 13.7	Cell line enhanced		HEL: 58.2;SiHa: 35.3;U-266/84: 182.5
TMPRSS5	MGC141886, MGC148044	ENSG00000166682	Transmembrane protease, serine 5	11	113687550-113706373	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010992			Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 10.1	salivary gland: 3.0	Cell line enhanced		CAPAN-2: 2.9;WM-115: 2.6
TMPRSS6	FLJ30744	ENSG00000187045	Transmembrane protease, serine 6	22	37065436-37109563	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Liver cancer:8.16e-6 (favourable)	Group enriched	Group enriched	6	liver: 40.8;testis: 8.6	stomach: 4.0	Cell line enhanced		Hep G2: 3.6;SCLC-21H: 10.1
TNFAIP3	A20, OTUD7C	ENSG00000118503	TNF alpha induced protein 3	6	137867188-137883312	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002116, HPA067479	Approved		Supported	Vesicles	Renal cancer:6.05e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 345.2	Cell line enhanced		Karpas-707: 118.8;REH: 135.9
TNIK	KIAA0551	ENSG00000154310	TRAF2 and NCK interacting kinase	3	171061339-171460408	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA012128, HPA012297	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 35.5	Cell line enhanced		HEL: 58.9;HMC-1: 63.1;WM-115: 53.8
TNNI3K	CARK	ENSG00000116783	TNNI3 interacting kinase	1	74235401-74544428	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	7	heart muscle: 39.5	testis: 5.3	Not detected		
TOPORS	LUN, RP31, TP53BPL	ENSG00000197579	TOP1 binding arginine/serine rich protein	9	32540544-32552553	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060640, HPA065661	Enhanced		Supported	Nucleoplasm	Renal cancer:6.64e-6 (favourable), Ovarian cancer:7.07e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.6	Expressed in all		
TP53	LFS1, p53	ENSG00000141510	Tumor protein p53	17	7661779-7687550	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	CAB002973, CAB039238, CAB039239, HPA051244, CAB072876	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.35e-4 (favourable), Prostate cancer:5.01e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 50.3	Expressed in all		
TPI1		ENSG00000111669	Triosephosphate isomerase 1	12	6867119-6870948	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050924, HPA053568	Uncertain		Enhanced	Nucleoplasm	Liver cancer:1.04e-5 (unfavourable), Renal cancer:6.54e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 942.7	Expressed in all		
TPP1	CLN2, SCAR7	ENSG00000166340	Tripeptidyl peptidase 1	11	6612763-6619461	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037709, HPA044868	Enhanced				Liver cancer:1.11e-4 (unfavourable), Head and neck cancer:4.31e-4 (unfavourable), Stomach cancer:4.46e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 206.9	Expressed in all		
TPR		ENSG00000047410	Translocated promoter region, nuclear basket protein	1	186311652-186375693	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA019661, HPA019663, HPA024336	Enhanced		Enhanced	Nuclear membrane	Liver cancer:1.06e-4 (unfavourable), Head and neck cancer:4.71e-4 (favourable)	Expressed in all	Expressed in all			testis: 79.0	Expressed in all		
TRAF3	CAP-1, CD40bp, CRAF1, LAP1	ENSG00000131323	TNF receptor associated factor 3	14	102777476-102911500	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002933	Uncertain				Liver cancer:1.02e-5 (unfavourable), Pancreatic cancer:2.42e-5 (favourable)	Expressed in all	Mixed			appendix: 25.7	Expressed in all		
TRAIP	RNF206, TRIP	ENSG00000183763	TRAF interacting protein	3	49828599-49856574	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036261, HPA036262	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:8.77e-5 (unfavourable)	Expressed in all	Mixed			testis: 11.3	Mixed		
TRDN		ENSG00000186439	Triadin	6	123216339-123637093	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038226, HPA058226	Enhanced		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Group enriched	21	heart muscle: 273.5;skeletal muscle: 650.2	prostate: 22.2	Cell line enhanced		MCF7: 1.4
TREH	MGC129621, TRE, TREA	ENSG00000118094	Trehalase	11	118657316-118679690	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA039913, HPA042045	Enhanced				Renal cancer:2.33e-6 (favourable), Liver cancer:3.76e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 60.6;small intestine: 72.6	kidney: 13.5	Cell line enhanced		BEWO: 1.5
TREX1	AGS1, DRN3	ENSG00000213689	Three prime repair exonuclease 1	3	48465811-48467645	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA035437, HPA046721	Supported		Supported	Cytosol		Not detected	Expressed in all			spleen: 30.9	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 66.5
TRIM2	CMT2R, KIAA0517, RNF86	ENSG00000109654	Tripartite motif containing 2	4	153152342-153339320	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035853, HPA035854	Enhanced		Approved	Centrosome	Renal cancer:6.58e-14 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 155.1	thyroid gland: 110.7	Cell line enhanced		AF22: 68.3
TRIM24	hTIF1, RNF82, TIF1, Tif1a	ENSG00000122779	Tripartite motif containing 24	7	138460334-138589993	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043495, HPA061717	Approved		Enhanced	Nucleoplasm	Lung cancer:6.57e-4 (favourable), Liver cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.6	Expressed in all		
TRIM27	RFP, RNF76	ENSG00000204713	Tripartite motif containing 27	6	28903002-28923989	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048684, HPA053408	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:3.50e-6 (unfavourable), Urothelial cancer:2.71e-4 (favourable)	Expressed in all	Mixed			appendix: 5.6	Mixed		
TRIM32	BBS11, HT2A, LGMD2H, TATIP	ENSG00000119401	Tripartite motif containing 32	9	116687302-116701300	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050060	Approved		Approved	Intermediate filaments	Head and neck cancer:4.53e-4 (unfavourable), Liver cancer:4.72e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 21.2	Mixed		
TRIM33	FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA	ENSG00000197323	Tripartite motif containing 33	1	114392777-114511160	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004345	Supported		Approved	Nucleoplasm<br>Vesicles	Colorectal cancer:6.20e-4 (favourable), Head and neck cancer:8.93e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.2	Expressed in all		
TRIM37	KIAA0898, MUL, POB1, TEF3	ENSG00000108395	Tripartite motif containing 37	17	58982638-59106921	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021911	Uncertain				Liver cancer:4.99e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 117.5	Expressed in all		
TRIO	ARHGEF23	ENSG00000038382	Trio Rho guanine nucleotide exchange factor	5	14143702-14532128	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008157, HPA064664	Supported		Approved	Vesicles<br>Cytosol	Renal cancer:3.11e-5 (unfavourable), Endometrial cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 47.2	Cell line enhanced		hTEC/SVTERT24-B: 190.1;U-87 MG: 248.3
TRMT5	KIAA1393, TRM5	ENSG00000126814	TRNA methyltransferase 5	14	60971451-60981358	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000943	Supported		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 31.3	Expressed in all		
TRMU	FLJ10140, MTO2, TRMT	ENSG00000100416	TRNA 5-methylaminomethyl-2-thiouridylate methyltransferase	22	46330875-46357340	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000824, HPA035273, HPA043300	Uncertain		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:5.63e-6 (unfavourable), Liver cancer:3.04e-5 (unfavourable), Pancreatic cancer:6.86e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.0	Expressed in all		
TRNT1	CCA1, CGI-47, MtCCA	ENSG00000072756	TRNA nucleotidyl transferase 1	3	3126916-3150879	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036938	Uncertain		Enhanced	Mitochondria		Expressed in all	Expressed in all			prostate: 24.5	Expressed in all		
TRPC3		ENSG00000138741	Transient receptor potential cation channel subfamily C member 3	4	121879027-121951754	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA037969	Uncertain					Not detected	Tissue enhanced		smooth muscle: 4.1	cerebral cortex: 2.1	Cell line enhanced		HEK93: 1.6;HEL: 2.4;Karpas-707: 1.9;U-2 OS: 1.8
TRPC6	FSGS2, TRP6	ENSG00000137672	Transient receptor potential cation channel subfamily C member 6	11	101451564-101872562	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA045098, HPA062164	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		placenta: 30.1	lung: 20.0	Cell line enhanced		A549: 4.4;ASC diff: 6.0;BJ hTERT+: 3.9;HEL: 4.3;RPTEC TERT1: 16.5
TRPM1	CSNB1C, LTRPC1, MLSN1	ENSG00000134160	Transient receptor potential cation channel subfamily M member 1	15	31001061-31161273	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA014779, HPA014785	Supported		Uncertain	Nucleoplasm<br>Cytosol		Tissue enriched	Group enriched	26	skin: 4.8;testis: 2.1	kidney: 0.1	Cell line enriched	91	SK-MEL-30: 9.1
TRPM4	FLJ20041	ENSG00000130529	Transient receptor potential cation channel subfamily M member 4	19	49157741-49211836	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA041169	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:2.53e-7 (favourable), Endometrial cancer:2.88e-7 (favourable)	Expressed in all	Mixed			prostate: 29.4	Cell line enhanced		RT4: 47.8
TRPM6	CHAK2, FLJ22628, HOMG, HSH	ENSG00000119121	Transient receptor potential cation channel subfamily M member 6	9	74722495-74888094	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enhanced		colon: 13.1;rectum: 18.2	small intestine: 8.7	Cell line enhanced		BEWO: 3.7;HeLa: 1.5;RT4: 3.0
TRPM7	CHAK1, LTRPC7, TRP-PLIK	ENSG00000092439	Transient receptor potential cation channel subfamily M member 7	15	50552473-50686815	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA052173	Enhanced		Approved	Nucleoplasm		Expressed in all	Tissue enriched	7	parathyroid gland: 216.4	thyroid gland: 29.0	Expressed in all		
TRPV4	CMT2C, OTRPC4, TRP12, VR-OAC, VRL-2, VROAC	ENSG00000111199	Transient receptor potential cation channel subfamily V member 4	12	109783085-109833401	Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA007150	Uncertain				Renal cancer:4.12e-5 (favourable), Ovarian cancer:8.10e-4 (unfavourable)	Expressed in all	Mixed			kidney: 11.8	Cell line enhanced		BEWO: 9.1;HaCaT: 13.9
TSEN2	MGC2776, SEN2, SEN2L	ENSG00000154743	TRNA splicing endonuclease subunit 2	3	12484432-12539623	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027120, HPA027125, HPA027268	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.13e-5 (unfavourable), Urothelial cancer:3.49e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 14.7	Expressed in all		
TSEN34	LENG5, SEN34, SEN34L	ENSG00000170892	TRNA splicing endonuclease subunit 34	19	54189938-54194536	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041111, HPA048208	Approved		Supported	Nucleus	Liver cancer:1.44e-7 (unfavourable)	Expressed in all	Mixed			fallopian tube: 37.2	Mixed		
TSPAN12	NET-2, TM4SF12	ENSG00000106025	Tetraspanin 12	7	120787320-120858402	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051570, HPA058244	Uncertain		Approved	Vesicles<br>Microtubules		Expressed in all	Mixed			kidney: 91.5	Cell line enhanced		HEK93: 47.4;HUVEC TERT2: 48.1;RH-30: 50.5;RPTEC TERT1: 63.2;RT4: 52.1
TSPAN7	A15, CD231, DXS1692E, MRX58, MXS1, TALLA-1, TM4SF2	ENSG00000156298	Tetraspanin 7	X	38561370-38688920	CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003140, CAB062566, CAB068245	Enhanced				Renal cancer:5.48e-7 (favourable), Pancreatic cancer:1.70e-4 (favourable), Endometrial cancer:3.40e-4 (unfavourable)	Expressed in all	Tissue enriched	6	cerebral cortex: 574.4	adrenal gland: 99.2	Cell line enhanced		HDLM-2: 39.2;MOLT-4: 141.6;SCLC-21H: 109.6;U-266/70: 47.0
TTBK2	KIAA0847, SCA11	ENSG00000128881	Tau tubulin kinase 2	15	42738734-42920809	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018113, HPA049866	Approved		Uncertain	Intermediate filaments		Mixed	Tissue enhanced		testis: 61.5	cerebral cortex: 16.6	Mixed		
TTN	CMD1G, CMH9, CMPD4, FLJ32040, LGMD2J, MYLK5, TMD	ENSG00000155657	Titin	2	178525989-178830802	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007042, CAB022682, HPA030048	Enhanced					Tissue enhanced	Tissue enriched	7	skeletal muscle: 322.5	heart muscle: 46.7	Mixed		
TUSC3	MGC13453, MRT7, N33, OST3A	ENSG00000104723	Tumor suppressor candidate 3	8	15417215-15766649	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049851, HPA049974	Approved				Thyroid cancer:7.86e-4 (favourable)	Expressed in all	Mixed			epididymis: 143.1	Mixed		
TWNK	C10orf2, FLJ21832, IOSCA, PEO, PEO1, TWINKLE, TWINL	ENSG00000107815	Twinkle mtDNA helicase	10	100987367-100994401	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002532	Uncertain					Expressed in all	Expressed in all			testis: 13.6	Expressed in all		
TYK2	JTK1	ENSG00000105397	Tyrosine kinase 2	19	10350529-10380676	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005157	Uncertain		Supported	Cytosol	Head and neck cancer:1.05e-5 (favourable), Pancreatic cancer:1.02e-4 (favourable), Urothelial cancer:4.16e-4 (favourable), Renal cancer:4.43e-4 (unfavourable), Endometrial cancer:9.62e-4 (favourable)	Expressed in all	Expressed in all			spleen: 68.2	Expressed in all		
TYMP	ECGF1, MNGIE	ENSG00000025708	Thymidine phosphorylase	22	50525752-50530056	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000530, HPA001072, CAB002518	Enhanced		Approved	Nuclear bodies<br>Golgi apparatus	Renal cancer:3.50e-8 (unfavourable), Endometrial cancer:4.34e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 100.6	spleen: 53.1	Cell line enhanced		CAPAN-2: 37.3;HHSteC: 84.7;Karpas-707: 72.1;U-266/70: 36.4
UBA1	A1S9T, CFAP124, GXP1, POC20, UBE1, UBE1X	ENSG00000130985	Ubiquitin like modifier activating enzyme 1	X	47190861-47215128	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000289, HPA001506, CAB019435, CAB073410	Approved		Enhanced	Nucleoplasm	Liver cancer:6.10e-5 (unfavourable), Thyroid cancer:1.78e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 239.4	Expressed in all		
UBE2A	HHR6A, RAD6A, UBC2	ENSG00000077721	Ubiquitin conjugating enzyme E2 A	X	119574467-119591083	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003875, HPA051765, HPA065898			Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:2.20e-6 (unfavourable), Cervical cancer:2.16e-4 (favourable), Head and neck cancer:9.07e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 76.5	Expressed in all		
UBE2QL1	FLJ25076	ENSG00000215218	Ubiquitin conjugating enzyme E2 Q family like 1	5	6448623-6494909	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057414			Supported	Nucleus<br>Plasma membrane	Renal cancer:6.81e-8 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 41.8	seminal vesicle: 10.4	Cell line enhanced		Karpas-707: 29.4;PC-3: 32.0;SCLC-21H: 37.2;U-266/70: 57.9;U-266/84: 50.5
UBE2T	FANCT, HSPC150	ENSG00000077152	Ubiquitin conjugating enzyme E2 T	1	202331657-202341980	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002831			Approved	Nucleus<br>Nucleoli	Renal cancer:2.22e-16 (unfavourable), Liver cancer:4.79e-6 (unfavourable), Ovarian cancer:6.90e-6 (favourable)	Expressed in all	Mixed			testis: 36.0	Expressed in all		
UBE3A	ANCR, AS, E6-AP, EPVE6AP, FLJ26981, HPVE6A	ENSG00000114062	Ubiquitin protein ligase E3A	15	25333728-25439056	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009723, HPA039410, HPA040380	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 86.1	Expressed in all		
UBE3B		ENSG00000151148	Ubiquitin protein ligase E3B	12	109477402-109536705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041012	Approved		Approved	Nuclear speckles<br>Mitochondria	Renal cancer:2.49e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.1	Expressed in all		
UBR1		ENSG00000159459	Ubiquitin protein ligase E3 component n-recognin 1	15	42942897-43106113	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038838	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 27.4	Expressed in all		
UCHL1	PARK5, PGP9.5, Uch-L1	ENSG00000154277	Ubiquitin C-terminal hydrolase L1	4	41256413-41268455	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002580, HPA005993, CAB079024	Enhanced	Supported	Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:4.08e-5 (unfavourable), Urothelial cancer:1.93e-4 (unfavourable)	Expressed in all	Tissue enriched	7	cerebral cortex: 785.9	adrenal gland: 107.9	Cell line enhanced		EFO-21: 912.4;SCLC-21H: 1141.2;U-87 MG: 916.2
UCP3	SLC25A9	ENSG00000175564	Uncoupling protein 3	11	74000281-74009435	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB010771, HPA072225	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	19	skeletal muscle: 71.2	testis: 3.8	Group enriched	5	HDLM-2: 13.8;RH-30: 3.3
UFSP2	C4orf20, FLJ11200	ENSG00000109775	UFM1 specific peptidase 2	4	185399540-185425985	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039985, HPA043298	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:1.07e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.0	Expressed in all		
UGT1A1	GNT1, UGT1, UGT1A	ENSG00000241635	UDP glucuronosyltransferase family 1 member A1	2	233760248-233773299	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	33	duodenum: 199.5;liver: 155.8;small intestine: 81.9	kidney: 4.3	Cell line enhanced		HaCaT: 12.7;PC-3: 6.0;RT4: 27.4
UGT1A4	HUG-BR2, UGT1D	ENSG00000244474	UDP glucuronosyltransferase family 1 member A4	2	233718778-233773299	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	31	liver: 212.3	duodenum: 6.7	Not detected		
UHRF1	FLJ21925, ICBP90, Np95, RNF106, TDRD22	ENSG00000276043	Ubiquitin like with PHD and ring finger domains 1	19	4903080-4962154	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049408, HPA055446	Enhanced		Supported	Nucleoplasm	Pancreatic cancer:4.52e-5 (unfavourable), Liver cancer:1.63e-4 (unfavourable), Melanoma:6.81e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 18.8	bone marrow: 17.5	Expressed in all		
UHRF2	MGC33463, NIRF, RNF107, TDRD23, URF2	ENSG00000147854	Ubiquitin like with PHD and ring finger domains 2	9	6413151-6507054	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026633, HPA026697			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 32.8	Expressed in all		
ULK4	FAM7C1, FLJ20574, REC01035	ENSG00000168038	Unc-51 like kinase 4	3	41246599-41962430	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017930	Uncertain		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Mixed	Tissue enhanced		testis: 38.1	parathyroid gland: 14.4	Mixed		
UMPS		ENSG00000114491	Uridine monophosphate synthetase	3	124730366-124749273	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036178, HPA036179	Uncertain		Supported	Cytosol	Prostate cancer:9.20e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland,spleen: 3.4	Expressed in all		
UNC93B1	UNC93	ENSG00000110057	Unc-93 homolog B1 (C. elegans)	11	67991104-68004982	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038716, HPA038717, HPA042803	Approved		Approved	Nucleoplasm	Pancreatic cancer:1.73e-4 (unfavourable), Renal cancer:7.38e-4 (unfavourable)	Expressed in all	Mixed			spleen: 54.4	Cell line enhanced		CAPAN-2: 111.1;RPMI-8226: 250.7
UNG	DGU, HIGM4, UDG, UNG1, UNG2	ENSG00000076248	Uracil DNA glycosylase	12	109097574-109110992	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011605	Uncertain		Approved	Cytosol	Melanoma:3.06e-4 (unfavourable), Liver cancer:6.40e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 56.2	Expressed in all		
UPB1	BUP1	ENSG00000100024	Beta-ureidopropionase 1	22	24494107-24528390	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000728	Enhanced				Liver cancer:2.30e-7 (favourable)	Tissue enriched	Group enriched	23	kidney: 51.2;liver: 161.7	testis: 4.6	Cell line enhanced		CACO-2: 6.0;NB-4: 1.9;THP-1: 2.7;U-937: 3.5
UPK3A	UPK3	ENSG00000100373	Uroplakin 3A	22	45284982-45295874	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018407, HPA018415	Enhanced		Uncertain	Nuclear membrane<br>Nuclear bodies		Group enriched	Group enriched	7	parathyroid gland: 13.0;prostate: 35.0;skeletal muscle: 12.6;urinary bladder: 15.4	thyroid gland: 2.6	Group enriched	6	Hep G2: 20.8;RT4: 40.2
UQCRC2	QCR2, UQCR2	ENSG00000140740	Ubiquinol-cytochrome c reductase core protein II	16	21952660-21983660	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007998, HPA019146	Enhanced		Enhanced	Mitochondria	Renal cancer:6.58e-9 (favourable)	Expressed in all	Expressed in all			heart muscle: 151.1	Expressed in all		
UROC1	FLJ31300, HMFN0320	ENSG00000159650	Urocanate hydratase 1	3	126481281-126517773	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA069863	Enhanced					Tissue enriched	Tissue enriched	126	liver: 43.0	fallopian tube: 0.3	Cell line enriched	7	NB-4: 2.6
UROD		ENSG00000126088	Uroporphyrinogen decarboxylase	1	45012147-45015575	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027468, HPA028668, HPA030350	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 115.4	Expressed in all		
UROS		ENSG00000188690	Uroporphyrinogen III synthase	10	125784980-125823248	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044038	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.27e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 84.7	Expressed in all		
USP16	Ubp-M	ENSG00000156256	Ubiquitin specific peptidase 16	21	29024629-29054488	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021140	Supported		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 57.2	Expressed in all		
USP27X	USP27	ENSG00000273820	Ubiquitin specific peptidase 27, X-linked	X	49879948-49882565	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA077264			Approved	Nucleoplasm<br>Vesicles	Liver cancer:6.14e-4 (unfavourable), Pancreatic cancer:9.31e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 19.7	cerebral cortex: 10.3	Mixed		
USP6	HRP1, Tre-2, TRE17, Tre2, TRESMCR	ENSG00000129204	Ubiquitin specific peptidase 6	17	5116438-5175034	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046969			Uncertain	Vesicles		Tissue enriched	Group enriched	5	ovary: 3.5;skeletal muscle: 7.5;testis: 17.1	smooth muscle: 1.8	Mixed		
USP9X	DFFRX, FAF, MRX99	ENSG00000124486	Ubiquitin specific peptidase 9, X-linked	X	41085635-41236579	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011618, HPA047417, CAB070164	Approved		Uncertain	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 90.1	Expressed in all		
USP9Y	DFFRY	ENSG00000114374	Ubiquitin specific peptidase 9, Y-linked	Y	12701231-12860839	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057687			Uncertain	Vesicles		Tissue enhanced	Tissue enhanced		prostate: 9.9	seminal vesicle: 6.9	Cell line enhanced		RPTEC TERT1: 13.3
VAPB	ALS8, VAP-B, VAP-C	ENSG00000124164	VAMP associated protein B and C	20	58389122-58451101	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013144, CAB013722	Supported		Enhanced	Endoplasmic reticulum	Renal cancer:1.08e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 42.4	Expressed in all		
VARS2	DKFZP434L1435, G7a, KIAA1885, VARS2L, VARSL	ENSG00000137411	Valyl-tRNA synthetase 2, mitochondrial	6	30908242-30926459	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA062449, HPA070267	Approved		Approved	Mitochondria		Expressed in all	Mixed			esophagus: 5.2	Mixed		
VCP	IBMPFD, p97	ENSG00000165280	Valosin containing protein	9	35056064-35073249	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB005593, HPA012728, HPA012814	Supported		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:9.63e-7 (favourable), Endometrial cancer:7.30e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 94.2	Expressed in all		
VEGFC	VRP	ENSG00000150630	Vascular endothelial growth factor C	4	176683538-176792727	Cancer-related genes, Disease related genes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins, Transporters	Evidence at protein level						Lung cancer:7.88e-5 (unfavourable), Renal cancer:1.17e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 51.7	placenta: 30.7	Cell line enhanced		BJ: 135.8;HBF TERT88: 122.6;hTEC/SVTERT24-B: 129.0;LHCN-M2: 120.0
VRK1		ENSG00000100749	Vaccinia related kinase 1	14	96797304-96931722	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000660, HPA017929	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:4.15e-4 (unfavourable)	Expressed in all	Mixed			testis: 59.5	Expressed in all		
WBSCR17	GalNAc-T5L, GALNTL3	ENSG00000185274	Williams-Beuren syndrome chromosome region 17	7	71132169-71713600	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA013624, HPA047986	Approved		Uncertain	Nucleus<br>Nucleoli<br>Nuclear bodies<br>Golgi apparatus	Testis cancer:3.91e-4 (favourable), Ovarian cancer:4.60e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 76.4	ovary: 29.1	Cell line enhanced		AF22: 14.1;NTERA-2: 10.8;RPMI-8226: 8.6;SK-BR-3: 34.1
WFS1	DFNA14, DFNA38, DFNA6, DIDMOAD, WFS	ENSG00000109501	Wolframin ER transmembrane glycoprotein	4	6269849-6303265	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029128	Approved				Endometrial cancer:1.13e-6 (favourable), Thyroid cancer:3.13e-4 (unfavourable)	Expressed in all	Mixed			ovary: 61.5	Cell line enhanced		BEWO: 97.0
WNK1	HSAN2, HSN2, PPP1R167, PRKWNK1	ENSG00000060237	WNK lysine deficient protein kinase 1	12	752593-911452	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046541, HPA059157	Enhanced		Supported	Cytosol	Ovarian cancer:9.67e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 92.4	Expressed in all		
WNK4	PRKWNK4	ENSG00000126562	WNK lysine deficient protein kinase 4	17	42780678-42796936	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016500	Approved					Mixed	Tissue enhanced		kidney: 19.0;prostate: 15.4;rectum: 12.0	colon: 8.8	Cell line enhanced		fHDF/TERT166: 26.2;K-562: 34.7;TIME: 29.5;WM-115: 23.9
WRN	RECQ3, RECQL2	ENSG00000165392	Werner syndrome RecQ like helicase	8	31033801-31173769	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028661	Approved		Supported	Nuclear speckles		Expressed in all	Mixed			endometrium: 14.8	Expressed in all		
XIAP	API3, BIRC4, hILP	ENSG00000101966	X-linked inhibitor of apoptosis	X	123859724-123913979	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009203, HPA042428	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Breast cancer:9.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 35.4	Mixed		
XK	Kx, NA, NAC, X1k, XKR1	ENSG00000047597	X-linked Kx blood group	X	37685759-37732130	Blood group antigen proteins, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019036	Approved		Approved	Nucleoplasm<br>Vesicles<br>Mitochondria		Mixed	Mixed			rectum: 12.1	Cell line enhanced		HEL: 39.5;K-562: 25.8
XPNPEP2		ENSG00000122121	X-prolyl aminopeptidase 2	X	129738974-129769538	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA000339, CAB025136, CAB025269	Enhanced					Group enriched	Group enriched	12	duodenum: 128.1;kidney: 175.9;small intestine: 231.5	liver: 14.3	Cell line enhanced		ASC diff: 6.9;ASC TERT1: 36.6;HSkMC: 19.4
XPNPEP3	APP3, ICP55, NPHPL1	ENSG00000196236	X-prolyl aminopeptidase 3	22	40857077-40932815	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000527	Enhanced				Thyroid cancer:6.10e-4 (unfavourable), Breast cancer:8.19e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 14.5	Mixed		
XYLT1	PXYLT1, XT-I	ENSG00000103489	Xylosyltransferase 1	16	17101769-17470881	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA007478, HPA007966	Approved					Mixed	Mixed			cervix, uterine: 12.2	Cell line enhanced		ASC diff: 38.1;U-2197: 54.3
XYLT2	PXYLT2, XT-II	ENSG00000015532	Xylosyltransferase 2	17	50346092-50363138	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016456			Approved	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			stomach: 31.5	Expressed in all		
YARS	tyrRS, YRS, YTS	ENSG00000134684	Tyrosyl-tRNA synthetase	1	32775237-32818153	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017936, HPA018950, HPA018954	Enhanced		Enhanced	Cytosol	Renal cancer:1.02e-11 (unfavourable), Liver cancer:6.97e-11 (unfavourable), Urothelial cancer:6.57e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 81.5	Expressed in all		
YARS2	CGI-04, FLJ13995, mt-TyrRS	ENSG00000139131	Tyrosyl-tRNA synthetase 2	12	32727490-32755902	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038721, HPA057610, HPA074097	Uncertain		Supported	Nuclear bodies<br>Mitochondria	Liver cancer:3.19e-5 (unfavourable)	Expressed in all	Mixed			placenta: 11.1	Expressed in all		
YME1L1		ENSG00000136758	YME1 like 1 ATPase	10	27110112-27155266	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066953	Approved		Supported	Nuclear bodies<br>Mitochondria	Liver cancer:8.25e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 105.7	Expressed in all		
ZAP70	SRK, STD, ZAP-70	ENSG00000115085	Zeta chain of T-cell receptor associated protein kinase 70	2	97713560-97739862	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002625, HPA003134	Enhanced				Renal cancer:3.02e-8 (unfavourable), Endometrial cancer:9.66e-8 (favourable), Head and neck cancer:3.93e-6 (favourable), Cervical cancer:6.89e-5 (favourable)	Mixed	Tissue enhanced		appendix: 36.2;lymph node: 64.3;spleen: 37.7	tonsil: 16.2	Cell line enriched	16	MOLT-4: 144.9
ZDHHC15	FLJ31812, MRX91	ENSG00000102383	Zinc finger DHHC-type containing 15	X	75368427-75523502	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at transcript level	HPA003618	Uncertain		Approved	Nuclear speckles<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 4.8	Cell line enhanced		HEL: 2.8;MOLT-4: 1.9;NTERA-2: 2.0;RH-30: 3.0;SH-SY5Y: 2.7
ZDHHC9	CGI-89, CXorf11, ZDHHC10, ZNF379, ZNF380	ENSG00000188706	Zinc finger DHHC-type containing 9	X	129803288-129843909	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA031814	Uncertain		Supported	Golgi apparatus<br>Cytosol	Cervical cancer:4.64e-5 (unfavourable), Breast cancer:9.77e-5 (unfavourable), Head and neck cancer:2.45e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 71.1	Expressed in all		
ZMPSTE24	FACE-1, HGPS, PRO1, STE24, Ste24p	ENSG00000084073	Zinc metallopeptidase STE24	1	40258107-40294184	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006988	Approved		Approved	Golgi apparatus<br>Cytosol	Liver cancer:5.73e-6 (unfavourable), Thyroid cancer:6.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 90.5	Expressed in all		
